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In order to successfully invade a new species, lentiviruses must overcome 
restriction factors, dominant blocks to replication, and be able to make use of 
available host factors such as entry receptors for replication. Human 
immunodeficiency virus (HIV-1) infection is blocked at a post-entry stage by 
rhesus macaque TRIM5α, an effect that is enhanced by host factor cyclophilin A 
(CypA), but largely evades restriction by the human TRIM5α variant. HIV-1 
replication is also inhibited by simian APOBEC3G but is able to evade 
restriction by human APOBEC3G by inducing its degradation through expression 
of accessory protein Vif. Viral entry and tissue tropism are determined by an 
interaction of the viral Env glycoprotein with a cell surface receptor and a 
seven transmembrane domain co-receptor. The feline immunodeficiency virus 
(FIV) infects diverse felid species including the African lion, where infection 
has likely been endemic since at least the late Pleistocene, and the domestic 
cat, a more recent host. For domestic cat strains of FIV (FIV-Fca), entry is 
mediated by host proteins CD134 and CXCR4, but the identity of receptors in 
non-domestic strains of FIV is unknown.  
This thesis demonstrates that two strains of FIV isolated from lions (FIV-Ple 
subtypes B and E) differ in their receptor tropism and that subtype E shares 
entry receptors with FIV-Fca. The findings suggest that alternative receptor 
usage is a strategy employed by FIV in this species and has implications for the 
disputed pathology and tissue tropism of infection in African lions. Next, we 
tested the hypothesis that species which have harboured lentiviral infection for 
a long time are better able to prevent viral replication than recent hosts. 
Whilst we found that TRIM5α is non-functional in all felid species tested, 
evidence of potent APOBEC3 activity was found and, in lion cells, potently 
restricts production of infectious FIV. Moreover, lion primary T-cells prevent 
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replication of diverse FIV strains and restrict primate lentiviruses at post-entry 
stages, suggesting that co-evolution with lentiviruses has driven the selection 
of broad-ranging restriction factors. Structural and biophysical analyses suggest 
that whilst FIV’s interaction with CypA appears to be conserved in affinity with 
HIV-1, the interaction does not appear to be crucial for replication and, in the 
absence of restriction by TRIM5α, the role of the capsid-CypA interaction is 
discussed. Overall the study explains the permissivity of domestic cat cells to 
retroviral infection and identifies FIV infection of lions as an example of host 
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Chapter 1. Introduction 
1.1 Preface 
Investigating the mechanisms by which viruses appropriate host cell machinery 
to replicate themselves is crucial to our understanding of infections and their 
associated pathologies. In conjunction with studies of host immunity, such 
research can reveal the co-evolutionary battles between host and parasite and 
expose the interactions important for viral infection and suggest potential 
strategies of viral disruption. Lentiviruses are widespread mammalian 
pathogens and include the human and feline immunodeficiency viruses (HIV 
and FIV) which cause AIDS in their respective hosts. Humans and cat 
lentiviruses are proposed to have invaded their hosts after comparatively 
recent cross-species transmission events: within the past 150 years for humans 
and since the domestication event that gave rise to domestic cats. However, 
replication of these viruses is blocked in the cells of other species by a suite of 
proteins termed ‘restriction factors.’ Evolution of such restriction factors is 
proposed to have been driven by previous or ongoing encounters with 
pathogens. In this thesis, a comparison is made between infections in domestic 
cats and African lions, where FIV is thought to have been endemic for hundreds 
of thousands, if not millions of years. The study investigates the characteristics 
of FIV strains circulating in these species and asks what changes long-term 
lentiviral infection has brought about in host and pathogen with particular 
reference to restriction factors. 





Viruses are obligate intracellular parasites, reliant on host cell machinery to 
carry out the instructions encoded within their genomes. They must use the 
available host factors in a precise and controlled order to carry out each 
sequential stage of the viral lifecycle. Several replication strategies are 
available to viruses with respect to the nature of their genomes and the 
manner of their replication, all of which must ultimately allow the expression 
of viral proteins through messenger RNA (Baltimore 1971). The Retroviridae 
virus family is characterised by a replication strategy of positive sense RNA 
genome that is reverse transcribed by viral enzyme reverse transcriptase (RT) 
into a double stranded DNA copy which is inserted into the host genomic DNA 
from which mRNA transcripts and novel genomic RNA transcripts can be 
derived. Members of the family are broadly categorised into simple or complex 
retroviruses, with simple viruses generally bearing three open reading frames 
(ORFs), gag (which encodes the major structural proteins), pol (encoding RT 
and other proteins necessary for replication) and env (encoding the envelope 
glycoprotein responsible for entry into cells). The simple retroviruses are 
subdivided into genera Alpha-, Beta- and Gammaretrovirus, whist the complex 
viruses are divided into the Spuma- and Lentivirus genera both of which 
possess a number of smaller ‘accessory’ genes (Figure 1-1). 





Figure 1-1 Genomic organisation of simple and complex retroviruses. Murine 
leukaemia virus (MLV) is a simple retrovirus belonging to the Gammaretrovirus genus 
and possesses three open reading frames, as well as 5’ and 3’ long terminal repeats 
(LTRs). Human immunodeficiency virus type I (HIV-1) belongs to the complex 
Lentivirus genus and has an additional suite of accessory genes. Some of these genes are 
shared by the feline immunodeficiency virus (FIV), which has an open reading frame 
termed orfA which encodes a protein which bears similarities to HIV-1 Vpr (Gemeniano 
et al. 2003). The gag-pol open reading frames are produced as polyproteins which are 
cleaved by viral protease into mature peptides matrix, MA; capsid, CA; nucleocapsid, 
NC; protease, PR; reverse transcriptase, RT; dUTPase, DU; and integrase, IN.  
The first demonstration of the infectious property of lentiviruses was the 
transmission of equine anaemia in serum filtrate, now known to bear equine 
infectious anaemia virus (EIAV; Vallee and Carre 1904). In Icelandic sheep, the 
maedi visna disease was introduced in the mid-twentieth century and the 
spread of the disease was shown to be caused by a transmissible virus 
(Sigurdsson, 1953), later demonstrated to be the prototypic  lentivirus, maedi 
visna virus (MVV; Haase and Varmus 1973). The viruses were given the prefix 
lenti- (lentus meaning slow in Latin) due to the long incubation period for 
pathological manifestations to occur. Symptoms of MVV infection include 
pulmonary infection and neurologic disease (meadi, laboured breathing, visna, 




wasting in Icelandic) but arise at least two years after infection. This slow 
progression of disease is a common feature of the lentiviruses but tissue 
tropism and the associated pathology is diverse (Narayan and Clements 1989). 
The field rose to prominence as a research subject with the discovery of human 
immunodeficiency virus type I (HIV-1) which infects and depletes CD4+ T-cells, 
compromising cellular immunity and causing acquired immunodeficiency 
syndrome (AIDS) (Barre-Sinoussi et al. 1983; Gallo et al. 1984). The Lentivirus 
genus is known to infect diverse mammalian orders including cattle (bovine 
immunodeficiency virus; BIV), goats (caprine arthritic encephalitis virus; 
CAEV), horses (EIAV) and primates (simian and human immunodeficiency 
viruses; SIV and HIV). However, the discovery of feline immunodeficiency virus 
(FIV; Pedersen et al. 1987b) was followed by the finding that, uniquely 
amongst non-primate lentiviruses, it causes an AIDS-like syndrome 
characterised by recurrent gingivitis-stomatitis, cachexia, neuropathology and 
an increased incidence of tumour development (Torten et al. 1991; Ackley et 
al. 1990; Yamamoto et al. 1989; Sparger et al. 1989; Pedersen et al. 1987a; 
Hosie et al. 1989; Pedersen 1993; Callanan et al. 1992; Callanan et al. 1996). 
FIV infects an estimated 10% of domestic cats in the UK and species-specific 
strains of FIV have now been identified in at least 15 non-domestic felid and 
hyenid species (Brown et al. 1994; Troyer et al. 2004; Barr et al. 1995; 
Carpenter et al. 1996; Hofmann-Lehmann et al. 1996; Troyer et al. 2005). As 
well as being a major veterinary pathogen, FIV has attracted considerable 
attention as a model for investigating common principles of AIDS progression 
and in the development of vaccines for the prevention of lentiviral infection. 
On the 25th anniversary of the description of AIDS, a co-discoverer of HIV 
declared “we can safely say that we know as much about HIV as we do of any 
pathogen and about AIDS as we do any human disease” (Gallo 2006). Despite 
this, the virus is now responsible for a global pandemic infecting 40.3 million 
people, with at least two-thirds of cases occurring in the developing world 




(World Health Organisation 2005). It is therefore of necessity and substantial 
value to investigate the mechanisms by which lentiviruses replicate and 
interact with their hosts.   
The lentiviral lifecycle is superficially simple: particles invade the cell, reverse 
transcribe and integrate their genomes, translate their proteins and bud from 
the cell surface. However, the lifecycle is dependent on a vastly complex array 
of interactions with host proteins. For instance, in July 2009, the HIV-1 Human 
Protein Interaction Database lists 1,737 entries for Env alone (Fu et al. 2009), a 
number that will no doubt grow substantially. What's more, the information to 
carry out these functions is encoded by a genome of only 9,000-10,000 base 
pairs (bp), resulting in gene products that must carry out multiple functions. 
For the most part, host-virus interactions promote the viral lifecycle, but it is 
becoming increasingly clear that an additional suite of host factors that 
evolved specifically to interfere with retroviral replication must also be 
overcome for successful replication. These agents are known as ‘restriction 
factors’ and are considered as part of the innate immune system or as 
members of a separate ‘intrinsic immune system’ (Bieniasz 2004). This 
separate classification is justified by their constitutive expression in a wide 
range of host cells and their absence of requirement for pathogen stimulation 
or intercellular communication. To date, the main restriction factors of 
retroviral replication fall into three classes, the post-entry restriction factors 
(including murine Fv1 and mammalian TRIM5α), hypermutation-inducing 
restriction factors (the APOBEC3 family of proteins) and inhibitors of budding 
(tetherin). A variety of counter-measures have been devised on the part of the 
virus, including host-specific escape mutants and the generation of entire new 
genes that disrupt the activities of the restriction factors.  




1.3 Cross-species transmission of lentiviruses in the primates and 
felids 
In order to successfully infect a new species, a lentivirus requires a 
transmission event (zoonosis) and subsequent acquisition of adaptations that 
facilitate replication and transmission in the new host. There are currently 36 
primate species known to be infected with lentiviruses, confined to Africa and 
Asia (Santiago et al. 2005). The causes of AIDS, HIV-1 and HIV-2, were 
introduced to humans as multiple cross-species transmissions from nonhuman 
primates. The chimpanzee (Pan troglodytes) simian immunodeficiency virus 
(SIVcpz) crossed into humans on at least three separate occasions during the 
19th and 20th centuries, giving rise to HIV-1 groups M (major), O (outlier) and N 
(non-M, non-O) (Keele et al. 2006; Gao et al. 1999). HIV-2, originating from 
SIVsm of sooty mangabeys (Cercocebus atys), is thought to have been 
transmitted to humans on at least eight occasions, giving groups A to H 
(Damond et al. 2004). However, six of the groups have only been identified as 
individual infections, with only groups A and B showing evidence of human-
human transmission (Damond et al. 2004) and even these groups remain largely 
confined to West Africa. Additionally, a virus has been identified in a 
Cameroonian woman that resembles SIV strains circulating in gorilla 
populations (Plantier et al. 2009). Thus it seems likely that lentiviruses have 
crossed from apes and monkeys into humans on numerous occasions, no doubt 
many or most of these unnoticed. Only one transmission event, from 
chimpanzees to humans around 1904 and giving rise to HIV-1 group M, has given 
rise to the global pandemic (Keele et al. 2006; Worobey et al. 2008). The 
comparative rarity of successful zoonosis events in the primates implies that 
species-specific blocks to replication (be they dominant host blocks or the 
inability to use host factors in the new host) must be overcome for successful 
transmission. 




Of the 37 known species of felids, 21 species have been shown to harbour 
antibodies reactive to FIV and many of these species harbour viral sequences 
consistent with species-specific strains (VandeWoude and Apetrei 2006; Troyer 
et al. 2008). Unlike the primate lentiviruses, prevalence of FIV is worldwide, 
with infections occurring in both old and new world species. However, not all 
branches of felids are infected which suggests that virus colonised these hosts 
after the modern felid species radiation in the late Miocene ~10.8 million years 
ago1 (mya; Johnson et al. 2006). The co-occurrence of diverse primate, 
ungulate and feline lentiviruses in Africa, and the paucity of FIV in Asia (only 
one endemic Asian species has tested FIV seropositive, the Mongolian species 
Pallas cat (Barr et al. 1995)), has lead to the hypothesis that FIV originated in 
Africa and was subsequently disseminated worldwide (Troyer et al. 2008; 
Pecon-Slattery et al. 2008b). Unlike most felid taxa, all six species belonging to 
the Panthera genus are infected with FIV, and in lions, six highly divergent 
viral subtypes (A to F) are circulating (Pecon-Slattery et al. 2008b). These 
observations are consistent with an ancient infection in this species. The range 
of modern lions is confined to the African continent and a relic population in 
the Gir forest of India. However, fossil evidence points to a much larger former 
distribution, including Asia and North America. The virus is proposed to have 
colonised the Panthera lineage before spreading to America through movement 
of species across the Bering Straits. Two opportunities for this dissemination 
have arisen: during periods of low sea level dated to 4.5 mya that allowed the 
movement of ocelot lineage members that subsequently diverged into cheetahs 
and pumas, and a more recent event in the late Pliocene/early Pleistocene 
(3.6 – 2.5 mya) that permitted the movement of lions into North America 
(Troyer et al. 2008; Johnson et al. 2006). The low sequence diversity of FIV in 
cheetahs points to a relatively recent introduction of FIV, probably since the 
extirpation of North American cheetah subspecies 10,000 years ago (Pecon-
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 N.B. A phylogeny of the Feliformia is presented in Appendix 4. 




Slattery et al. 2008b; Menotti-Raymond and O'Brien 1993), making it unlikely 
that the ocelot lineage was infected with lentivirus at the time of migration to 
North America. It is therefore possible that lions, where infection is more 
ancient, were vehicle for FIV dissemination into the new world during their 
migration in the late Pliocene/early Pleistocene. Analysis of mitochondrial and 
genomic DNA markers in African lions suggests episodes of population 
fragmentation occurred during the Pleistocene (1.8 mya - 10,000 years before 
present; Antunes et al. 2008). Geographical concordance between FIV-Ple 
subtypes and hypothesised historical sub-population ranges is consistent with 
an invasion of FIV-Ple that pre-dates the expansion of modern lion populations 
estimated between 324,000–169,000 years before present (Antunes et al. 
2008). Diversity of FIV in the North American species puma (also known as 
cougar or mountain lion; Puma concolor with FIV strain FIV-Pco) is also high 
with substantial divergence between the two clades A and B (Troyer et al. 
2005), pointing to this species as an early host for new world colonisation for 
FIV. In contrast, the closest relative of the domestic cat, Felis sylevstris, the 
wildcat (Driscoll et al. 2007), is free from FIV infection, suggesting that the 
zoonosis into domestic cats took place after their domestication, estimated at 
10,000 years ago from archaeological evidence (Vigne et al. 2004). Thus in a 
similar manner to the primates, lentiviral infection is still spreading through 
the taxa, and comparisons between the transmissions of feline and primate 
lentiviruses have yielded some interesting insights into the relationship 
between host and pathogen. In the primates, cross-species transmissions tend 
to occur primarily between closely related species, so that the phylogenies of 
host and virus closely resemble each other (VandeWoude and Apetrei 2006). In 
contrast, zoonoses in the felids frequently take place between more distantly 
related species, resulting in discordant host and virus phylogenies 
(VandeWoude and Apetrei 2006). Such transmission has given rise to a 
phylogeographic distribution in the felids, where viral strains are more likely to 




resemble those endemic within the same geographical area than those present 
in closely related host species. 
1.4 Lentiviral entry 
1.4.1 Receptors for HIV-1 entry 
The Env-receptor interaction is a critical determinant for cell tropism and 
pathogenesis for lentiviral infection. For HIV-1, an interaction with surface-
expressed CD4 allows targeting of helper T-cells and cells of the 
macrophage/monocyte lineage whilst further subpopulation specificity is 
provided by the differential affinities for chemokine co-receptors, CXCR4 and 
CCR5. CD4 is a member of the immunoglobulin superfamily that is expressed on 
the surface of T-helper cells as a transmembrane glycoprotein. Its in vivo role 
is to act, along with the variable T-cell receptor (TCR), as a ligand for major 
histocompatability complex (MHC) class II, whilst cytotoxic T-cells, which 
express CD8, interact with MHC class I. MHC class II is expressed on the surface 
of antigen presenting cells and displays protease-digested oligopeptides in its 
peptide-binding groove. In the event that antigen presented by MHC class II 
molecules is recognised by TCR of a given T-helper cell, activation of that T-
cell will typically result leading to an antigen-specific clonal expansion. CD4 
aids in this process by amplifying the intracellular signal generated by TCR by 
recruitment of membrane-anchored tyrosine phosphatase Ick, initiating a 
downstream signalling pathway and resulting in the activation of transcription 
factors such as NFκB and NFAT which stimulate transcription of T-cell 
activation genes such as interleukin-2 (Janeway et al. 2001; reviewed in Delon 
and Germain 2000). The chemokine receptors (CCRs) are G-protein coupled 
receptors that belong to the 7-transmembrane domain super-family (7TM). 
CCRs are responsible for the binding of soluble ligands (chemokines) which 
effect intracellular responses in the target cell (for review see Rot and von 




Andrian 2004). Many chemokines act as chemo-attractants for specific cell 
types, and upon binding initiate intracellular signalling that typically results in 
a directional kinetic response. Members of the chemokine receptor family bind 
the various chemokines with differential specificity and chemokines are often 
promiscuous in their ligand specificity, resulting in various responses such as 
proliferation, adhesion, differentiation or barrier migration depending on the 
nature and context of the interaction (Rot and von Andrian 2004). 
1.4.2 Molecular mechanism of HIV-1 entry 
The majority of research into the mechanisms of lentiviral entry has been 
performed in the primate lentiviruses (HIV-1/SIVmac), but it is increasingly 
becoming clear that attributes of HIV attachment and fusion hold true for FIV 
entry. Moreover, gp120 and gp41 bear structural homology to viruses as distant 
as influenza A haemagglutanin HA1 and HA2 glycoproteins, suggesting a 
convergent or conserved mechanism for viral penetration (Weissenhorn et al. 
1997). The HIV particle supports several envelope ‘spikes’ protruding from the 
surface, each consisting of an exposed trimer of gp120 subunits (SU) anchored 
to the membrane through a non-covalent interaction with trimeric gp41 
transmembrane glycoprotein (TM), in such a manner that gp41 is generally 
sequestered by gp120 (Weiss et al. 1990; Kowalski et al. 1987). gp120 is a 
large, multiply-glycosylated protein, comprising several conserved domains 
(C1-C5), interspersed with variable domains (V1-V5) bounded by intramolecular 
disulphide bonds, creating loop structures (Starcich et al. 1986; Leonard et al. 
1990). Being exposed to the adaptive immune system, antibodies are 
generated to gp120, particularly to V2 and V3 (Moore et al. 1994), some of 
which are capable of neutralising infection (Karlsson Hedestam et al. 2008). A 
considerable degree of sequence variation is tolerated in the variable loops, 
allowing the expansion of mutants that escape antibody neutralisation but 




preserve fusogenic activity (Karlsson Hedestam et al. 2008). Although regions 
within V2 and V3 do play a part in receptor attachment (Wyatt et al. 1995; 
Trkola et al. 1996), a major function of the variable loops appears to be to 
provide a largely irrelevant antibody binding surface, whilst protecting 
conserved domains critical for entry mechanisms.  
Entry to cells expressing co-receptor alone can be promoted using soluble CD4 
(Moore et al. 1990). Antibodies directed to co-receptor do not normally inhibit 
infection, but after incubation with soluble CD4, entry is rendered antibody-
sensitive, suggesting that the initial attachment step of Env to CD4 promotes a 
conformational change that primes the virus for co-receptor attachment 
(Salzwedel et al. 2000). This conformation change, elucidated by differential 
sensitivity of V3 to proteases, exposes motifs within the V3 loop which are able 
to interact with cognate chemokine receptors (Sattentau and Moore 1991). In 
turn, the Env-chemokine receptor interaction allows gp41 to insert its 
hydrophobic N-terminus termed the ‘fusion peptide’ into the cell membrane 
with the simultaneous dissociation of gp120 (Sodroski 1999). Trimers of gp41 
are then thought to bring about the fusion of the two membranes by 
conformational rearrangement from a prehairpin state to a final six α-helical 
hairpin structure (Gallo et al. 2001; Weissenhorn et al. 1997). Once the 
membranes are fused, the viral contents are deposited within the cytoplasm 
and the intracellular stages of the lifecycle begin.  
1.4.3 Variable tropism of HIV-1  
HIV-1 strains have long been known to preferentially target either macrophages 
(MΦ-tropic) or T-lymphocytes (T-tropic) (Collman et al. 1989). For the most 
part, this specificity can be explained by the preferential use of CCR5 or CXCR4 
(R5 and X4 HIV-1 strains), since CXCR4 is widely expressed in helper T-cells, 
whereas CCR5 is found in the monocyte lineage. Further T-cell subpopulation 




tropism can also be explained by CCR use: the memory (CD45RA+) T-cell 
population expresses CCR5 and accordingly is targeted by R5 isolates. Likewise, 
infection of other cell types is dependent on alternative chemokine tropism: 
invasion of the central nervous system is associated with use of D6, expressed 
widely on astrocytes (Neil et al. 2005) and CCR3-using Envs have been isolated 
from neural tissue and macrophages (Aasa-Chapman et al. 2006; Peters et al. 
2004). However, not all specificity can be explained by CCR expression given 
that some macrophage-tropic strains use CXCR4 (Simmons et al. 1998), and 
some R5-using strains can only poorly infect macrophages (Peters et al. 2006). 
This apparent anomaly can be explained by the ability to use low levels of CD4 
and CCR efficiently, perhaps marked by an increased affinity for the receptors 
(Gray et al. 2005; Peters et al. 2006). Thus for HIV-1, cell tropism is a function 
of both co-receptor identity and the nature of the CD4 interaction, with 
variations in the ability to bind its two cell-surface receptors providing 
substantial subpopulation tropism.  
Studies of HIV-infection in humans have shown that tropism usually, but not 
always, progresses from R5 to X4 or dual-tropic R5X4 over the course of 
infection, a change that is accompanied by mutations in the V3 loop and an 
increase in cytotoxicity (Page et al. 1992; Chavda et al. 1994; Fenyo et al. 
1988; Connor et al. 1997). Individuals with a CCR5 mutation that prevents R5 
infection (CCR5-∆32) are largely resistant to infection with HIV, despite 
expressing normal CXCR4 (Dean et al. 1996; Liu et al. 1996). These data imply 
that replication of X4 variants is somehow restricted and early stages of 
infection are performed by R5 strains. The use of R5 by early variants appears 
to be a conserved mechanism in primates, with SIV strains from sooty 
mangabeys and rhesus macaques as well as HIV-1 and HIV-2 all employing the 
same strategy (Chen et al. 1998). The precise nature of the CXCR4 restriction is 
poorly defined, but is proposed to be a series of barriers to viral transmission 




at the mucosal surface and sub-mucosa that preferentially select R5 variants 
over X4, known as the gatekeeper hypothesis (Margolis and Shattock 2006). The 
expansion of X4 or R5X4 viruses in the later stages of infection is proposed to 
require a certain level of immune depletion, as a conserved gp120 
neutralisation epitope is protected in R5 HIV-1 variants but not in X4 and R5X4 
variants (Lusso et al. 2005). Thus changes in tropism are a major aspect of AIDS 
pathology and represent a mechanism of ensuring primate lentivirus survival 
through successful transmission and subsequent invasion of tissues. 
1.4.4 Receptors for FIV-Fca entry  
Although highly divergent at the primary protein sequence level, FIV Env is 
thought to share a similar domain architecture to HIV-1, with comparable 
variable loops defined by disulphide bridges (Pancino et al. 1993). In contrast 
to HIV-1, FIV uses CD134, a member of the tumour necrosis factor receptor 
family, as a primary receptor for entry (Shimojima et al. 2004). CD134, also 
referred to as OX40, is widely expressed on activated rat and human CD4+ T-
cells (Mallett et al. 1990), where its activation is required for activated T-cell 
survival and expansion (Song et al. 2005b; Gramaglia et al. 1998; Pippig et al. 
1999; for a review of CD134 function see Croft et al. 2009). CD134 is also found 
at low levels on CD8+ T-cells, macrophages and activated B-cells in humans 
(Baum et al. 1994). In domestic cats, CD134 is present on mitogen-stimulated 
T-cells in vitro (Shimojima et al. 2004; de Parseval et al. 2004) as well as CD4+ 
T-cells in vivo (Joshi et al. 2005) but absent from CD8+ T-cells (de Parseval et 
al. 2004). Accordingly, FIV replicates predominantly in activated CD4+ T-cells 
but during late stages of infection, an expansion of tropism to B-cells, 
macrophages and CD8+ T-cells is observed (Willett and Hosie 2008; de Parseval 
et al. 2004). FIV Env is able to use feline but not human CD134 for entry, a fact 
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require additional CRD2 interactions are able to use chimeric hCD134/fCRD1 (Willett et 
al. 2006b; de Parseval et al. 2005). 
For FIV strains such as GL8 and CPG41 (‘early’ or acute stage isolates), entry is 
contingent on expression of both CD134 and CXCR4. However, other strains 
circulate with a reduced requirement for the CRD2 domain (Willett et al. 
2006b; de Parseval et al. 2005). These strains, such as PPR and B2542 (‘late’ or 
chronic stage isolates), are more sensitive to inhibition by soluble CD134L 
(Willett et al. 2006b) and are able to infect cells expressing a chimeric CD134 
that bears the CRD1 domain of feline CD134 in a human CD134 background 
(hCD134/fCRD1) (de Parseval et al. 2005). The finding recapitulates in vitro 
experiments where it was shown that long term passage of FIV in CD134-
negative CrFK cells induces the generation of replication-competent viruses 
with mutations in the ES(E/D) motif of the V3 loop of Env (Shimojima et al. 
1998). For both in vivo and in vitro isolates, the mutations at this loop involve 
a charge switch to lysine at one of the glutamates which allows the virus to use 
CXCR4 directly, with reduced requirement for CD134 (Willett et al. 1997a; 
Willett et al. 1997b; Willett et al. 2007). 
A model of FIV progression is emerging that links the molecular mechanisms of 
virus-plasma membrane fusion to the broadening of target cell tropism and 
development of feline AIDS (Willett and Hosie 2008). In the early stages of 
infection, viral entry is characterised by a more complex Env-receptor 
interaction involving CD134 CRD1 and CRD2. As with HIV-1, the two-step 
primary receptor attachment followed by a conformational change allows the 
sequestration of the relatively invariant CXCR4-binding domain from the 
humoral immune response until it is required for mediation of entry. In 
contrast, during the chronic stages of infection, immunity is compromised and 
correspondingly, viruses have a reduced need for protecting the CXCR4-




interacting domain and isolates become less reliant on CD134. Accompanying 
the reduced CD134 requirement is a broadening of cell tropism and invasion of 
new tissue types, reminiscent of the switch from R5 to X4 in HIV-1. Although 
still dependent on CD134 and CXCR4, late stage FIV infection requires a low 
complexity and possibly low affinity interaction with CD134, similar to HIV-1 
isolates that are able to alter their tropism by altering the nature of the CD4 
interaction (Peters et al. 2006; Gray et al. 2005). Substantiation of this model 
will come from longitudinal studies following the progression and relative 
prevalence of viral mutants within individual cats, coupled with an 
understanding of the molecular basis of infection.  
1.4.5 Receptor tropism of non-domestic cat FIV 
Very little is known about the receptor usage of non-domestic cat lentiviruses. 
However, domestic cat mitogen-stimulated peripheral blood mononuclear cells 
(PBMCs) may be infected with FIV isolates from lion (FIV-Ple for Panthera leo) 
and puma (FIV-Pco for Puma concolor) (VandeWoude et al. 1997b) but CD134 
and CXCR4 are not down-regulated during infection as would be expected if 
entry was mediated by these receptors (Willett et al. 2006a). Furthermore, 
infection by FIV-Ple and FIV-Pco cannot be inhibited by CXCR4 inhibitor 
AMD3100 or by SDF-α, a CXCR4-binding chemokine and a CD134-negative cell 
line 3201 supports the replication of both viruses but not domestic cat strains 
of FIV (FIV-Fca) (Smirnova et al. 2005). Taken together, these data suggest that 
FIV-Ple and FIV-Pco do not require CD134 and CXCR4 as receptor and co-
receptor, using in preference an unknown cell surface receptor. Multiple 
strains of FIV-Pco as well as FIV-Ple B 458 have been used to successfully infect 
domestic cats (VandeWoude et al. 2003; VandeWoude et al. 1997a; Terwee et 
al. 2005). The in vivo manifestations of these strains are distinct from FIV-Fca 
infection, characterised by reduced pathogenicity and altered tissue tropism, 




with strains such as FIV-Pco-1695 showing a greater propensity to infect 
intestinal tract mucosa (Terwee et al. 2005). Infected domestic cats were 
either able to mount a robust humoral and cellular immune response to PBMC-
replicating virus (VandeWoude et al. 2003), or were able to prevent PBMC 
infection and clear pro-viral load three months post-infection (Terwee et al. 
2005). It has been suggested that the lengthy period that FIV-Ple and FIV-Pco 
are proposed to have co-evolved with their hosts has reduced their 
pathogenicity through host-adaptation [burk] (Carpenter and O'Brien 1995). 
However, it is possible that differential Env-receptor tropism is at least in part 
responsible for the altered pathology and, until the identification of the FIV-
Ple/Pco receptor/receptors, the relevance of this will remain unknown. 
Recently, phylogenetic analysis of wild FIV-Ple isolates in Africa revealed that 
env of FIV-Ple subtype E is more closely related to the envs of FIV-Fca than to 
other FIV-Ple subtypes or FIV-Pco (Pecon-Slattery et al. 2008a). The E subtype 
appears to be the result of a recombination event with other viruses, as trees 
drawn using the gag-pol open reading frame indicate a monophylogenetic 
relationship with other strains of FIV-Ple. Chapter 3 presents a study of the 
comparative receptor requirements of FIV-Ple isolates and finds that FIV strains 
with alternate receptor tropism are circulating in wild lion populations, raising 
important questions about the evolution and pathogenicity of FIV in this 
species. 
1.5 Post-entry restriction 
In order to replicate, lentiviruses are dependent on the presence of compatible 
host factors, use of which they have specifically evolved to incorporate into 
their lifecycles. As has been described, infectivity of lentiviruses is conditional 
on the presence of cognate entry receptors and their absence precludes 
replication. Thus non-functional receptors, such as human CD134 for FIV, are 




thought to provide a substantial barrier to cross-species transmission. The 
restriction factors provide another barrier to replication that must also be 
overcome for successful infection and cross-species transmission. This study is 
primarily concerned with hypermutation inducing enzyme APOBEC3 and post-
entry restriction factor TRIM5α and its modulator cyclophilin A.  
1.5.1 Murine Fv1 system 
The first system of retroviral restriction to be described was the murine Friend 
Virus susceptibility (Fv) system (Lilly 1967). Allelic variants of the Fv1 gene 
display strain-specific restriction to the simple retrovirus murine leukaemia 
virus (MLV). Cells of genotype Fv1n/n, present in the NIH strain of mice, are 
able to restrict strain MLV-B but permit infection by MLV-N while cells bearing 
Fv1b/b, present in BALB/c mice, display the opposite phenotype. The alleles are 
co-dominant so that Fv1n/b heterozygotes are restrictive to both strains (Pincus 
et al. 1971). Fv1 encodes an endogenous retroviral gag gene (Best et al. 1996), 
prompting speculation that Fv1 is able to multimerise with MLV capsid proteins 
and prevent early stages of infection. However, Fv1 is almost entirely 
unrelated to the MLV capsid gene (Best et al. 1996) and its mode of function 
remains unknown. Retroviral restriction was thought to be confined to mice 
until it was shown that non-murine cells of diverse species, including those of 
human origin, exhibit a phenotype akin to cells bearing Fv1b/b: they specifically 
restrict MLV-N (Towers et al. 2000; Hofmann et al. 1999). This property was 
historically termed Ref1 in humans and Lv1 in primates, both now known to be 
functions of the α-splice variant of host protein TRIM5. Curiously, the viral 
determinant of N versus B tropism in the Fv1 system has been shown to map to 
capsid residue 110, precisely the same residue that confers MLV-N resistance to 
TRIM5α restriction in human cells (Towers et al. 2000).  




1.5.2 TRIM5α restriction 
TRIM5α provides a potent, pre-reverse transcription block to replication. The 
gene was identified by cDNA screen as the factor responsible for the Lv1 
restriction phenotype in rhesus macaque cells (Stremlau et al. 2004). TRIM5 
belongs to the TRIM (tripartite motif) family of proteins (Reymond et al. 2001), 
which is found in species extending from the nematode Caenorhabditis elegans 
to primates. A large expansion of TRIM genes has occurred, resulting in 68 
genes in the human genome including the cluster of closely related 
TRIM6/34/5/22 on human chromosome 11 which is found as a syntenic region 
in many mammalian genomes (Reymond et al. 2001; Sardiello et al. 2008). Of 
note, the cluster is absent from the chicken genome, suggesting a mammalian 
origin and its absence from the possum genome indicates that the genes arose 
sometime after the marsupial/eutherian (placental) mammal split dated to 90-
180 mya (Sawyer et al. 2007). In some lineages, TRIM5 itself is the subject of 
multiple duplications, with eight predicted tandem copies in the bovine 
genome and seven in the murine genome (termed TRIM12 and TRIM30 in the 
mouse) (Sawyer et al. 2007; Tareen et al. 2009). It is presumed that the gene 
duplications are maintained as they may provide restriction factors able to 
simultaneously combat specific pathogens, although the pathogens that have 
driven the evolution of each paralogue have in most cases not been identified. 
In contrast, several taxa possess non-functional pseudogenes of TRIM5. 
Humans, for example have a non-functional inverted duplication of TRIM5 
named TRIMP1 (Reymond et al. 2001) and the canine TRIM5 has been disrupted 
by the insertion of the transcript of an apparently unrelated gene PNRC1 
(Sawyer et al. 2007). Interestingly, in taxa such as the canids which lack TRIM5, 
positive selection of the TRIM5 locus seems to have been compensated for by 
an increase in selection of TRIM22, perhaps suggestive of an overlap in antiviral 
function of these two genes (Sawyer et al. 2007). 




The tripartite motif (TRIM) gene family is characterised by the presence of 
three domains: a RING (really interesting new gene) domain capable of E3 
ubiquitin ligation, one or more B-Box domains and a coiled-coil domain 
responsible for formation of multimers (Reymond et al. 2001). Several 
members of the gene family (60% of those in humans), including the longest 
(alpha) isoform of TRIM5 possess an additional C-terminal B30.2 domain (also 
known as a PRY-SPRY domain). In some primate species, a retrotransposition 
event has resulted in the B30.2 domain being replaced by a cyclophilin domain, 
resulting in a TRIM5-CypA fusion, termed TRIMCyp (Newman et al. 2008; Wilson 
et al. 2008; Virgen et al. 2008; Sayah et al. 2004). Subcellular localisation of 
TRIM proteins is found to be diverse with localisation typically nuclear, 
cytoplasmic or both (Reymond et al. 2001). For TRIM5α, localisation is in the 
cytoplasm, where it is able to form discrete puncta termed cytoplasmic bodies 
when over-expressed. However formation of cytoplasmic bodies is not a 
prerequisite for restriction activity of TRIM5α (Perez-Caballero et al. 2005b), 
and the biological role of these structures is unknown. Amongst the primate 
TRIM5α orthologues, an ability to inhibit the replication of a broad range of 
exogenous and endogenous retroviruses has been documented, including 
members of the lenti-, beta-, gamma- and spuma- retroviruses. (Saenz et al. 
2005; Song et al. 2005a; Keckesova et al. 2004; Kaiser et al. 2007; Diehl et al. 
2008; Yap et al. 2008). The precise mechanism of the restriction ability of 
TRIM5α remains the subject of enquiry, but roles for the individual domains 
have been described, allowing hypotheses for the overall mechanism of 
restriction to be advanced. 
1.5.3 Virus interaction maps to TRIM5 B30.2 or CypA domain 
The B30.2 domain is a conserved protein domain found uniquely in vertebrates 
that possess adaptive immune systems (Rhodes et al. 2005). The domain is a 




composite of two more ancient domains: the PRY domain, which contributes 
the N-terminal 50-60 amino acids, and the SPRY domain, first identified in 
fungus Dictyostelium, which contributes the C-terminal ~140 amino acids. The 
resulting B30.2 (also referred to as PRY-SPRY domain) is present in more than 
150 human proteins in eleven gene families in the human genome including the 
BTN immunoglobulin receptors and DEAD-box domain proteins (Rhodes et al. 
2005; Woo et al. 2006).  
The TRIM5α B30.2 domain is thought to engage the incoming viral core in the 
cytoplasm by recognition of specific features in the capsid N-terminal domain 
(Owens et al. 2004; Stremlau et al. 2004). An alignment of mammalian TRIM5 
B30.2 domains reveals the presence of three areas of variability termed v1 to 
v3 (Song et al. 2005a). Structures have been solved of the B30.2 domain of 
TRIM21 (a close relative of the TRIM5/6/32/22 family which is known to bind 
IgG and is involved in Sjorgen’s syndrome (Keeble et al. 2008)) and of a related 
Drosophila protein, GUSTAVUS (Woo et al. 2006), which show the SPRY forming 
a β-sandwich pocket formed by the conserved β-strands, referred to as β1 to 
β13. Protruding from this core structure are the variable loops, forming a 
surface capable of protein-protein interaction. For TRIM21, and potentially 
TRIM5, a separate pocket derived from the PRY subdomain is formed and with 
an exposed surface analogous to TRIM5α v1 (James et al. 2007). Part of this 
region is lacking in Macaca nemestrina TRIM5 isoform TRIM5θ, a deletion which 
impacts negatively on retroviral restriction (Brennan et al. 2007). Experimental 
data for TRIM21 suggest the presence of a conformationally rigid binding 
surface that does not alter its shape upon interaction with its substrate 
(induced-fit model)(Keeble et al. 2008). Thus in a manner reminiscent of 
immunoglobulins, a conserved backbone supports variable loops capable of 
protein-protein interaction.  




The variable regions of primate TRIM5α B30.2 exhibit a substantial number of 
substitutions, insertions and lineage-specific length polymorphisms. The 
significance of variation in these domains has been highlighted by the finding 
that the difference in phenotype between rhTRIM5α, which restricts HIV-1, and 
huTRIM5α, which does not, maps to P332R (P in rh) within the v1 domain 
(Perez-Caballero et al. 2005a; Stremlau et al. 2005; Yap et al. 2005). Similarly, 
restriction of MLV-N by huTRIM5α is specific to acidic residues in the v3 loop 
(E405 and E406) (Perron et al. 2006a). Comparison with TRIM21 reveals that 
these positions correspond to the points of contact for the protein-protein 
interaction (James et al. 2007). Length polymorphisms have also been 
documented: v1 is typically longer in the old-world (catarrhine) monkeys (17 
amino acids in squirrel monkey versus 46 amino acids in African green monkeys 
(Song et al. 2005a)), whilst v3 is typically longer in the new world (platyrrhine) 
monkeys (32 residues in most catarrhines including apes, compared to 41 
residues in squirrel monkeys). For the most part, these length polymorphisms 
are the result of internal tandem duplications. It has been noted that those 
species with most duplications exhibit the widest repertoires of restriction. For 
example, African green monkey (agm) TRIM5α, with an expanded v1 domain, is 
able to target several retroviruses and may have become prevalent due to the 
selective advantage of increased breadth of capsid targets (Keckesova et al. 
2004; Yap et al. 2004). Accordingly, the duplicated sequences in the variable 
loops are also more likely to have substitutions suggesting that the duplicated 
sequence may selectively target different capsids (Sawyer et al. 2005).  
In some primate species, the B30.2 domain of TRIM5α is replaced by host factor 
cyclophilin A (CypA), creating fusion protein TRIMCyp. CypA is known to 
interact with lentiviral capsid (Luban et al. 1993; Franke et al. 1994; Thali et 
al. 1994) and its association with TRIM5 creates a potent restriction factor 
capable of targeting lentiviruses whose capsids interact with CypA, such as 




HIV-1 and FIV (Sayah et al. 2004; Lin and Emerman 2006). The first TRIMCyp to 
be described was in the new world species owl monkey (Aotus trivirgatus) and 
formed by a retrotransposition event placing it downstream of exon 7 (Nisole 
et al. 2004; Sayah et al. 2004). Subsequently, TRIMCyps were found in old 
world pigtail, rhesus and long-tailed macaque species (Macaca nemestrina, M. 
mulatta and M. fascicularis respectively) (Newman et al. 2008; Virgen et al. 
2008; Wilson et al. 2008). Remarkably, these TRIMCyps were created by an 
event independent of the owl monkey TRIMCyp as the CypA exon is located 
downstream of exon 8, and the coding transcript is generated by exon skipping. 
This indicates that capsid-specific restriction has arisen independently at least 
four times during mammalian evolution, targeting the same viral determinant. 
Since lentiviruses are the only retroviruses known to interact with CypA, the 
independent genesis of TRIMCyps would appear to highlight the strong selective 
pressure to devise novel restriction factors to circulating lentiviruses. 
However, no lentiviruses have been discovered in owl monkeys, or indeed any 
platyrrhine monkey, making the pathogen that drove the evolution of the owl 
monkey TRIMCyp uncertain. Once fused with the TRIM5 RBCC (the collective 
term for the RING, B-Box and coiled-coil), the CypA domain of rhesus TRIMCyp 
appears to have undergone point mutations that allow differential restriction 
of lentiviruses: tropism has changed from HIV-1-binding to HIV-2-binding 
through the acquisition of two point mutations that remodel the hydrophobic 
pocket (Price et al. 2009).  
1.5.4 Adaptive evolution of TRIM5α  
Evolution at the molecular level is characterised by the generation of 
mutations that may be deleterious, in which case natural selection will prevent 
their spread (purifying selection), or advantageous, in which case natural 
selection will seek to increase their prevalence (Darwinian or positive 




selection). In addition, genetic changes may be driven to fixation by random 
genetic drift. Thus the presence of high levels of mutations between copies of 
a gene belonging to different species may be the result of very different 
evolutionary forces. Either 1) changing environmental circumstances may have 
relaxed the effect of purifying selection allowing new mutations to increase in 
frequency by genetic drift or 2) positive selection has driven the new 
mutations to fixation, suggesting a biologically important role. The two 
scenarios can be differentiated by the calculation of the synonymous (silent) to 
non-synonymous (amino acid substituting) changes at the nucleic acid level, 
since synonymous changes are assumed to be neutral with respect to natural 
selection and therefore give a background rate of the accumulation of changes 
(Yang 2005). The ratio of non-synonymous to synonymous changes (dN/dS ratio) 
is therefore an indicator of the nature of the selection that has occurred during 
evolution, with values >1, 1 and <1 representing positive selection, neutral 
selection and purifying selection respectively.  
Primate TRIM5α has been evolving under episodes of positive selection for at 
least the past 33 mya (Sawyer et al. 2005). Evidence of particularly strong 
positive selection is found in the hominid lineage and maps to several residues 
in the B30.2 domain variable loops and four residues in the coiled coil domain, 
some displaying a dN/dS ratio as high as 8.8. This analysis highlighted a patch 
of residues in the v1 loop as under very strong adaptive selection, including the 
R332P codon that is largely responsible for the change in specificity between 
hu and rh TRIM5α variants (Perez-Caballero et al. 2005a; Stremlau et al. 2005; 
Yap et al. 2005). Analysis of the five confirmed protein-coding bovine TRIM5 
paralogues and the murine TRIM12/TRIM30 genes reveals that positive 
selection of TRIM5α is also present in these species and therefore not unique to 
the primates (Sawyer et al. 2005; Tareen et al. 2009). The selective pressure 
also maps to the v1 loop, consistent with the paralogues evolving to target 




diverse pathogens. However, the viral targets for most of the genes is 
unknown, although bovine TRIM5-3 has been found to restrict retroviral 
replication in a manner similar to primate TRIM5α, specifically targeting MLV-N 
(Ylinen et al. 2006; Si et al. 2006). The data imply that antiretroviral activity 
of TRIM5α is an ancestral phenotype which has been conserved in diverse 
mammalian taxa. Furthermore, the repeated findings of positive selection in 
the B30.2 domain are consistent with TRIM5α’s critical role in the permissivity 
of the host to infection by widespread pathogens.  
1.5.5 Contribution of RBCC domain to restriction 
Target specificity of TRIM5α is provided by the B30.2 domain. However, the 
RING, B-Box and coiled-coil domains are canonical features of TRIM family 
proteins, and each domain contributes to TRIM5α-mediated restriction. The 
coiled coil domain is an approximately 100 residue domain encoded by human 
TRIM5α exons 2, 3 and 4. Coiled coil domains typically consist of a 7 residue 
repeat ‘abcdefg’ where amino acids a and d represent hydrophobic residues 
responsible for homo-oligomerisation and the other residues are polar (Harbury 
et al. 1995; Lupas et al. 1991). For TRIM5α, the coiled coil and the downstream 
linker 2 region between the coiled coil and B30.2 domain mediate 
oligomerisation (Mische et al. 2005; Javanbakht et al. 2006a; Langelier et al. 
2008), although conflicting evidence has been provided as to whether it forms 
dimers or trimers. Experiments have been confounded by the rapid turnover of 
TRIM5α and its tendency to form aggregates when purified. These problems 
have been resolved by the use of chimeric protein with the RING domain of 
TRIM21 and expression in insect cells to demonstrate that TRIM5α self-
associates as a dimer (Langelier et al. 2008). Previous confusing results from 
cross-linking experiments were obtained due to the anomalously slow migration 
of TRIM5α dimers by SDS-PAGE. Mutation of hydrophobic residues predicted to 




form the surface for self-association dramatically reduces capsid binding 
(Javanbakht et al. 2006a) and the efficiency of rhTRIM5α to restrict HIV-1 
(Javanbakht et al. 2006a; Mische et al. 2005), suggesting that dimerisation of 
the protein is important for increasing the avidity of the TRIM5α-capsid 
interaction. Coiled-coil domains expressed alone (and other truncated TRIM5α 
constructs such as human splice variant TRIM5γ and TRIM5δ) are able to 
prevent restriction by full length TRIM5α presumably by forming dimers with 
full length protein in the cytoplasm (Perez-Caballero et al. 2005a).  
The RING domain belongs to the E3 ubiquitin ligase class of enzymes which 
facilitate the transfer of ubiquitin from an E2-conjugating enzyme to a lysine 
residue of the target protein. TRIM5α is capable of transferring the ubiquitin 
peptide to itself (auto-ubiquitinylation) which is thought to direct the protein 
to proteasome-mediated degradation, in turn leading to a high rate of turnover 
(Diaz-Griffero et al. 2006a; Javanbakht et al. 2005). It appears that incoming 
retroviral cores that have been bound by TRIM5α are also subject to 
proteasome degradation, as inhibition of the proteasome with MG132 prolongs 
the lifetime of cores in the cytoplasm (Campbell et al. 2008) and TRIM5α 
appears to increase in turnover rate upon inoculation with a restricted virus 
(Rold and Aiken 2008), suggesting a functional link between proteasome 
degradation and restriction. However, deletion of the RING domain impairs but 
does not abolish TRIM5α-mediated restriction and the impairment of restriction 
could partly be attributed to alteration of subcellular localisation (Javanbakht 
et al. 2005). Likewise inhibition of the proteasome with MG132 does not 
restore infectivity (Anderson et al. 2006; Wu et al. 2006), suggesting that 
although TRIM5α does mediate proteasomal cleavage of the viral core, this is 
not crucial for its antiviral activity and TRIM5α depends additionally on other 
mechanisms to prevent retroviral infection.  




The B-Box 2 domain is present in the majority of TRIM family proteins and is 
sometimes accompanied by an adjacent B-Box 1 domain. The domains are 
unique to the TRIM family but their function is poorly characterised (Reymond 
et al. 2001). TRIM5α possesses a single B-Box 2 domain which, when deleted, 
severely impacts on retroviral restriction (Stremlau et al. 2006b; Javanbakht et 
al. 2005). Homology modelling with a TRIM29 B-Box 2 structure reveals it to be 
a globular structure with a highly charged surface (Diaz-Griffero et al. 2007). 
Mutation of some of these residues (such as rhTRIM5α R119) results in the loss 
of antiretroviral activity, despite retaining the ability to self-associate and 
interact with capsid, suggesting that the B-Box is involved in an effector 
function of TRIM5α-mediated restriction (Diaz-Griffero et al. 2007). The nature 
of this function is unknown but may involve the recruitment of other cellular 
proteins. It also appears that the charged surface is involved in modulating the 
stability of the protein in the cytoplasm and in the formation of higher-order 
complexes of TRIM5α (Diaz-Griffero et al. 2007; Li and Sodroski 2008), 
although, again the mechanism regulating its longevity is unknown but 
independent of proteasome degradation (Diaz-Griffero et al. 2007).  
In studying the contributions of the individual domains of TRIM5α, several non-
mutually exclusive hypotheses for the mechanism of TRIM5α antiviral activity 
have been advanced. The simplest model is that incoming cores are bound by 
TRIM5α, which is poly-ubiquitinylated and with a high level of turnover, 
resulting in degradation of viral proteins. Evidence for this model comes from 
the finding that under normal conditions, retroviral cores are degraded by the 
proteasome before they have the chance to reverse transcribe (Wu et al. 2006; 
Anderson et al. 2006). Although this method of restriction may represent the 
likely fate of restricted viruses in vivo, the persistence of restriction after 
addition of MG132 suggests that other mechanisms are operating (Campbell et 
al. 2008). The nature of this block is unknown, although interference with the 




uncoating process has been suggested (Stremlau et al. 2006b). Uncoating is a 
poorly defined stage thought to involve the dissassembly of the capsid core and 
a restructuring of the viral proteins in order for reverse transription of the viral 
RNA genome to occur. Evidence that the process occurs is provided by findings 
that CA protein is present only at very low levels after reverse transcription 
(Fassati and Goff 2001) and electron microscopy shows cores disintegrating 
soon after fusion (Grewe et al. 1990). Furthermore, restriction factor TRIMCyp 
is only able to restict HIV-1 in the first 30-60 minutes post-entry (Perez-
Caballero et al. 2005b). It is thought that uncoating is a temporally regulated 
event that must proceed at the correct speed to allow association with cellular 
factors whilst retaining the ability to perform necessary viral functions, notably 
reverse transcription (Forshey et al. 2002). By following the levels of 
multimeric or soluble capsid post infection, it was suggested that TRIM5α 
promotes the rapid conversion of HIV-1 and MLV-N capsid structures to the 
soluble (disassembled) form (Perron et al. 2006b; Stremlau et al. 2006b). In a 
similar manner CypA, which has been hypothesised to aid uncoating by 
performing a proline isomerisation reaction, is able to act as a restriction 
factor for HIV-1 when multimerised (Yap et al. 2007; Javanbakht et al. 2007). 
This supports the accelerated uncoating hypothesis but disruption of other 
essential activities such as formation of the reverse transcription complex and 
translocation across the nuclear membrane has not been ruled out. Indeed, the 
accelerated uncoating hypothesis does not explain the effect of mutations of 
charged residues in the B-box which ablate restriction. Nor does it explain the 
low levels of retroviral restriction by hu or rhTRIM5α when exogenously 
expressed in dog cells(Berube et al. 2007). These findings suggest that TRIM5α 
binding to viral cores alone is insufficient for full levels of restriction and the 
protein may recruit other cellular factors that are required for optimal levels 
of restriction.  




1.6 The role of Cyclophilin A in lentiviral replication 
1.6.1 Cyclophilin A and its inhibitors 
The cyclophilins are a large protein family found in both prokaryotes and 
eukaryotes. The family are members of the peptidyl proline isomerases 
superfamily (immunophilins), a name which reflects their ability to catalyse 
cis-trans isomerisation around peptidyl-proline bonds (Gothel and Marahiel 
1999). The 18 kDa human protein CypA was discovered as the intracellular 
receptor of immunosuppressive drug cyclosporine A (CsA) (Takahashi et al. 
1989). There are at least eight Cyp genes expressed in humans, with many 
other mammalian forms also found, all with sequence identity of >50% (Gothel 
and Marahiel 1999), but with variable subcellular localisation. For instance 
CypB is found exclusively in the endoplasmic reticulum (Price et al. 1991), 
whilst CypA is found at high levels in the cytoplasm (3-7µg per mg total protein 
(Ryffel et al. 1991)). CsA is a cyclic peptide isolated from the fungus 
Tolypocladium inflatum and is widely used in immune suppression for 
recipients of allografts. CsA exerts its immunosuppressive effect by binding 
CypA with a high affinity (IC50 ~6nM (Liu et al. 1991)). Once bound, the 
complex creates a novel binding surface which is able to bind and inhibit 
calcineurin, a serine/threonine kinase capable of dephosphorylating, and 
hence activating, transcription factor NF-AT (nuclear factor of activated T-
cells), which is required for IL-2 expression associated with activated T-cells 
(for review of CsA's role in T-cell activation see Clardy 1995). Under CsA 
inhibition, T-cell receptor (TCR)-mediated activation and subsequent expansion 
of T-cell clones, which rely on this signalling pathway, are therefore inhibited, 
seriously compromising cellular immunity. Non-immunosuppressive analogues 
of CsA have been manufactured, notably NIM811 and Debio-025, which retain 




their ability to bind CypA, but do not provide the calcineurin binding surface 
(Rosenwirth et al. 1994; Ptak et al. 2008). 
1.6.2 CypA is a cofactor of HIV-1 replication 
CypA was first associated with lentiviral replication when it was found to be 
packaged into HIV-1 virions via an association with unprocessed Gag 
polyprotein (Luban et al. 1993; Franke et al. 1994; Thali et al. 1994). These 
studies found that disruption of the interaction with CsA prevented CypA 
incorporation into virions and impacted negatively on HIV-1 replication. 
However it is during the early stages of viral infection, not incorporation, that 
CypA impacts on the viral lifecycle (Towers et al. 2003). CypA binds to 
incoming viral cores via an interaction between the catalytic hydrophobic 
pocket of the enzyme and an exposed proline-rich loop between CA helices 4 
and 5 on the external surface of capsid N-terminal domain (Gamble et al. 
1996). This loop appears to be confined to the lentiviruses as it is absent in 
other groups of retroviruses. However, whilst the CA-CypA interaction has been 
demonstrated for HIV-1, SIVagm and FIV (Lin and Emerman 2006; Diaz-Griffero 
et al. 2006b; Zhang et al. 2006) the interaction is not a feature of all 
lentiviruses: SIVmac, HIV-2 and EIAV do not bind CypA (Lin and Emerman 2006; 
Yoo et al. 1997; Braaten et al. 1996). 
HIV-1 CA exists as a mixture of cis and trans isomers around the G89-P90 
peptide bond with 14% of molecules in the cis and the remainder in the trans 
conformation (Gitti et al. 1996). Most peptide linkages are made in the trans 
conformation during translation, but peptidyl-proline linkages can be made in 
cis or trans, and the activity of peptidyl-proline isomerase (PPI) enzymes is 
thought to aid proper folding (Gothel and Marahiel 1999). Isomer heterogeneity 
is therefore rare in folded proteins making HIV-1 CA an unusual case (Fischer et 
al. 1998). It has been shown that CypA catalyses the inter-conversion of the CA 




G89-P90 cis and trans isomers, increasing isomerisation by about 100-fold but 
maintaining the same cis:trans ratio in a CsA-inhibitable manner (Bosco et al. 
2002). The finding supports the idea that CypA performs a catalytic role 
promoting the dissociation of the capsid core upon infection of a target cell. 
HIV-1 CA mutants G89V/A and P90V/A result in a 30-150-fold reduction in CypA 
binding affinity (Yoo et al. 1997) and display a similar phenotype to wildtype 
virus in the presence of CsA, with reduced infectivity in human cells.  
1.6.3 CypA can have alternative effects on lentiviral replication 
The effects of CypA on the replication of lentiviruses are not identical in 
different contexts. CsA treatment results in an increase in HIV-1 infectivity 
upon entry to rhesus macaque cells, but only in the presence of TRIM5α, 
suggesting that CypA promotes an isomerisation that increases the 
susceptibility of HIV to post-entry restriction (Keckesova et al. 2006; Berthoux 
et al. 2005; Stremlau et al. 2006a). Conversely, a reduction in infectivity of 
HIV-1 in human TE671 cells treated with CsA remains even after knockdown of 
TRIM5α (Keckesova et al. 2006; Sokolskaja et al. 2006). This phenotype is cell-
type specific as TE671 sub-clone 17H1, selected for loss of MLV-N restriction, is 
permissive for HIV-1 in a CypA-independent manner but maintains wildtype 
expression levels of TRIM5α, suggesting that in humans, CypA protects HIV from 
an unknown restriction factor (Sayah and Luban 2004). Long-term passage of 
HIV-1 in the presence of CsA results in the out-growth of mutants A92E and 
G94D (Aberham et al. 1996). Infectivity of HIV-1 bearing these mutations is 
subsequently dependent on the presence of CsA in HeLa but not TE671 cells 
(Hatziioannou et al. 2005; Sokolskaja et al. 2006). Recently it has been shown 
that the CsA dependence in HeLa cells is due to high CypA expression levels in 
HeLa cells compared to TE671, but interestingly the HIV A92E and G94D 
mutants do not differ in their affinity for CypA (Ylinen et al. 2009). The finding 




supports the notion of CypA playing a role in uncoating but that the mutants 
arising from CsA inhibition differ in their sensitivity to CypA-aided uncoating, 
rather than their affinity for CypA. Also arising from this study is the suggestion 
that the CA-CypA affinity appears to be maintained within a narrow range of 
values (all studies to date report Kd values within 5 – 15 µM (Yoo et al. 1997; 
Price et al. 2009; Ylinen et al. 2009)) even for the CsA inhibition-dependent 
mutants. The reasons for this are unclear, but may involve maintaining the 
correct level of isomerase activity to uncoat the virus in the appropriate 
manner. However research in the field has been hampered by the absence of 
CypA mutants that bind CA but do not perform the isomerase activity. Mutating 
the G89-P90 bond that prevents isomerisation also prevents CypA binding (Yoo 
et al. 1997), making it difficult to distinguish between the relative 
contributions of binding and isomerisation.  
In some primate species, cyclophilin replaces the B30.2 domain of TRIM5α, 
creating TRIMCyp (Wilson et al. 2008; Virgen et al. 2008; Sayah et al. 2004; 
Newman et al. 2008). The CypA domain of the new world primate owl monkey 
(omk) TRIMCyp binds to a similar repertoire of viruses as human cytosolic CypA, 
and accordingly restricts HIV-1 and FIV but does not restrict HIV-2 or SIVmac 
(Sayah et al. 2004; Virgen et al. 2008; Wilson et al. 2008). Newly discovered 
forms of TRIMCyp, created by an independent retrotransposition event in the 
Macaca genus (rh), have an altered capsid specificity, specifically targeting 
HIV-2 but no longer restricting HIV-1 (Wilson et al. 2008; Virgen et al. 2008). 
This switch in specificity is attributable to two substitutions, D66N and R69H. 
These mutations cause a comparatively large (~16Å) rearrangement of a ten-
residue loop at the binding surface of Cyp, changing from a ‘closed fist’ to 
‘open palm’ conformation and permitting micromolar binding to HIV-2 CA 
(Price et al. 2009). Curiously, FIV is restricted by both rh and omkTRIMCyp 
(Virgen et al. 2008; Wilson et al. 2008; Saenz et al. 2005). So far FIV appears to 




be unique in this property suggesting an alternative CypA binding mechanism 
and making an interesting comparison with the primate lentiviruses, where 
binding is exclusive to either omkTRIMCyp/CypA or to the structurally modified 
rhTRIMCyp. This issue is addressed in Chapter 5, where biophysical techniques 
confirm the dual-specificity of FIV and a crystal structural of FIV CA reveals 
structural differences to the primate lentiviruses. 
1.7 Induction of hypermutation by APOBEC3 
1.7.1 Discovery of human APOBEC3G 
The discovery of the role of APOBEC enzymes in the lifecycle of retroviruses 
stems from work on viral infectivity factor (Vif) in HIV-1. Vif is a highly basic 
protein of 22-29kDa found in all lentiviruses with the exception of equine 
infectious anaemia virus (EIAV; Kawakami et al 1987). Early work on the gene 
(known at that time as gene ‘A’ or sor) revealed that Vif was required for 
replication in certain ‘non-permissive’ cell lines including macrophages, 
monocyte and some T-cell derived cells (e.g. CEM, H9 and HUT78) but 
dispensable in other ‘permissive’ cell lines such as T-cell lines CEM-SS, Jurkat 
and non-lymphoid cells such as HeLa (von Schwedler et al. 1993; Gabuzda et 
al. 1992). It was shown that Vif is packaged into virus particles where it is 
required for the formation of phenotypically normal virions (von Schwedler et 
al. 1993; Ohagen and Gabuzda 2000). Furthermore it was shown that packaging 
of Vif into virus particles is essential for overcoming the block in non-
permissive cells (von Schwedler et al. 1993). Thus the phenotype of ∆vif 
viruses is dependent on the permissivity of the virus producing cells: ∆vif 
viruses produced in permissive cells are infectious for a single cycle regardless 
of the permissiveness of the target cells, whilst ∆vif viruses produced in non-
permissive cells are uninfectious regardless of the nature of the target cells. 




The factor responsible for the differential permissivity between CEM and CEM-
SS cells was isolated by subtractive cloning coupled with a cDNA screen 
(Sheehy et al. 2002). The gene identified was APOBEC3G (huA3G), a member of 
the cytidine deaminase enzyme family. There are 12 members of the gene 
family in the human genome residing in four gene clusters: APOBEC1 and AID 
are separated by 1 megabase on chromosome 12, A2 resides alone on 
chromosome 6, an expanded cluster of seven A3 genes (A, B, C, DE, F, G and H) 
is located on chromosome 22, and A4 is located on chromosome 1. The family 
takes its name after the apolipoprotein B mRNA-editing catalytic polypeptide 1 
(APOBEC1), for which only a single role has been described: to deaminate a 
single nucleoside of APOB mRNA transcripts at position C6666 to generate a 
truncated protein (Teng et al. 1993). The B-cell expressed protein AID 
(activation-induced deaminase) is responsible for the generation of somatic 
hypermutation leading to the diversification of antibody (Martin et al. 2002; Di 
Noia et al. 2007) and also triggers antibody class switching, both operating at 
the DNA level (Muramatsu et al. 1999). The identification of huA3G as the 
factor responsible for the non-permissivity of certain cell lines therefore 
presented a potential mechanism for its activity: host mutation of viral nucleic 
acids.  
1.7.2 Antiviral activity of human APOBEC3G 
The cytidine deaminases all bear a catalytic domain (CD) that comprises a Zn-
coordinating H/C-X-E-X23-28-P-C-X2-C motif which is thought to generate zinc 
hydroxide that is able to deaminate the pyrimidine ring of cytidine by 
nucleophilic attack resulting in a uracil residue (Harris and Liddament 2004). 
Several of the huA3 genes (A3B, DE, F and G) possess two CDs: an N-terminal 
domain (CD1; also known as the pseudocatalytic domain) that is catalytically 
inactive, and a catalytically active C-terminal domain (CD2; Huthoff and Malim 




2007). The domains have distinct functions and antiviral activity of huA3G is 
dependent upon both the domains.  
The huA3G CD2 deaminase specifically targets cytosine residues of single 
stranded (ss) minus sense DNA but is catalytically inactive on HIV-1 genomic 
RNA, double stranded DNA and RNA-DNA heteroduplexes (Yu et al. 2004b). 
Crystal and NMR structures of CD2 reveal a positively charged nucleic acid 
binding groove that permits interaction with the negatively charged single-
stranded DNA backbone and brings the target cytosine into close proximity with 
the Zn-coordinating catalytic domain (Holden et al. 2008; Chen et al. 2008). 
The deamination activity of CD2 converts cytosine to uracil in the minus strand 
DNA. Subsequent reverse transcription results in a guanosine to adenosine 
transition in the coding strand for the most part of the HIV genome (the 
exceptions being the U3 region of the 5’ LTR and the primer binding sites 
which exist as single stranded DNA flaps after reverse transcription and 
accumulate cytosine to thymine mutations (Yu et al. 2004b)). The mutagenesis 
proceeds from 3’ to 5’ end of the ssDNA, following the generation of single 
stranded DNA and digestion of template RNA by reverse transcriptase and 
RNaseH respectively (Chelico et al. 2006). The sites of mutation are not 
completely random. Firstly, gradients of A3G-induced mutations exist, 
increasing in the 5’ to the 3’ end of the positive sense genome which is thought 
to reflect the time that single stranded DNA is exposed to huA3G (Yu et al. 
2004b; Suspene et al. 2006). These gradients reach their peak just 5’ of the 
polypurine tracts which are the origins of reverse transcription (Suspene et al. 
2006; Yu et al. 2004b). Additionally, mutational hotspots for APOBECs have 
been identified: most prevalently for huA3G, the GG dinucleotide (substrate 
residue underlined) is most commonly mutated, and in particular in the TGGG 
tetranucleotide (Yu et al. 2004b; Bishop et al. 2004b; Suspene et al. 2006; 
Harris et al. 2003). Interestingly, in protein-coding regions, this mutation 




frequently results in a TGG to TAG change which alters a tryptophan codon to a 
stop codon, potentially causing a damaging truncating mutation to the viral 
protein. Thus the activity of APOBEC3G against HIV-1 ∆vif is thought to be the 
introduction of mutations (hypermutation) to such a level (as many as 10% of 
guanosines may be mutated to adenosines) that the virus is impaired in its 
ability to produce infectious progeny virions. When the level of hypermutation 
renders the virus unable to faithfully replicate and therefore unable to sustain 
infection it is said that the error catastrophe threshold has been surpassed.  
1.7.3 Encapsidation of human APOBEC3G 
The fact that the permissivity of the virus producing cell rather than the target 
cell is the determinant for viral replication suggests that APOBEC3G present in 
the target cell is not sufficient for inhibition of viral replication. Indeed it has 
been shown that huA3G is encapsidated into HIV-1 ∆vif and this ability is likely 
to depend on interaction between huA3G CD1 and both viral Gag p55 
nucleocapsid region and viral RNA (Mangeat et al. 2003; Khan et al. 2005). The 
precise mechanisms and relative contributions of each of these interactions is 
currently under study but is thought to involve multimers of huA3G forming 
complexes with viral RNA, cellular RNA species 7SL and p55 polyprotein which 
are then packaged into budding virus particles (Svarovskaia et al. 2004; Wang 
et al. 2007). Final levels of huA3G are dependent on the levels of expression in 
the virus producing cell, calculated at 7 enzyme copies per virion when 
produced in PBMCs but capable of much higher levels of incorporation when 
overexpressed in vitro (Xu et al. 2007). Interestingly, even in the presence of 
Vif, huA3G particles are thought to be packaged into HIV-1 particles with 0.3 to 
0.8 molecules per virion (Nowarski et al. 2008), and low levels of G to A 
mutations are observed in high passage number HIV-1 cultures (Zhang et al. 
2003). As with many pre-integration stages of the retroviral lifecycle, 




interactions of huA3G with the reverse transcription complex in the target cell 
are much less well understood, but presumably require interactions that 
prevent disassociation of huA3G from the target nucleic acids and allow the 
transition from RNA binding to single-stranded DNA cytidine deamination. 
It has been reported that induced hypermutation is not sufficient to explain 
the antiviral activity of huA3G and huA3F, giving rise to the possibility of a 
deamination-independent role of APOBECs on viral replication. Mutation of the 
conserved zinc coordinating histidine and cysteine residues or the catalytic 
glutamic acid residues of CD2 abolishes deaminase activity but does not fully 
destroy antiviral activity (Newman et al. 2005). Recently, a likely mechanism 
for deaminase-independent activity has been proposed which involves the 
inhibition of the progression of the reverse transcriptase enzyme along the 
template RNA in the newly infected cell (Bishop et al. 2008). However the 
relative contributions of the deaminase-dependent and -independent roles of 
huA3G are not fully clear and may have different relative contributions 
depending on the cell type in question (Thielen et al. 2007). 
1.7.4 Antiviral activity of other human APOBEC3 genes 
The presence of an expanded gene family of APOBEC3 genes raises the 
possibility that other members of the family possess antiviral activity. Several 
studies have now been performed confirming that this is indeed the case and 
anti-lentiviral activity has been associated with several of the two-domain 
APOBECS, namely 3B (Bishop et al. 2004a), 3DE (Dang et al. 2006), 3F (Zheng 
et al. 2004) and anti-SIVmac activity has been associated with the one-domain 
A3C (Yu et al. 2004a; Bishop et al. 2004a). Of these, the gene with largest 
impact on HIV-1 replication is huA3F which is widely co-expressed with huA3G 
in non-permissive cells (Wiegand et al. 2004; Liddament et al. 2004; Zheng et 
al. 2004). Strong evidence of the importance of huA3F in HIV-1 replication is 




that, like huA3G, HIV-1 Vif counteracts its activity and its preferred mutational 
hotspot (WGAA where W is A or T) is detectable in clinical isolates of HIV-1 
(Fitzgibbon et al. 1993). However further analysis reveals that huA3G’s 
preferred substrate (GG dinucleotide) is more frequently mutated than huA3F’s 
(GA), suggesting that the role of huA3G is greater in the biological context of 
HIV-1 replication (Zennou and Bieniasz 2006). Interestingly, the antiretroviral 
activity of huA3B is resistant to HIV-1 Vif in tissue culture experiments but 
expression is very low in CD4+ T-cells, making it unlikely to severely hinder 
HIV-1 replication (Bogerd et al. 2007).  
Also of significance is the breadth of targets that APOBECs are able to 
deaminate whilst being able to distinguish self from non-self. Of the human A3 
genes, all seven have now been associated with antiretroviral or 
antiretroelement activity with individual enzymes such as huA3F able to 
deaminate targets as diverse as HIV-1 (Wiegand et al. 2004), AluI, a 
transposable element present in multiple copies in the human genome 
(Muckenfuss et al. 2006), Ty1, a yeast transposable element (Schumacher et al. 
2005) and hepadnavirus hepatitis B virus (Rosler et al. 2005), all of whose 
lifecycles involve RNA intermediates. This suggests conserved mechanisms for 
interaction and deamination of target nucleic acids.  
1.7.5 The role of Vif in overcoming APOBEC3G and 3F restriction 
HIV-1 viral infectivity factor (Vif) is a small accessory protein of 23kDa which 
allows the virus to replicate almost unaffected by the presence of huA3G and 
huA3F. Vif acts to decrease the levels of huA3G and huA3F protein levels 
dramatically in T-cells, reducing the half-life of APOBECs from hours to as little 
as 5 minutes (Stopak et al. 2003; Marin et al. 2003; Marin et al. 2003; 
Conticello et al. 2003). Crucial to this activity are three interactions made by 
Vif: 1) the Vif motif SLQ(Y/F)LA which resembles mammalian BC-box domain 




present in SOCS-box proteins and recruits the cellular factor elongin C, an E3 
ubiquitin ligase (Mehle et al. 2004b; Yu et al. 2003) 2) a non-canonical zinc-
coordinating HCCH motif which interacts with cullin5 (Yu et al. 2004c; Mehle et 
al. 2004a) and 3) the N-terminal YRHHY and DRMR domains that interact with 
huA3G and huA3F respectively (Russell and Pathak 2007). The interactions 
result in the recruitment of a ubiquitylation complex comprising 
Vif/elonginC/elonginB/APOBEC3/cullin5/Rbx1 that polyubiquitylates the target 
APOBEC and induces proteasome-mediated destruction (Marin et al. 2003; 
Sheehy et al. 2003; Yu et al. 2003).  
Vif proteins exhibit a certain level of species specificity. For example, Vif from 
HIV-1 is unable to counteract the A3G from African green monkeys (agmA3G). 
This specificity was found to map to the Vif-A3G interaction site: in huA3G, 
128DPD130 is responsible for the interaction with Vif DRMR motif whilst in 
agmA3G, a D128K substitution allows the APOBEC to escape Vif-mediated 
destruction (Bogerd et al. 2004; Mangeat et al. 2004). However, SIVagm 
overcomes this mutation as its Vif is able to bind agmA3G and mark it for 
proteasome destruction. Thus the site of interaction between Vif and APOBEC 
represents a potential arms-race battle ground in the host-virus relationship.  
1.7.6 Positive selection of APOBECs 
In a similar manner to TRIM5α, primate APOBEC3 genes have been exposed to 
periods of intense positive selection over the past 33 mya, indicating the 
importance of these genes in protecting against retroviral infection (Sawyer et 
al. 2004; OhAinle et al. 2006). Residues under positive selection in A3G map to 
the catalytic domain, pseudocatalytic domain and to the Vif-interacting 
domain, but evidence of ancient adaptive selection is also found outside these 
regions (Sawyer et al. 2004). This is interpreted as the results of previous 
antagonistic host-virus relationships with now-extinct retroviruses. However 




the targets of previous episodes of positive selection are unknown and are 
likely to be extinct, save for any sequences remaining as endogenised 
genomes. Interestingly, a human endogenous retrovirus, HERV-K, was found to 
be targeted by huA3F, and to a lesser extent huA3G, but not by any TRIM5α 
orthologues examined (Lee and Bieniasz 2007). High expression of A3 is found 
not only in T-lymphocytes, the target of current lentiviral infections, but also 
in testis and ovary tissue, organs that must be infected by endogenous 
retroviruses in order to ensure their propagation (Jarmuz et al. 2002; Sheehy 
et al. 2002). Thus it seems likely that the APOBEC family targets both 
horizontally-transmitted and endogenous retroviruses, and the diverse nature 
of the targets goes some way to explaining the maintenance of multiple A3 
gene copies. 
1.7.7 An expanded cluster of feline APOBEC3 genes 
Recently an analysis of feline APOBECs in the nascent cat genome located the 
genomic positions of APOBEC1, 2, 3 and 4 (Munk et al. 2008). Interestingly, 
four APOBEC3 genes were found in an expanded cluster on domestic cat 
chromosome B4, comprising three copies of APOBEC3C (feA3Ca, feA3Cb and 
feA3Cc) and one copy of APOBEC3H. All the feline A3 genes identified possess a 
single catalytic domain. Comparisons with other felids revealed that the 
duplications of feA3C occurred in two successive events, one duplication of the 
ancestral feA3C which generated feA3Cc took place after the divergence of the 
Felis and Panthera lineages about 10.8 mya and a subsequent duplication of 
the same ancestral gene generating feA3Ca and feA3Cb took place after the 
divergence with pumas about 6.7 mya (Johnson et al. 2006; Munk et al. 2008). 
Of particular interest was the finding that the A3C locus underwent 
independent duplication events in other lineages: in the Panthera lineage a 
duplication gave rise to two A3C genes in the modern lion (liA3C1 and liA3C2) 




and in lynxes, three duplications gave rise to four current A3C genes. Analysis 
of the felid A3C genes revealed strong positive selection, suggesting strong 
selection of new variants that confer benefits to the host, selection 
presumably imposed by pathogens. In contrast the A3H gene was present as a 
single copy in all felids examined and is not under positive selection, leading 
the authors to suggest its viral target may be an endogenous retrovirus. 
Interestingly a read-through transcript comprising components of feA3Ca, 3Cb 
and 3H, generating a two-domain protein was detected in domestic cats and 
was also found in lions, tigers, pumas and lynxes and referred to as 
APOBEC3CH. 
 
Figure 1-3 Representation of feline APOBEC3 genomic locus and transcripts. The 
feline APOBEC3 genes reside in a cluster extending ~30kb on domestic cat chromosome 
B4 (black line). Previously described transcripts (Munk et al. 2008) are represented by 
dashed grey lines. Readthrough transcript A3CH is also shown and incorporates exons 1-
3 from A3Ca, an exon 4 variant from A3Cb that lacks the terminal stop codon and exons 
2-5 of A3H.  
Munk et al. (2008) tested the antiviral activity of domestic cat APOBEC3 genes 
against feline retroviruses and found that while single-domain protein feA3C 
was able to restrict Feline Foamy Virus (FFV), none of the single domain 
proteins were active against FIV (Munk et al. 2008; Lochelt et al. 2005). In 
contrast, the two-domain A3CH potently inhibited infectious FIV virus 
production, suggesting that, like human A3G, two domains are required for 
virion packaging and deaminase activity.  




1.7.8 Vif of Feline Immunodeficiency Virus 
Like HIV, the FIV genome bears a vif gene but homology at the protein level is 
minimal save the BC-box SLQ(Y/F)LA motif. The presence of this motif suggests 
that like HIV-1, FIV recruits the elonginC ubiquitylation complex to induce 
degradation of A3. Conflicting data exist for the subcellular localisation of FIV 
Vif. Initially, it was reported Vif localises predominantly to the nucleus 
(Chatterji et al. 2000), unlike HIV Vif which localises to the cytoplasm 
(Goncalves et al. 1994). Furthermore, Vif was not detected in FIV particles, 
suggestive perhaps of an alternative mechanism of action. However, these data 
are potentially explained by problems in exogenous Vif expression as the 
protein has a high turnover and nuclear export of transcripts is inefficient for 
HIV-1 Vif (Nguyen et al. 2004). Indeed a further study has shown that a 
eukaryotic codon-optimised Vif derived from FIV-Oma (from Pallas cat) 
invariably and uniquely localises to the cytoplasm (Paul et al. 2007).  
1.8 Scope of this thesis 
This thesis compares the host and viral factors that affect replication and 
cross-species transmission of lentiviruses in domestic and non-domestic cats. 
Specific attention is paid to the domestic cat and African lion, as these species 
are thought to represent recent and ancient lentiviral infections respectively. 
It is anticipated that antagonistic relationships between host and virus will 
have promoted changes in lion factors that interact with viral proteins. In 
particular, attention is given to the restriction factors which, in primates, are 
under positive selection driven by retroviral infection, and the hypothesis that 
lentiviral restriction will be more potent in the lion is tested.  
• Chapter 3 explores recent findings that FIV strains with highly divergent 
env genes are present in wild African lion populations. The study finds 




that the diversity within env corresponds to alternative receptor usage 
with implications for the evolution and pathology of infection in this 
species.  
• Chapter 4 investigates the post-entry restriction factor TRIM5 in cats and 
finds that a mutation that ablates function is present in the felids. 
Further analysis reveals that the mutation is widespread amongst the 
Feliformia, dating the time of mutation to just after the Caniformia-
Feliformia split, with implications for cross-species transmission and 
control of lentiviral infection in the carnivores.  
• In Chapter 5, the lentiviral co-factor cyclophilin A is examined in the 
context of FIV replication. Tissue culture experiments and biophysical 
assays reveal the interaction is important for replication and occurs with 
a conserved binding affinity. Furthermore, a crystal structure is solved 
for FIV capsid and feline CypA, the first reported structures for both 
these proteins, and provides insight into the mechanism of the CA-CypA 
interaction.  
• Finally in Chapter 6, the ability of lentiviruses to infect domestic cat and 
lion cells is investigated and a post-entry block to replication in lion 
cells is described. Investigation of APOBEC3 genes from both species 
finds that these restriction factors are active in felids, particularly in 
lions. The study provides evidence that is in concordance with theories 
of host-virus antagonistic relationships and shows evidence that a lack of 
TRIM5α can be compensated for by other post-entry restriction 
mechanisms.  
 
 Chapter 2. Materials and Methods 
2.1 Molecular cloning  
2.1.1 Nucleic acid extraction and PCR 
Total RNA was prepared from domestic cat-derived cell lines CrFK and Mya-1 as 
well as non-domestic cat T-cells by homogenising 106 cells using QIAshredder 
Spin Columns (Qiagen, Crawley, UK) and extraction with RNeasy Mini Spin 
Columns (Qiagen) in a UV-treated laminar flow hood. RNA was eluted in RNase-
free water (Invitrogen, Paisley, UK) prior to quantification of RNA by 
spectroscopy at 260 nm and storage at -80 °C. First strand cDNA synthesis was 
performed using 1 µg RNA with an oligo d(T) primer and AffinityScript Reverse 
Transcriptase (Stratagene, Stockport, UK), according to the manufacturer’s 
instructions before downstream applications. DNA was prepared from tissue 
culture samples by harvesting from 106 cells with DNeasy Blood and Tissue kit 
(Qiagen). DNA extractions from non-domestic Feliform species used 50-100 mg 
brain tissue or 1 ml blood and were performed using the same kit using the 
appropriate protocol. All DNA preparations were eluted with EB buffer and 
stored at -20 °C.  
Polymerase chain reaction (PCR) was performed using Phusion HotStart 
(Finnzymes, Hitchin, UK) polymerase. Reactions were set up on ice in a PCR 




clean room UV-treated laminar flow hood. Reaction mix and cycling 
parameters were typically as per manufacturer’s instructions although 
optimisation of annealing temperature was occasionally necessary by 
performing multiple reactions as a gradient. Standard conditions were HF 
buffer 4 µl, dNTPs 200 µM each, primers 0.5 µM each, DMSO 3% v/v, 0.02 U/µl 
Phusion, 50-200 ng template DNA. For FIV-Ple B 458 env, Phusion proved 
unsuccessful and KOD HotStart (Novagen, Nottingham, UK) was used instead. 
Lyophilised primers were ordered from MWG Operon and were resuspended in 
sterile distilled water to a stock concentration of 100 pmol/µl and to working 
stock concentrations of 10 pmol/µl. Primers were stored at -20 °C. A list of 
primers used is displayed in Appendix 1 and buffers and solutions is displayed 
in Appendix 2. 
2.1.2 Cloning techniques 
For molecular cloning, PCR products were purified by running on a 0.8-1.5% 
agarose gel, made with TBE buffer. DNA bands were observed on a UV 
transilluminator and excised using a sterile scalpel. Gel extraction was 
performed using QIAquick Gel Extraction Minicolumns (Qiagen) and DNA was 
eluted in 35-50 µl EB. Purified PCR products and vectors were digested using 
restriction endonucleases at 1 U/µl at 37 °C for 1 hr 30 min in 20 μl reactions 
with the buffer recommended by the manufacturer (Invitrogen). Digested DNA 
was purified using QIAquick PCR purification kit (Qiagen) and ligated using T4 
DNA ligase at 1 U/µl at 15 °C overnight. DNA was transformed into DH5α 
chemically competent Escherichia coli (Invitrogen) using the heat shock 
protocol according to the manufacturer and plated onto agar plates bearing 
ampicillin or kanamycin at 50 μg/ml (Sigma-Aldrich, Dorset, UK). Colonies were 
picked and grown in 5 ml LB nutrient broth at 37 °C on an orbital shaker set to 
200 rpm. When cloning env genes, an incubation temperature of 30 °C was 




used to aid plasmid stability. Plasmid DNA was extracted from cultures using 
QIAprep Spin Miniprep kit (Qiagen) and digested as previous. Clones bearing 
inserts were identified by agarose gel electrophoresis and a large-scale DNA 
prep was performed by inoculating 500 ml LB flasks with bacterial clones. DNA 
was prepared from overnight cultures using PureLink HiPure Filter Plasmid 
Maxiprep Kit (Invitrogen). Pelleted DNA was resuspended in TE buffer and 
stored at 4 °C. Glycerol stocks of clones were made by diluting cultures to a 
final concentration 15% glycerol (v/v).  
2.1.3 Sequencing of DNA 
Chain termination sequencing reactions were set up in house using BigDye v1.1 
and thermally cycled according to manufacturer’s instructions (Applied 
Biosystems, Warrington, UK). Reactions were precipitated using 70% ethanol, 
resuspeded in 20 μl HiDi (Applied Biosystems) and ran on an ABI 7000 genetic 
analyser using the E80 protocol (Applied Biosystems). Sequence traces were 
analysed in DNA Dynamo (Blue Tractor Software, UK). 
2.1.4 FIV Envelopes 
FIV-Ple E Sangre env gene was PCR amplified using primers (LLV-E 5’ Sal and 
LLV-E 3’ Not) directed to published FIV-Ple subtype E 1027 sequence (Genbank 
FJ22537). Template cDNA was obtained from total cellular RNA of Mya-1 
infected with FIV-Ple E Sangre following first strand cDNA synthesis. FIV-Ple B 
458 env was amplified from viral supernatant pelleted in an SW28 
ultracentrifuge rotor at 28,000 rpm in a Beckman L8-70 ultracentrifuge. Viral 
membrane and protein cores were disrupted using 0.1% Triton X-100 PBS and 
RNA was extracted using RNeasy miniprep kit (Qiagen) and reverse transcribed 
as above. PCR amplification was performed using primers (LLV-B 5’ Sal and 
LLV-B 3’ Not) directed to published FIV-Ple B sequence (Genbank EU117991). 




Amplicons were cloned into eukaryotic expression vector VR1012 using SalI and 
NotI digestion sites. Cloned VR1012-env plasmids were used for the generation 
of HIV luciferase pseudotypes and were assayed onto target cells in 96 well 
plates as described below. 
2.1.5 CD134 and CXCR4 
Feline variants of CD134 and CXCR4 have been cloned and described previously 
(Shimojima et al. 2004; Willett et al. 1997b). Lion homologues of CD134 and 
CXCR4 were amplified from Angola-1 cDNA using primers directed to the feline 
homologues (feCD134 F, feCD134 R, feCXCR4 F and feCXCR4 R; Genbank 
accession numbers AB1288982 and U63558 respectively) and the products were 
cloned into pCR 2.1-TOPO vector (TOPO TA cloning kit, Invitrogen) and 
sequenced. Lion CXCR4 and CD134 sequences were deposited in Genbank with 
accession numbers EU915482 and EU915483 respectively. For expression in 
eukaryotic cells, fragments were then sub-cloned into pDONAI (Takara, Lonza 
Ltd, Wokingham, UK) using BamHI and SalI restriction sites. 
2.1.6 TRIM5 
Forward primers directed to conserved regions of the RBCC domain (Ts2, 
feT5fwd and Ts3) and reverse primers from non-variable regions within the 
B30.2 domain (Ts12, feT5rev and Ts16) were used in RT-PCR reactions using 
cDNA from domestic cat cell lines CrFK and Mya-1. Products were obtained for 
the Ts3-Ts12 and feT5fwd-feT5rev RT-PCR reactions. These amplicons were 
then sequenced and used to probe the nascent cat genome project database 
(Pontius and O'Brien 2007) using the NCBI BLAST tool (Altschul et al. 1990). The 
BLAST search returned sequences of whole genome shotgun (WGS) fragments 
bearing exact matches to exon 2 (GenBank accession number AANG01555594) 
and exon 8 (AANG01581224) that had been assembled to chromosome D1 of the 




cat genome. From these fragments, PCR primers directed to the 5’ end (wam4) 
and 3’ end (wam13) of the open reading frame were designed, and the full 
length product was sequenced. Cloning primers wam4e and wam13c were used 
to amplify RT-PCR products from Mya-1 template cDNA and the amplicon was 
cloned into expression vector CXCR using EcoRI and Csp45I to produce feCTCR. 
Correct insertion of feTRIM5 was verified by cycle sequencing. Rapid 
amplification of cDNA ends (RACE) was performed using 5’/3’ Second 
Generation RACE Kit (Roche) using cDNA from Mya-1 cells according to 
manufacturer’s instructions. A PCR-based mutagenesis strategy was employed 
to introduce a stop codon at proline 306 of huTRIM5α to generate huTRIM5 
P306STOP. Forward and reverse mutagenic primers (huT5stopF and 
shuT5stopR) were used with flanking CXCR specific primers (GT282 and GT283) 
in two individual reactions. The resulting products were mixed 1:1 and used as 
a template for a reaction using the flanking primers. The product was cloned 
into CXCR using EcoRI and Csp45I restriction sites. The sequence of feline 
TRIM5 was deposited in Genbank (Accession number: GQ183880). A separate 
TRIM5 exon 8 PCR was also used in order to screen other carnivore species for 
the sequence of the TRIM5 B30.2 domain. Degenerate primers (gex8 feT5 f and 
gex8T5 r) were designed that allowed amplification from genomic DNA from 
divergent carnivore species, cat and dog. Expected sizes of amplicon were 
525bp for dog and 536bp for cat and sequencing was performed directly from 
PCR products. 
2.1.7 Capsid and cyclophilin A 
N-terminal capsid domain (CAN) was amplified from a molecular clone of FIV-
Fca GL8 and from cDNA from Mya-1 cells infected with FIV-Ple B 458. The 
region amplified spans residues 136-273 of GL8 gag, and is analogous to the 
monomeric HIV-1 CA domain whose structure has been solved previously (Yoo 




et al. 1997). For FIV-Fca, the expressed protein has a molecular weight of 15 
kDa and is expressed with a C-terminal His tag, giving a total mass of 16.4 kDa. 
Primers used were G8 CAN5’ Nde, G8 CAN 3’Mlu, LLV CA 5’ Nde, and LLV CA 3’ 
Mlu. For putative feline cyclophilin A genes encoded by Genbank contigs 
AANG01610851 and AC235013, Mya-1 RNA was treated with DNase I on the 
Qiagen RNeasy column prior to elution as indicated by the manufacturer and 
subsequent amplification. Differentiation between the two sequences was 
performed by using alternative 5’ primers: feCypA R69 5’ amplifies the 
sequence present in AANG01610851, whilst feCypA C69 5’ amplifies the ORF 
present in Genbank: AC235013. 3’ primer for both sequences was feCypA R/C 
3'. Once the nature of the CypA expressed in T-cell was identified as 
AANG01610851, cDNA from Mya-1 and Angola-1 was used as a template for PCR 
using primers feCypA Nde 5’ and feCypA Mlu 3’. Fragments were cloned into 
prokaryotic expression vector pOPTH. 
2.1.8 APOBEC3 and vif 
Feline and lion APOBECs were amplified from cDNA derived from Mya-1 and 
Angola-1 T-cells respectively. Primers were based on published domestic cat 
sequences single domain proteins feA3H (EU109281; primers feA3H F and feA3H 
R) and feA3Ca (AY971954; primers feA3C F and feA3C R). For read-through 
transcripts, forward primer feA3C F was used in conjunction with feA3H R. The 
amplicons were cloned into VR1012 using SalI and NotI restriction sites 
introduced by the primers. FIV-Fca vif was cloned from a molecular clone of 
strain GL8 using primers GL8 Vif F and GL8 Vif R, whilst FIV-Ple vifs were 
cloned from proviral DNA isolated from infected Mya-1 cells. Primers used were 
LLV-E Vif F and LLV-E Vif R for FIV-Ple E and for FIV-Ple B, sufficient homology 
to the E strain was present to use the LLV-E Vif F forward primer with strain 




specific reverse primer LLV-B Vif R. Clones were sequenced as described 
above. 
2.2 Cells and viruses 
2.2.1 Adherent cells 
Adherent cell lines were grown in disposable plastic tissue culture dishes 
(Corning, Ewloe, UK) and maintained in Dulbecco's modification of Eagle's 
medium (DMEM; Invitrogen) supplemented with 10% foetal bovine serum, 2 mM 
glutamine, 0.11 mg/ml sodium pyruvate, 100 IU/ml penicillin, and 100 µg/ml 
streptomycin. Each cell line has certain growth characteristics and so were 
split when confluent rather than at a regular time point. When confluent, the 
monolayer was washed with PBS, and dissociated from the culture plate by 
incubation with 0.5-2ml 0.05% trypsin (Invitrogen) for a few seconds or minutes 
at 37°C. Trypsin activity was stopped by suspension in complete DMEM. Cells 
were then pelleted at 1000 rpm (~400 xg) in a benchtop centrifuge before 
resuspension in complete DMEM and seeding of new cultures at the required 
density. Where required, culture medium was supplemented by selection 
antibiotics G418 (400µg/ml; Invitrogen) or puromycin (1.25 µg/ml; Sigma 
Aldrich).  
2.2.2 Suspension cells  
Cells in suspension were cultured in RPMI 1640 medium (Invitrogen) 
supplemented with 10% foetal bovine serum, 2 mM glutamine, 0.11 mg/ml 
sodium pyruvate, 50 µM β-mercaptoethanol, 100 IU/ml penicillin, and 100 
µg/ml streptomycin. Cells were passaged by centrifugation at 1000 rpm and 
resuspension in complete RPMI at the required density. Selection antibiotics 
were used as for adherent cells. Cell lines frequently used in this study the 




canine lymphocytic leukaemia (CLL) and feline MCC lines (Cheney et al. 1990). 
CLL was generated by prolonged in vitro culture of leukaemic domestic dog 
PBMCs; the established line is CD3+ CD4− CD8− CD134−. When stably transduced 
with FIV primary receptor CD134, these cells can support replication of FIV to 
high titre (Willett et al. 2006a). MCC is a CD134− domestic cat cell line 
amenable to ectopic expression of CD134 variants to dissect the role of CD134 
on FIV entry (Willett et al. 2006a; Willett et al. 2006b). 
2.2.3 Primary T-cells 
Domestic cat primary T-cell line Mya-1 (Miyazawa et al. 1989) was cultured in 
RPMI 1640 medium supplemented as above. A source of interleukin-2 (IL-2) was 
provided by further supplementing the medium with previously frozen 
conditioned medium from a murine cell line (L2.3) transfected with a human 
IL-2 expression construct (1:50 dilution, equivalent to 100 U/ml of recombinant 
human IL-2; provided by T. Miyazawa). African lion, European wildcat, puma, 
tiger, Amur leopard and cheetah peripheral blood mononuclear cells (PBMCs) 
were cultured as above and T-cells were expanded by stimulation with 
concanavalin A (2µg/ml; Sigma Aldrich) periodically. Blood samples from which 
PBMCs were obtained were kindly provided by Sarah Cleaveland, University of 
Glasgow, UK and John Lewis, ALTA Amur Leopard Conservation. PBMCs were 
also expanded from a seronegative Angolan lion and were periodically frozen 
down to generate a large back stock and referred to as Angola-1. Lion samples 
were collected by Pieter Kat and Rodrigo Serra of the Investigacao Veterinaria 
Independente, Lisbon, Portugal. Cells were grown in a cyclical manner, with a 
blasting stage following ConA stimulation in which polarised T-cells were 
apparent. During this stage, cells were grown at high density in order to 
promote cell-cell interactions, but large clumps were broken up in order to 
prevent isolation from nutrients. Blasts were preferentially selected for by 




centrifugation at 800 rpm without brake, and resuspended in the same volume 
of medium. When a sufficient density of cells was obtained, cells were either 
split 1 in 2 or expanded to a larger tissue culture flask. During this phase, 
culture typically existed as single cell blasts until next ConA stimulation or in 
the case of Mya-1, sufficient density was obtained for clumping to 
recommence.  
Cell line Species Adherent or 
Suspension 
Reference 
3201 Cat S (Hardy, Jr. et al. 
1980) 
AH927 Cat  S Nelson-Rees, WA 
Angola-1 Lion S This study 
CLL Dog S (Willett et al. 2006a) 
CrFK Cat A (Crandell et al. 1973) 
HEK 293T Human A (Graham et al. 1977) 
HeLa Human A  
HT1080 Human A (Rasheed et al. 1974) 
MCC Cat S (Cheney et al. 1990) 
MDTF Mouse A (Lander and 
Chattopadhyay 1984) 
Mv1 Lu CCL 64 Mink A (Henderson et al. 
1974) 
Mya-1 Cat S (Miyazawa et al. 1989) 
NP2 Human A (Soda et al. 1999) 
TE671 Human A (Stratton et al. 1989) 
Table 2.A Cell lines used in this study 
 
2.2.4 Replication-competent FIV  
Supernatant containing clonal FIV was produced by transfection of 293T cells 
with full length FIV molecular clones using Superfect transfection reagent. 




Strains used in this study include Glasgow 8 (GL8), a field isolate from the UK 
(Hosie and Jarrett 1990), B2542, a clade B USA isolate (Diehl et al. 1995) and 
PPR, a clade A USA isolate from a cat in the symptomatic stage of infection 
(Phillips et al. 1990). Three days post-transfection, 293T cells were co-
cultivated with Mya-1 cells and FIV replication was monitored by p24 ELISA. 
293T cells were removed and infected cultures were expanded by addition of 
fresh Mya-1 cells. Supernatant was collected, filtered at 0.45µm and frozen in 
1ml aliquots at -80 °C until required.  
FIV-Ple was isolated from lion PBMCs prepared from whole blood of an FIV-
positive lion sampled in the Moremi reserve in Botswana (Sangre). Sangre was 
an eight-year old male lion in good health at the time of sampling and was 
previously confirmed as seropositive by western blot. In order to expand the 
viral stock from Sangre, concanavalin-A-stimulated PBMCs were co-cultivated 
with Mya-1 cells and confirmation of replication-competent virus was sought by 
reverse transcriptase assay (see 2.3.2). Aliquots of viral supernatant were 
stored and frozen at -80 °C for future use and infected cells were pelleted and 
harvested for total cellular RNA. 
2.2.5 Tissue culture infection with replication competent FIV  
Infections were performed by incubating target cells with viral inocula. For 
adherent lines, cells were seeded at low density (1x105 cells per well in a 6 
well plate) and left to adhere overnight. Standard conditions for suspension 
cells were: 1x106 Mya-1/primary PBMC or 5x105 CLL-CD134 in a 5 ml tube 
(Falcon). Cells were then incubated with viral inoculum (100-500µl) diluted 1 in 
2 with complete medium as appropriate at 37 °C for 3 hours. Cells were 
washed twice with PBS and resuspended in complete medium. Cell-free 
aliquots were taken periodically and frozen at -80 °C until required for viral 
quantification by p24 ELISA or reverse transcriptase assay. 




2.2.6 Drugs and inhibitors 
Inhibitors of cyclophilin, cyclosporine A (CsA; Sigma), NIM811 (a kind gift of 
Prof. Anthony Page, University of Glasgow) and Debio-025 (obtained from 
Debiopharm) were diluted to 5 mM working stock in ethanol or DMSO and 
stored at -20 °C until required. Toxicity was measured by incubating cell lines 
Mya-1 and CLL with CsA, NIM811 and Debio-025 at 2 µM for five days before 
enumerating live cells using a haemocytometer with Trypan blue (Invitrogen) 
dye exclusion as a marker for viability. The effect of the drugs on the 
replication of FIV in canine and feline cells was assayed by incubating 106 CLL 
or Mya-1 with FIV-Fca GL8 for three hours before washing twice with PBS and 
resuspension in 1 ml RPMI, supplemented with IL-2 in the case of Mya-1, with 
CypA inhibitors at 2 µM or an equivalent volume of solvent. 
Proteasome inhibitor MG132 (N-(benzyloxycarbonyl)leucinylleucinylleucinal) 
and As2O3 were obtained from Sigma. MG132 was prepared by dissolving in 
ethanol at a stock concentration of 1 mg/ml and stored at -20 °C. As2O3 was 
prepared as (Berthoux et al. 2003) by initially dissolving in 1 M NaCl before 
neutralisation with HCl to final pH 7.0. The solution was diluted further to a 
concentration of 1 mM with PBS, filter sterilised at 0.2 µm before storage at -
20 °C. 1 x 105 cells were incubated with MG132 or As2O3 for 3 hr before 
aspiration of the drug and washing with PBS. Cells were reseeded in 100 µl 
replete RPMI with IL-2 and challenged with pseudotype. 
AMD3100 (Donzella et al. 1998), a bicyclam inhibitor of the FIV Env-CXCR4 
interaction (Egberink et al. 1999; Richardson et al. 1999), was prepared for 
tissue culture by dissolving in PBS and filter sterilising at 0.2µm and stored at -
20 °C. Inhibition of Env-CD134 interaction was performed using trimeric sFc-
TNC-CD134L. The preparation and purification of this construct was performed 
previously (Willett et al. 2009). The construct consists of a haemagglutinin 




signal peptide, the hinge and Fc domain of human IgG1 (residues 104–330 of 
GenBank: P01857), a linker with sequence RSPQPQPKPQPKPEPEGSLH, the 
trimerisation domain of chicken tenascin-C (TNC), a linker with sequence 
GTGGGSGGRGLQ, and the extracellular domain (residues 52–183) of feline 
CD134L. The construct had previously been transfected into 293T cells using 
Superfect (Qiagen) by other lab members and supernatant harvested after 
three days and concentrated 10-fold using an Amicon 10kDa molecular weight 
cut off centrifuge spin-concentrator (Millipore) and stored at -80 °C before 
use. 
2.2.7 Stable transduction of cell lines 
In order to create cell lines stably expressing TRIM5, pseudotyped MLV 
infectious particles were produced by transfecting HEK293T cells with plasmids 
CMVi, a cytomegalovirus promoter-driven MLV gag-pol expression vector, pMDG 
bearing pantropic vesicular stomatitis virus G-glycoprotein (VSV-G) envelope 
and CTCR which encodes a dsRed reporter gene (Clontech, Wokingham, UK) 
and the desired TRIM5 under the control of the cytomegalovirus promoter as 
previously described (Besnier et al. 2002), except that Superfect (Qiagen) 
transfection agent was used according to manufacturer’s instruction. 
Supernatant was harvested 3 days post-transfection, filtered at 0.45µm and 
used to transduce target cell lines plated at 5x104 cells per well in 6-well 
plates. Successful transduction was confirmed by enumerating RFP-expressing 
cells on a Beckman Coulter EPICS MCS-XL flow cytometer. Data were analyzed 
using EXPO 32 ADC Analysis (Advanced Cytometry Systems). 
Lion CXCR4 was expressed as a fusion protein with enhanced green fluorescent 
protein as has previously been described for feCXCR4 (Willett et al. 2002). For 
stable dual expression of CXCR4 and CD134 in the NP2 cell line, cells were first 
transduced with pDONAI vectors bearing lion or domestic cat CXCR4-eGFP 




fusion proteins and stable transductants were transduced again with lion or 
domestic cat CD134 and immuno-enriched by staining firstly with 7D6 anti-
feline CD134 (AbD Serotec, Oxford, U.K.) then goat-anti-mouse IgG-coated 
microbeads (Miltenyi Biotec Ltd., Bisley, U.K.) followed by enrichment on MS 
columns using an OctoMACS™ separator (Miltenyi Biotec Ltd.). Eluted cells were 
maintained in G418 supplemented medium and expanded in culture for use in 
pseudotype infection assays. 
2.2.8 Pseudotype production 
Retroviral particles capable of single round infection, which deliver a marker 
gene to the target cell, were used to analyse viral and cellular determinants of 
infection. The constructs allow the generation of retrovirus particles that bear 
reporter genes that allow the efficiency of transduction to be assayed. 
Pseudotypes in this study bore either luciferase (luc) or green fluorescent 
protein (GFP) and transduction was quantified using alternative techniques. 
The use of vesicular stomatitis virus G-glycoprotein (VSV-G) allows efficient 
entry to mammalian cells and obviates the effects of differential expression of 
receptors. Pseudotypes are denoted VIRUS-reporter(ENVELOPE). For example 
HIV-luc(FIV) indicates an HIV particle, bearing a luciferase gene, pseudotyped 
with FIV Env.  
HIV-luc(FIV) vectors were prepared in HEK293T cells by two-plasmid co-
transfection. The day before transfection, 4x106 293T cells were seeded in 10 
cm poly D-lysine coated plates (BD). To transfect, 10 µl Superfect transfection 
reagent (Qiagen) was mixed with 7.5 µg pNL4-3-Luc-E−R−, an HIV-1 NL4-3 
strain-based vector with firefly luciferase inserted into the nef gene and 
defective env and vpr genes (Connor et al. 1995), and 7.5 µg VR1012-env, a 
mammalian expression plasmid bearing FIV env in 300 µl serum-free DMEM. 
Complexes were allowed to form at room temperature for 15 minutes before 




addition of 3 ml complete DMEM and incubation on 293T cells at 37 °C for 3 
hours. Cells were then washed with PBS to reduce toxic effect and prevent any 
transfection complexes affecting downstream procedures. 10 ml fresh, 
complete DMEM was added to cells and supernatant was harvested after 72 
hours incubation at 37 °C. Supernatant was filtered at 0.45µm, aliquoted and 
frozen at -80 °C.  
For other retroviral vectors, a three-plasmid co-transfection protocol was used. 
Plasmids expressing a gag-pol, a viral vector and pMDG were transfected into 
293T cells at a ratio of 1:1:1 (5 µg each). The protocol follows that of (Besnier 
et al. 2002) except that Superfect (Qiagen) was usually used instead of Fugene-
6, as higher titres were given by the former. Plasmids used for production of 
VSV-G pseudotyped N- and B-tropic MLV, HIV-1, HIV-2, SIVmac and FIV are 
given in Table 2.B. Supernatant was collected after three days, filtered at 
0.45µm and stored at -80 °C. When produced in the presence of drugs, NIM811 
and cyclosporine A, pseudotypes were pelleted in a Beckman ultracentrifuge in 
an SW40 rotor over a 2 ml 20% sucrose cushion to remove drugs. The pellet was 






Function Reporter  Reference 
pCIG3N MLV-N gag-pol  (Bock et al. 2000) 
pCIG3B MLV-B gag-pol  “ 
CNCG MLV packaged sequence GFP “ 
CNCR MLV packaged sequence dsRed “ 
p8.91 HIV-1 gag-pol (∆Vif)  (Naldini et al. 1996) 




p8.2 HIV-1 gag-pol (+Vif)  “ 
SIN CSGW HIV-1 packaged sequence GFP “ 
SIN CSRW HIV-1 packaged sequence dsRed “ 
pNL4-3-
Luc-E−R− 
HIV-1 gag-pol and 
packaged sequence 
luciferase (Connor et al. 
1995) 
SIV4+ SIV mac gag-pol (∆Vif)  (Negre et al. 2000) 
SIV3+ SIVmac gag-pol (+Vif)  “ 
SIV eGFP SIV mac packaged sequence GFP “ 
pSVR∆NBDM HIV-2 gag-pol  (Griffin et al. 2001) 
pSVR∆NB-
GFP-∆H 
HIV-2 packaged sequence “ 
FP93 FIV gag-pol  (Poeschla et al. 
1998) 
GinSin FIV packaged sequence GFP “ 
pMDG VSV envelope  (Yee et al. 1994) 
Table 2.B Plasmids used for pseudotype production. Packaged sequence denotes 
plasmids that encode an RNA genome that is packaged within pseudotypes. 
2.2.9 Pseudotype assay 
For luciferase reporter gene assays, 5x104 target cells were seeded in 50 µl 
complete medium in a CulturPlate-96 assay plate (Perkin-Elmer, Waltham, MA, 
USA). For adherent cell lines, the cells were allowed to settle overnight whilst 
suspension cells were used immediately. 50µl supernatant containing the 
pseudotype was added to wells and each condition was repeated in triplicate. 
Expression of luciferase was quantified after 48-72 hours by addition of 100µl 




Steadylite HTS luciferase substrate (Perkin-Elmer) and measurement by single 
photon counting on a MicroBeta luminometer (Perkin-Elmer).  
When using GFP or dsRed reporter genes, target cells were seeded at 1x105 
cells per well in a 6 well plate and allowed to adhere overnight. Supernatant 
was thawed and titrated onto target cells in the presence of hexadimethrine 
bromide (polybrene; Sigma Aldrich) dissolved in PBS at 5 µg/ml. After 48-72 hr, 
GFP expressing cells were harvested and pelleted in 5 ml flow cytometry tubes 
(Falcon). Cells were resuspended in 0.5-1 ml PBA buffer and kept on ice. GFP-
positive cells were enumerated by observing 10,000 events on a Beckman 
Coulter EPICS MCS-XL flow cytometer. Gates were adjusted so that negative 
control untransduced cells gave 0% infection. Data were analyzed using EXPO 
32 ADC Analysis (Advanced Cytometry Systems). Where necessary, multiplicity 
of infection (moi) was subsequently calculated using the formula moi = -lnP[0] 
where P[0] is the proportion of uninfected cells. 
A modified protocol was employed for the production of FIV-GFP(VSV) 
pseudotypes in the presence of APOBEC proteins. 293T cells were plated at 2 x 
105 cells per well in a 24 well plate and allowed to adhere overnight at 37 °C in 
500 µl replete medium. The next day, transfections were performed using 
Superfect (Qiagen) transfection reagent with a modified protocol. 0.3 µg each 
of pMDG, GinSin, FP93, 0.5 µg VR1012-A3 and, where indicated, 0.5 µg VR1012-
Vif or empty vector were mixed in 20µl serum free DMEM before addition of 2 
µl Superfect. Transfection complexes were allowed to form for 15 minutes 
before the addition of 50 µl replete DMEM and dropwise addition to the 293T 
cells. Medium was not changed after this stage. Supernatant was collected 
three days post transfection and centrifuged at 5,000 xg to remove cellular 
debris. The titre of infectious virus was assayed by plating onto 293T or CrFK 




cells in the presence of polybrene (5 µg/ml) and GFP expression monitored 
after three days by flow cytometry. 
2.2.10 RNA interference 
Small hairpin (sh) RNAs against domestic cat TRIM5 were designed using shRNA 
Sequence Designer (Clontech). The chosen target sequences for constructs 
feT5sh1 and feT5sh2 were GCATCACTGCAAAGACCAA and 
CTGTAAGACGGATGGGAAG respectively, or a firefly luciferase sequence for 
shLuc negative control. Top and bottom strand 60bp oligonucleotides were 
designed using Clontech online shRNA Sequence Designer and synthesised by 
Eurofins MWG Operon. Nucleotides were annealed by heating to 95 °C and 
cooling slowly to room temperature. Annealed oligonucleotides were cloned 
into pSIREN Retro-Q (Clontech) using BamHI and EcoRI restriction sites 
according to manufacturer’s instructions. Infectious MLV particles were 
generated by co-transfecting pSIREN Retro-Q feT5sh1, feT5sh2 or shLuc with 
CMVi and pMDG as above. Supernatant was used to transduce CrFK cells 
expressing feline CD134 (Shimojima et al. 2004), which were exposed to 
puromycin selection 2 days post transduction. Knockdown of endogenous TRIM5 
in these cells was monitored by RT-PCR on serial dilutions of cDNA using 
primers wam4 and wam13c. RNA was prepared and reverse transcribed as 
above using 1µg total RNA isolated from 106 cells. Reaction conditions were 98 
°C 60s, then 30 cycles of 98 °C 10s, 67 °C 30s, 72 °C 30s then 72 °C 2mins on 
1µl target cDNA with Phusion High-Fidelity DNA Polymerase (New England 
Biolabs), using the reaction components described above (Section 2.1.1). 
Agarose gel electrophoresis images were scanned using an Epson 3200 
Perfection flat-bed scanner; contrast and brightness were adjusted in Adobe 
Photoshop. 




2.3 Quantitative techniques and immunoloblotting  
2.3.1 p24 ELISA 
For monitoring the levels of infection in replication-competent FIV assays, cell-
free supernatant from infected cells was collected periodically and stored in a 
96 well plate at -80 °C until required. Viral replication was measured by 
enzyme-linked immunosorbent assay (ELISA) of FIV p24 ELISA by coating 
immunoabsorbant 96-well plates (Greiner Bio One, Stonehouse, UK) with 100µl 
anti-p24 antibody vpg-62 diluted 1 in 500 with serum free DMEM and incubated 
at 4 °C overnight. Plates were blocked with 125µl 2% milk powder (ASDA) 
dissolved in PBS for 2h before washing with 0.2% Triton X-100 PBS. 
Alternatively pre-coated ELISA plates (Pet-check anti-FIV IDEXX, Chalfont St 
Peter, UK) were used. Antigen capture was performed using 100µl thawed cell 
culture supernatant with 10µl 0.5% Triton X-100 dissolved in PBS to release 
viral cores at room temperature for 30min. Plates were washed with ELISA 
wash buffer according to manufacturer’s instructions and 100µl anti-FIV HRPO 
conjugate Ab (IDEXX) was added before development with HRPO substrate 
(IDEXX). Plates were read on an Ascent Multiscan plate reader (Labsystems) at 
450nm. 
2.3.2 Quantification of reverse transcriptase activity 
In cases when p24 ELISA was not appropriate, for example when monitoring 
non-domestic cat strains of FIV for which no commercial antibodies are 
available, reverse transcription activity was assayed using a Lenti-RT 
nonisotopic RT assay kit (Cavidi Technology, Uppsala, Sweden). The technique 
uses sample dilution buffer (SDB) to release RT which is quantified by its ability 
to reverse transcribe a poly(rA) template using an oligo(dT) primer and 
incorporation of nucleotide analogue, 5-bromo-deoxyuridine-5′-triphosphate 




(BrdUTP) during incubation at 33 °C. The reaction is stopped by washing in 
ELISA wash buffer or with wash buffer supplied with the kit and BrdU levels 
quantitated using an anti-BrdU Ab and chromogenic detection by alkaline 
phosphate-conjugated secondary Ab using para-nitrophenyl phosphate 
substrate followed by reading on an Ascent Multiscan plate reader at 405 nm. 
2.3.3 Real-time PCR 
TRIM5 knockdown was quantified using real-time PCR with primers feT5 
TaqMan 5’ and feT5 TaqMan 3’ and fluorescently-labelled feT5 Probe 5’ 3’. 
RNA was prepared from CrFKs or CrFKs transduced with feT5sh1 and feT5sh2 
and 2µg was used in reverse transcription using Roche High Fidelity 
Transcriptor with an oligo d(T) primer in a 20 µl reaction according to 
manufacturer’s instructions. 2 µl of the resulting cDNA was mixed with primer 
at 0.24 pM and probe at 0.12 pM and was used in a reaction with 2x Universal 
TaqMan Mastermix (Applied Biosystems) in a 50 µl reaction. Cycling conditions 
were 95 °C 5 min, followed by 40 cycles of 95 °C 15s, 55 °C 60s on an ABI 7500 
thermal cycler (Applied Biosystems). Data were analysed using Sequence 
Detection Software v1.4 (Applied Biosystems). 
2.3.4 SDS-PAGE & Immunoblotting 
For the analysis of seroprevalence in wild lions, FIV-Ple 458-infected Mya-1 
supernatant was filtered at 0.45 µm and virus was pelleted in an SW28 
ultracentrifuge rotor (Beckman, UK) at 28,000 rpm. The viral pellet was 
resuspended in SDS loading buffer. For Ranbp2 western blot, 1,000 293T cells 
were lysed directly with SDS-PAGE loading buffer. Proteins were boiled for 5 
min before being run on Tris-Acetate minigels (Invitrogen). Antigens were 
transferred to nitrocellulose membrane using rapid dry blotting system (iBlot, 
Invitrogen) and blotted overnight in Western Blocking Buffer. Antigens were 




detected using lion sera from either field isolates or pooled sera from FIV-
seronegative or seropositive domestic cats. For Ranbp2, a rabbit monoclonal 
Ab was used (AbCam ab2938) at 1:1000 dilution. Bound antibody was detected 
using biotinylated goat anti-cat IgG for FIV-Ple antigens or anti-rabbit IgG for 
Ranbp2 (Vector laboratories) followed by chromogenic development by the 
Vectastain® ABC system (Avidin: Biotinylated enzyme Complex) and 5-bromo-4-
chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT) substrate.  
2.3.5 Far western blot 
For far western blotting (also known as overlay assay), HeLa and CrFK cell 
lysates were fractionated by incubation with CHAPS lysis buffer on ice for 10 
min to lyse cell membranes before centrifugation in a benchtop centrifuge for 
10 min at 13k rpm (~16,000 xg). Supernatant (cytoplasmic extract) was 
removed and diluted in 2x SDS-PAGE loading buffer. The pellets (nuclei) were 
resuspended by dropwise addition of 1x SDS-PAGE loading buffer without 
bromophenol blue, with vigourous vortexing after the addition of each drop, 
before dilution in 2x SDS-PAGE buffer corrected for levels of bromophenol 
blue. For 293T cells, 1,000 cells were lysed directly with 1x SDS-PAGE loading 
buffer. Proteins were subjected to SDS-PAGE and transferred to nitrocellulose 
membranes as above and incubated overnight in FW blocking buffer at 4 °C in 
the absence of harsh detergent to promote protein refolding. Far western 
protocol follows (Einarson et al. 2007), but uses immunodetection in place of 
autoradiography. 30-90 µg recombinant CA or CAN was diluted in FW interaction 
buffer and allowed to bind at 4 °C with gentle shaking. The membranes were 
washed three times for 10 min each with FW wash buffer 1 before a final wash 
with FW wash buffer 2. A western blot for capsid was then performed using a 
mixture of monoclonal mouse anti-FIV CA antibodies AE11, DF3 and DF10 
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2.4 Biophysical and structural techniques
2.4.1 Recombinant protein purification 
Expression, purification and biophysical techniques were performed at the MRC 
Laboratory of Molecular Biology, Cambridge in collaborat
with guidance from Amanda Price. His
coli cultures grown in TY broth at 37 °C by induction with 0.1 mM IPTG. Cells 
were lysed on ice with Bug Buster (Novagen) with 3 min sonication and proteins 
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Protein was eluted by increasing salt concentration, using 10% buffer B (75mM 
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Figure 2-2 Gel filtration of recombinant proteins.
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Figure 2-3 Ion exchange chromatography for FIV
increasing the proportion of buffer B. Lanes 1
B, whilst the final fraction,
was repeated for all capsid variants and mutants. Pure proteins were pooled, concentrated 
and snap-frozen before further use.
2.4.2 Isothermal Titration Calorimetry
ITC is a technique that measures the ch
interaction of two molecular species 
1999). The apparatus consists of a reference cell and a reaction cell pre
with one of the interacting samples (species A) into which species B is 
repeatedly injected. Changes in enthalpy in the reaction cell associated 
each injection of B produce a change in the power supplied to the reference 
cell in order to keep the temperature in the cells the same. Thus, the raw data 
produced from each experiment is a time
in µcal/s, with neg
the first few injections of species B will result in all B being bound, giving 
several large spikes. As 
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subsequent injections will result in smaller changes in enthalpy until no binding 
is observed. Integration of the spikes allows the calculation of the total change 
in heat for each injection and curve fitting, along with accurate measurements 
of the concentrations of the species, allows the calculation of molar 
stoichiometry (N), dissociation constant (Kd) and the molar change in enthalpy 
(∆H). The dissociation constant, Kd, is a measure of the strength of interaction 
and has a value in molar concentration that corresponds to the concentration 
at which half of the binding sites are occupied, so that lower values represent 
stronger binding. ∆H has a value in cal/mol, reflecting the change in heat 
associated with one mole of interactant binding its ligand. The change in heat 
reflects the preference of the ligand for its binding partner over the solvent, 
with negative values indicating enthalpically favoured interactions. In the 
context of protein-protein interactions, hydrogen-bonding, burial of 
hydrophobic solvent-exposed surfaces and Van der Waals can all contribute to 
the ∆H.  
For the experiments in this study an ITC200 (MicroCal) machine was used, 
previously calibrated with EDTA CaCl2 according to manufacturer’s 
instructions. Cell and syringe samples were dialysed overnight at 4 °C into the 
same beaker of potassium phosphate buffer (20 mM KxHxPO4, 20 mM NaCl, 5 
mM β-mercaptoethanol, pH 7.0). Proteins were then diluted to 600 µM for 
syringe sample and 60 µM for cell sample and re-quantified by measuring 
absorbance at 280 nm. ITC was performed at 10 °C. 
2.4.3 X-ray crystallography 
Initial crystal screens varying in buffer constitution were performed in 200 nl 
droplets comprising 100 nl protein and 100 nl reservoir buffer in sitting drop 
vapour diffusion 96-well plates. Reservoir buffers and protein were dispensed 
by Screenmaker 96+8 robot (Innovadyne). Proteins were at a typical 
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were found to consist of single protein species. Data were collected on a 
Rigaku rotating anode X-ray set with Mar research image plate and solved by 
Dr. Leo James. Figures were generated by manipulation of pdb files in PyMol. 
Superimposition of structures was performed using EBI DaliLite server 
(http://www.ebi.ac.uk/DaliLite) and aligned pdb files were viewed in PyMol. 
2.5 In silico techniques 
2.5.1 Phylogenetic analysis 
Amino acid sequences of full length TRIM open reading frames and viral FIV-Ple 
E Sangre, FIV-Ple B 1027 and FIV-Fca GL8 sequences were aligned using Clustal 
W (Thompson et al. 1994) with manual adjustment in Bioedit (Hall 1999). env 
and gag alignments were created using multiple alignments of FIV sequences 
available in Genbank. The codon-optimised nucleic acid sequences were used 
to construct trees using the Neighbour-Joining method in Mega 4.0 software 
(Tamura et al. 2007; Saitou and Nei 1987) with 1000 replicates to allow 
calculation of bootstrap values. The evolutionary distances were computed 
using the Maximum Composite Likelihood method (Tamura et al. 2004) and are 
in the units of the number of base substitutions per site. All positions 
containing gaps and missing data were eliminated from the dataset, meaning 
for TRIM5 that only the RBCC domain was used in the analysis. For viral 
sequences, almost identical trees were obtained using Maximum Likelihood 
method (not shown), suggesting that the trees shown represent a robust fit. N-
linked glycosylation sites were predicted using NetNGlyc online tool 
(http://www.cbs.dtu.dk/services/NetNGlyc) to locate NX(S/T) motifs, where X 
is any amino acid except proline. Routine manipulation of sequences, primer 
design and analysis of sequencing runs was performed with DNADynamo 
(BlueTractor Software). 




2.5.2 Graphs and statistics 
All graphs were drawn with SigmaPlot 8.0 and, where shown, error bars 
represent the standard error. Unpaired two-tailed student’s t-tests were 
performed using the same software. 
2.5.3 Homology modelling 
Templates for a homology model of feline A3H were sought using HHpred 
software (Soding et al. 2005) to identify the human A2 (2NYT; Prochnow et al. 
2007) and A3G CD2 (3E1U; Holden et al. 2008) structures as sharing the highest 
degree of homology with the query protein. Conservation of secondary 
structures was confirmed using the Ali2D software on the Max Planck 
Bioinformatics Server (http://toolkit.tuebingen.mpg.de), which predicted a 
shared secondary structure with A3G CD2. Subsequently, MODELLER 9v3 (Eswar 
et al. 2007) was used to create a 3-dimensional model of feline A3H using both 
A2 and A3G CD2 crystal structures as templates. For feline CD134, the crystal 
structure of the human homologue (2HEY; Compaan and Hymowitz 2006) was 
used as a template. Predicted structures were superimposed on A3G CD2 
crystal structure using Dailite and structures were viewed in PyMol.
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immunodeficiency virus isolates from African 
lions. 
3.1 Summary 
The feline immunodeficiency virus (FIV) is a major pathogen of domestic cats 
but also infects non-domestic species including the African lion (Panthera leo). 
Recent analysis of the proviral genome of two African lion FIV (FIV-Ple) field 
isolates belonging to subtypes B and E suggests that the env open reading 
frame of the E subtype shares greater homology with FIV strains that infect 
domestic cats (FIV-Fca) than to other strains of FIV-Ple (Pecon-Slattery et al. 
2008a). In this study we ask whether this shared identity between FIV-Fca and 
FIV-Ple E corresponds with shared receptor tropism. Despite only 53% amino 
acid identity in Env SU, FIV-Ple E is found to share use of CD134 as the primary 
receptor for attachment. Furthermore, infection by FIV-Ple E is also CXCR4-
dependent and can be inhibited by CXCR4 antagonist AMD3100 and soluble 
trimeric CD134-ligand. We also confirm previous studies which have suggested 
that FIV-Ple B uses an alternative entry receptor (Smirnova et al. 2005; Willett 
et al. 2006a): productive infections of the B subtype could be established in 
CD134 negative lines, whilst replication of the E subtype was dependent on 
ectopic expression of feline CD134. The shared usage of CD134 and CXCR4 in 
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FIV-Fca and FIV-Ple E suggests that a relative of FIV-Fca has recombined with 
African lion strains of FIV, preserving its use of receptor. The findings give an 
indication of the in vivo cell tropism of FIV-Ple E and have implications for 
future research into the pathogenicity of FIV in wild lion populations.  
3.2 Results 
In the light of findings that lentiviruses with divergent env genes circulate in 
African lion populations (Pecon-Slattery et al. 2008a), it was attempted to 
assess whether diversity between FIV-Ple subtypes B and E extended to 
alternative receptor usage.  
3.2.1 Sera from wild lions show immunoreactivity to FIV-Ple 
A representative of FIV-Ple subtype B was available (FIV-Ple B 458), but not a 
subtype E virus. A panel of lion sera was therefore obtained from wild lions in 
the Moremi reserve in the Okavango Delta, and screened for seroreactivity to 
viral antigens. Proteins of pelleted FIV-Ple 458 (B subtype) were run on an SDS-
PAGE gel, transferred to a nitrocellulose membrane and blotted using the sera 
of 27 wild lions (Figure 3-1). As controls, pooled sera from uninfected and FIV-
Fca-infected cats were also included in the assay. Immunoreactivity to the 
principal determinant p24 is found in 24 of the 27 serum isolates (89%), in line 
with previous estimates of populations east of the Kalahari desert (Kalahari 
game reserve 71% positive (Ramsauer et al. 2007); Okavango Delta 96% (Roelke 
et al. 2009); Serengeti ~100% positive (Brown et al. 1994)). Unlike typical 
immune responses to FIV-Fca and HIV-1, previous studies have found only 
immunoreactivity in FIV-Ple infections to the proteins derived from the Gag 
polyprotein. Here we find evidence of a humoral response to Env in 13 out of 
24 (54%) of the seropositive lions. The specificity of the immunoreactivity to 
Env is revealed by the fact that serum from an infected domestic cat does not 
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Sangre by RT-PCR and the amplicon was cloned into VR1012 using SalI and NotI 
digestion sites. The Env of FIV-Ple B 458 (Brown et al. 1994) was also cloned 
and used as a representative of FIV-Ple B subtype. Analysis of the sequences 
reveals that FIV-Ple E Sangre shares 88% amino acid identity with the FIV-Ple E 
1027 isolate used for the genomic sequence of FIV-Ple E subtype (Pecon-
Slattery et al. 2008a) and 53% identity with FIV-Fca GL8. A Neighbour-Joining 
tree was constructed by aligning the entire gag and env genes from several 
published FIV isolates available in the NCBI GenBank (Figure 3-2). In a similar 
finding to (Pecon-Slattery et al. 2008a), phylogenetic relationships for the two 
genes show substantial differences, suggesting alternative evolutionary 
histories for the gag and env genes, and highlighting the relevance of inter-
genomic recombination events in the evolution of FIV. The env gene of the 
virus isolated from Sangre is found to cluster closely with FIV-Ple E 1027 (E 
subtype), and distally from other FIV-Ple strains B and C, confirming its 
identity as a subtype E virus. More widely, the env gene phylogeny forms two 
distinct groupings: those related to the puma group, including FIV-Ple B and 
FIV-Oma and those related to the domestic cat group, including both FIV-Ple E 
1027 and FIV-Ple E Sangre.   
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Figure 3-2 Phylogenies of FIV gag and env reveal contrasting evolutionary 
relationships. Neighbour-Joining trees were constructed using full coding regions of 
published FIV sequences available in Genbank as well as FIV-Ple E Sangre env, with 
bootstrap of 1000 iterations. When phylogenetic analysis is performed using the gag 
gene, the tree bears four discernable groups: the puma, domestic cat, lion/Pallas cat and 
outlier FIV-Pco 14. In contrast, when a tree is drawn with env, FIV-Ple E groups with 
FIV-Fca, whilst FIV-Oma and FIV-Ple B 458 (EU117991) form a monophyletic group 
and bear more similarity to FIV-Pco. FIV-Ple E Sangre clusters closely with published 
FIV-Ple E 1027 (EU117992), confirming its identity as a lion clade E virus. 
Alignment of FIV-Ple E Sangre, FIV-Ple B 458 and FIV-Fca GL8 Envs (Figure 3-3) 
reveals that FIV-Ple E Sangre is a chimeric env, bearing homology with FIV-Ple 
B 458 in the N-terminus of SU and the C-terminus of TM. The central region 
more closely resembles FIV-Fca GL8, with 58% identity in this region, compared 
to 33% in the FIV-Ple B 458 homology region. Furthermore, the FIV-Ple strains 
share an 82 residue N-terminal sequence not present in the domestic cat 
strains. The functional significance of this is unknown but may represent extra 
signal peptide/leader sequence. Several other important structural features 
are also conserved between FIV-Fca and FIV-Ple E Sangre including all 7 
predicted disulphide bonds of GL8 and 17 out of 18 predicted N-linked 
glycosylation sites. The ES(E/D) motif present at the crown of the V3 loop is 
commonly found in field isolates of FIV-Fca but is often lost during cell culture 
adaptation (Figure 3-4). The presence of the ES(E/D) motif correlates with use 
of CD134 attachment receptor and an alteration of charge at one of the 
glutamate residues by a conversion to lysine reduces the requirement for 
CD134, allowing the virus to utilise CXCR4 directly for entry (Shimojima et al. 
1998; Willett et al. 1997b; Willett et al. 1997a; Willett et al. 2007). 
Interestingly the FIV-Ple E Sangre Env lacks the ES(E/D) motif but instead bears 
a TAT motif at this location.  
 




Figure 3-3 Env alignment of FIV-Ple E Sangre with FIV-Ple B 1027 and FIV-Fca 
GL8. Amino acid residues were aligned using ClustalW and reveal the N and C termini 
of the FIV-Ple strains are conserved (yellow bars), while the central section of FIV-Ple E 
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Willett and Hosie 2008), was able to replicate in the absence or presence of 
CD134 (Figure 3-5). This provides evidence that the lion E subtype of FIV uses 
CD134 as an entry receptor, and confirms that CD134 is not required for the 
replication of the FIV-Ple B subtype. 
 
Figure 3-5 Growth of FIV-Ple E Sangre is CD134-dependent in CLL cells. Cells 
were infected with isolates of FIV-Fca GL8, Ple E and Ple- B subtypes and culture 
supernatant aliquots were taken periodically and stored at -80oC for subsequent analysis 
of reverse transcriptase activity. Whilst FIV-Ple B 458 was able to replicate in CLL cells 
devoid of CD134, replication of FIV-Fca GL8 and FIV-Ple E Sangre was CD134-
dependent, providing evidence that FIV strains circulating in wild lion populations share 
CD134 as an entry receptor with FIV-Fca.  
3.2.4 Tropism of FIV-Ple pseudotypes 
To further characterise the attachment receptors of FIV-Ple, HIV-1 luciferase 
pseudotyped particles were generated and their receptor tropism was assessed 
on MCC cells transduced with human, feline or chimeric CD134. Human CD134 
is a non-functional receptor for FIV but FIV-Fca strains such as PPR and B2542 
need only to interact with cysteine-rich domain 1 (CRD1) of feline CD134 and 
are therefore able to use chimeric feline-human CD134 (fCRD1/hCD134) (de 
Parseval et al. 2005). Other strains such as GL8 and CPG41, typical ‘early’ 
isolates, require additional determinants in CRD2 and therefore cannot use the 
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chimeric receptor (Willett et al. 2006b). In domestic cat FIV strains that attain 
entry without feline CRD2 requirement (such as PPR and B2542), infection is 
readily inhibited by soluble trimeric feline CD134-ligand (sFc-TNC-CD134L) 
perhaps suggesting a weaker interaction between Env and CD134 (Willett et al. 
2007; Willett et al. 2009). Like FIV-Fca PPR, FIV-Ple E Sangre infection was also 
found to be readily inhibited by low concentrations of CD134L (Figure 3-6; 46% 
reduction in infectivity was seen at 2µg/ml sfeCD134L for FIV-Ple E Sangre 
compared to 21% for PPR and no decrease for GL8). Additionally, FIV-Ple E 
Sangre entry could be inhibited by AMD3100, a small molecule inhibitor of 
CXCR4-dependent entry in FIV-Fca, indicating that FIV-Ple E shares both entry 
receptor and co-receptor with FIV-Fca. Conversely entry of FIV-Ple B was 
unaffected, confirming its independence of CXCR4 and CD134.  
 
Figure 3-6 Like FIV-Fca, infection by FIV-Ple E can be inhibited with ligands of the 
receptor and co-receptor. Mya-1 cat T-cells were infected with HIV(luc) pseudotypes 
bearing envelopes of domestic cat FIV-Fca strains GL8 and PPR as well as FIV-Ple E 
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Sangre and B 458 in the presence of small molecule CXCR4 inhibitor AMD3100 (panels 
A and C) or soluble trimeric CD134L (sFc-TNC-CD134L; panels B and D) drawn as raw 
luciferase readings (A and B) or fold change in luciferase activity (C and D). In common 
with domestic cat strains of FIV such as PPR, FIV-Ple E Sangre was readily inhibited by 
CD134L and was also sensitive to AMD3100. In contrast, FIV-Ple B was insensitive to 
both these inhibitors. 
In domestic cat strains of FIV, a high degree of susceptibility to blocking by 
sCD134L is associated with a reduced requirement for the CRD2 domain of 
CD134 (Willett et al. 2006b). In order to test whether these features are 
associated in FIV-Ple infection, the virus was titrated onto a panel of cells 
expressing human, feline and chimeric fCRD1/hCD134. The co-occurence of 
high susceptibility to sCD134L with reduced requirement for CRD2 was not 
found to be the case for FIV-Ple E as entry was not supported by MCC cells 
bearing fCRD1/hCD134 (Figure 3-7). This finding suggests that FIV-Ple E makes 
more complex interactions with its receptor, as has been postulated for ‘early’ 
domestic cat stains such as GL8. FIV-Ple E Sangre is the first example of an Env 
displaying these properties and demonstrates that having both a weak 
interaction with the receptor but a more complex CRD2-dependent interaction 
are not properties that are mutually exclusive to an individual envelope 
glycoprotein. 




Figure 3-7 CD134 domain requirement for FIV-Ple E Sangre. As has been observed 
for certain strains of FIV-Fca such as GL8 (Willett et al. 2006b), FIV-Ple E is unable to 
use chimeric feline-human CD134, indicating that FIV-Ple E requires CD134 
determinants in both CRD1 and CRD2. 
The CD134 variants from domestic cat and lion were sequenced and aligned to 
human CD134 (Figure 3-8). Lion CD134 was deposited in Genbank (accession 
EU915483). Conservation between the homologues is high, with variable 
residues largely confined to the cleaved leader sequence. The only mutations 
within the mature peptide are within CRD1, namely K42R and G59S. 
Interestingly, residue 59 is one of the sites responsible for the differential 
permissivity between human and feline CD134, and forms part of the primary 
Env binding site (de Parseval et al. 2005), raising the possibility that one or 
both of these mutations could alter the Env binding site and have a profound 
effect on viral entry. 




Figure 3-8 Alignment of CD134 homologues. Lion and feline CD134 possess high 
levels of homology throughout the protein and differences between the homologues 
reside in the cleaved leader sequence (blue bar) and in cysteine rich domain 1 (CRD1). 
Residues critical for the FIV Env-receptor interaction that are non-permissive in the 
human (hu) homologue are marked with a black line and overlap the G59S mutation 
between cat and lion. Residues that are identical between at least two of the homologues 
are shaded dark grey and conserved residues light grey.  
To further characterise the relative requirements of receptor and co-receptor, 
plasmids encoding the lion and feline CD134 receptors were used to transduce 
CXCR4-negative human NP2 cells. The resulting cells were then further 
transduced with lion CXCR4. The presence of the mutations within lion CRD1 
could potentially affect the Env-CD134 interaction. Entry for FIV-Ple E Sangre 
was dependent on the presence of both CD134 and CXCR4 but, despite the 
differences in sequence, without preference for the species-specific CD134 
variants ( 
Figure 3-9).  




Figure 3-9 CD134 and CXCR4 are obligatory factors for FIV-Ple E entry. 
Expression of lion or feline CD134 or CXCR4 alone is insufficient for entry for both 
domestic cat GL8 and lion subtype E FIV variants. The viruses display no substantial 
preference for lion or feline CD134. 
To show that the FIV-Ple Env is capable of mediating membrane fusion, AH927 
cells stably expressing CXCR4 alone or CXCR4 and feline CD134 were 
transfected with plasmids bearing the env genes of FIV-Fca GL8 or FIV-Ple E 
Sangre. Transfection with either env resulted in the formation of large syncytia 
in AH927-fCXCR4-fCD134 (Figure 3-10) while AH927-fCXCR4 cells did not 
significantly differ from mock transfected cells, indicating that FIV-Ple E 
Sangre is able to mediate membrane fusion in a CD134-dependent manner. 
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Figure 3-11 FIV-Pco is able to replicate in CrFK independently of CD134. Human 
CD134 is a non-functional receptor for FIV infection (de Parseval et al. 2005). Here an 
FIV-Pco primary isolate was able to replicate in CrFKs in the presence of feline (fe) or 
human (hu) CD134, whilst FIV-Fca was only able to replicate in the presence of feline 
CD134, suggesting the puma virus uses an alternative receptor expressed in CrFKs.  
3.3 Discussion 
This study provides evidence that lion lentiviruses belonging to subtype E share 
usage of CD134 and CXCR4 as attachment receptors for viral entry with 
domestic cat variants of FIV. Phylogenetic analysis of the lentiviruses reveals 
that FIV-Ple is a monophyletic strain of FIV related to lentiviruses from puma 
(FIV-Pco) and Pallas cat (FIV-Oma) when analysis is performed over the gag 
open reading frame. However, using the env gene, it is shown that whilst FIV-
Ple B remains clustered with FIV-Oma and FIV-Pco, the E subtype is more 
closely related to FIV-Fca (Pecon-Slattery et al. 2008a). The results are 
suggestive of a recombination event, but given the relatively high sequence 
divergence between FIV-Ple E and FIV-Fca, either between circulating lion 
strains and an ancient ancestor of FIV-Fca, or a more recent recombination 
event with an FIV strain that resembles FIV-Fca circulating in lions or another 
species that is yet to be identified. Recombination in lentiviruses is not without 
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precedent: an increasing number of HIV-1 variants arising from presumed 
recombination events are being discovered, with 43 circulating recombinant 
forms (CRFs) listed in the HIV sequence database in July 2009 
(http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). 
Recombination has also been shown to be widespread in the evolution of the 
primate lentiviruses, with the ancestors of both HIV-1 and HIV-2 themselves 
mosaics of the six major SIV lineages (Salemi et al. 2003). Evidence exists of 
recombination in FIV env and gag-pol in Felis catus domestic and wild 
populations (Carpenter et al. 1998; Hayward and Rodrigo 2008). Recombination 
is therefore likely to be an important mechanism of generating diversity in 
lentiviruses that otherwise replicate in a clonal manner, lacking the ability to 
exchange genetic material.  
3.3.1 Potential implications of receptor use on FIV-Ple pathogenicity 
The virus-receptor interaction is a critical determinant of the host cell 
population targeted and therefore a significant factor in the cytopathicity of 
retroviral infection. HIV-1 uses CD4 and chemokine receptors CXCR4 or CCR5 to 
preferentially infect diverse cell populations (Edinger et al. 1997; Dragic et al. 
1996; Feng et al. 1996). In a similar manner FIV-Fca uses CD134 and CXCR4 to 
target activated T-cells, and changes in receptor tropism correlate with 
infection of other tissues and associated changes in pathogenicity (Willett et 
al. 2006b; Willett et al. 2006a; de Parseval et al. 2005). Studies of FIV-Ple 
infection have found evidence of CD4+ T-cell depletion in both wild (Roelke et 
al. 2009; Roelke et al. 2006) and captive lions (Bull et al. 2003). However the 
pathogenicity of FIV-Ple in lions is uncertain, with several studies suggesting 
that the presumed age of the lentiviral infection in lions has permitted 
adaptation to the host leading to attenuated pathogenicity, with findings of 
normal lifespans and fecundity in infected individuals and no association with 
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other disease correlates (Carpenter and O'Brien 1995; Hofmann-Lehmann et al. 
1996). In the most complete analysis of FIV-Ple pathology to date, Roelke et al. 
(2009) suggested that Botswanan and Serengeti lion populations suffer the 
typical manifestations of immunodeficiency syndromes including increased 
levels of lymphadenopathy, oral papilloma lesions and gingivitis as well as 
chronic inflammatory responses and abnormal red blood cell parameters. 
However, the finding that circulating subtypes of FIV-Ple use diverse 
attachment receptors has direct implications for the cytopathology of FIV-Ple, 
since the E subtype is presumably able to infect and deplete activated T-cells 
in a manner reminiscent of domestic cat lentiviral infections. Future studies of 
FIV-Ple infection in wild populations should attempt to correlate receptor 
usage with pathological manifestations of the immunodeficiency syndrome, as 
the use of alternate entry receptors may go some way to accounting for the 
discrepancies in the findings of recent studies. As for the identity of the FIV-
Ple B subtype receptor, it is tempting to speculate that it is a more widely 
expressed cell surface molecule, given that high titres of replicating virus can 
be obtained in canine CLL cells, (Figure 3-5) and that infection is supported by 
3201 cells (Smirnova et al. 2005). Additionally, a strain of North American 
puma virus FIV-Pco, which is proposed to be a distant relative of FIV-Ple 
(Pecon-Slattery et al. 2008a), is able to replicate to high titres in CrFK cells 
that lacked feline CD134 (Figure 3-11). For FIV-Fca, replication in CrFKs that 
lack feline CD134 requires a period of adaptation which corresponds to 
mutations in env that allow CD134-independent entry (Siebelink et al. 1995; 
Verschoor et al. 1995). In contrast, FIV-Pco replicates to high titres by day 2 
post infection, suggesting that FIV-Pco is able to use an alternative receptor 
expressed on CrFK without a prior adaptation phase (Figure 3-11). Given the 
divergent origins of these cell lines (CLL is a naive canine CD3+ T-cell line 
(Willett et al. 2006a), 3201 is a feline lymphosarcoma cell line (Hardy, Jr. et 
al. 1980) and CrFK is a feline kidney derived epithelial cell line (Crandell et al. 
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1973)), it appears likely that the receptor or receptors for these viruses is 
widely expressed. The ability to replicate in these cells is therefore perhaps 
indicative of a group of FIV strains including FIV-Ple B, FIV-Pco and FIV-Oma, 
which share usage of an alternative and perhaps broadly expressed receptor or 
receptors. Experimental infection of domestic cats with FIV-Ple B 458 and FIV-
Pco 1697 showed that these viruses are able to replicate in T-cells, causing 
acute lymphopoenia (VandeWoude et al. 2003; VandeWoude et al. 1997a; 
Terwee et al. 2005) but can be confined to gut-associated lymphoid tissue 
when inoculation is oronasal (Terwee et al. 2005). In the light of the findings 
presented here, a comparison of tissue tropism of FIV-Ple E and B strains in 
domestic cats would be of substantial interest, as it may yield insights into the 
cellular targets and pathology induced by the alternative Env tropism.  
3.3.2 Comparison of FIV-Ple E and FIV-Fca receptor usage. 
Although FIV-Ple E was found to share receptor tropism for CD134 and CXCR4 
with FIV-Fca, it did not fall into the like typical ‘early’ or ‘late’ classifications 
of FIV-Fca. Current understanding of FIV-Fca tropism suggests that viruses 
isolated from the early stages of infection such as GL8 and CPG41 require a 
more complex interaction with main receptor CD134 involving determinants in 
both CRD1 and CRD2 (de Parseval et al. 2005; Willett et al. 2006b). Studies of 
the mechanics of FIV entry, and comparisons with HIV-1 entry, suggest that an 
initial interaction between the SU V3 loop and CD134 result in a conformational 
change that exposes the relatively invariant CXCR4-interacting domain which 
promotes co-receptor binding followed by TM-mediated fusion with the cell 
membrane. The two-step receptor, co-receptor binding mechanism is thought 
to sequester the invariant CXCR4-interacting domain providing cover from 
humoral immunity. Although the host will typically generate antibodies 
directed to the variable loops, neutralisation is presumably quickly overcome 
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by expansion of escape mutations in these regions. Late stage viruses such as 
PPR and B2542, which are relieved of their CRD2 requirement, are possibly 
permitted to circulate by the absence of full levels of host immunity, and 
display a broader cell tropism (Willett and Hosie 2008). This transition is 
accompanied by an increase in sensitivity to blocking activity of CD134L 
(Willett et al. 2009; Willett et al. 2007). It is therefore of interest that FIV-Ple 
E Sangre behaves like early FIV-Fca strains in that it requires components of 
feline CRD2 for entry but like late FIV-Fca strains, receptor attachment is 
readily blocked by low concentrations of CD134L. FIV-Ple E Sangre therefore 
represents the first example of a viral Env simultaneously displaying both these 
properties. The relevance of these findings is unknown, but may be indicative 
of a different mechanism of viral entry or of a host-specific adaptation. Also 
unknown is the stage of virus that FIV-Ple E Sangre represents; although the 
host was healthy at the time of sampling, Sangre was 8 years old and from a 
population with high seroprevalence, making an early stage infection unlikely. 
Further research should establish whether the phenotype that FIV-Ple E Sangre 
displays is typical amongst subtype E-infected lions and if and how receptor 
usage and sensitivity to blocking changes during the course of infection.  
3.4  Conclusions 
All six member species of Panthera lineage bear species-specific strains of FIV, 
whilst in contrast, the Felis lineage harbours only two seropositive species (F. 
catus and the Jungle cat, F. chaus) (Pecon-Slattery et al. 2008b). The distinct 
pattern of infection in these taxa is evidence of an ancient infection in the 
Panthera, with evidence suggesting infection before the end of the Pliocene 
(2.53 mya) that has subsequently spread into other species. Consistent with the 
age of the infection, the diversity of FIV in free-ranging lions is large [burk] 
and this study reveals that the diversity extends to use of alternate attachment 
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receptors. Learning the identity of the attachment receptor of other FIV-Ple 
subtypes such as subtype B will provide an important insight into the evolution 
of the lentiviruses. Furthermore if the infection of alternative cell populations 
is demonstrated for FIV-Ple B, there are likely to be diverse pathogenic 
manifestations attributable to the use of distinct attachment receptors, with 
implications for the management of free-ranging and captive breeding lion 
populations.  
The domestic cat separated from its closest relatives about 10,000 years ago 
and the absence of FIV in the other Felis species suggests that the zoonosis of 
the virus into domestic cats took place after this divergence. Thus the two 
species represent an interesting comparison between an ancient and a 
relatively new host for lentiviral infection. Models of pathogen infection 
suggest that attenuation of viruses over time will occur to a limited extent 
given certain criteria (May and Anderson 1979). Consistent with a certain 
degree of attenuation, seroprevalences in lions can approach 100% and it is 
apparent that lions are able to survive and breed given the continued existence 
of these populations. Nevertheless, evidence exists for the continued 
manifestations of immunodeficiency in lion lentiviral infections. Our knowledge 
of primate intrinsic immunity suggests that in past infections the host gained 
immunity that prevents retroviral infection, rather than viruses persisting as 
asymptomatic infections. Chapter 6 will probe the ability of lions to restrict 
lentiviral infection and show that lion T-cells possess a broad anti-retroviral 
post-entry restriction mechanism. Furthermore the nature of the APOBEC3 
genes in this species is examined and shown to provide a potent block to 
lentiviral replication, suggestive of an ongoing struggle between host and 
parasite. 
 Chapter 4. An investigation of antiretroviral 
factor TRIM5 in Feliformia 
4.1 Summary 
TRIM5α is an intracellular restriction factor that interferes with or ‘restricts’ 
incoming retrovirus particles in the cytoplasm and prevents efficient reverse 
transcription and integration (Stremlau et al. 2004). The gene was originally 
described in primates, where it is proposed to provide a block to cross-species 
transmission of retroviruses. The protein interacts with incoming retroviral 
cores in the cytoplasm via an interaction between variable regions in the C-
terminal B30.2 domain and the capsid core (Stremlau et al. 2005). In a manner 
similar to the restriction provided by murine factor Fv1b/b, TRIM5α variants 
from most species are able to restrict the N-tropic strain of MLV but not the B-
tropic strain, and the viral determinant of restriction maps to the exposed 
surface of capsid (Bishop et al. 2001; Cowan et al. 2002; Kozak and Chakraborti 
1996). TRIM5α variants from non-primate species such as cows (Bos taurus) 
(Ylinen et al. 2006; Si et al. 2006) and rabbit (Oryctolagus cuniculus) (Schaller 
et al. 2007) have also been shown to posses TRIM5α with antiretroviral 
properties, suggestive of a mammalian TRIM5α common ancestor with 
antiretroviral properties. In dogs, TRIM5 has been shown to be disrupted by the 
insertion of an unrelated gene PNRC1 and the genomic remnants of the gene 
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are redundantly pseudogenised (Sawyer et al. 2007). However, the nature of 
TRIM5 in cats is unknown, except that domestic cat cell line CrFK shows none 
of the characteristics of TRIM5α restriction suggestive of a TRIM5α-null 
genotype (Towers et al. 2000). For this reason CrFKs are commonly used for 
the exogenous expression and assay of other mammalian TRIM5α proteins. 
This chapter presents a study of domestic cat TRIM5 and shows that while 
transcripts can be amplified, the encoded protein is truncated early in the 
B30.2 domain. Further investigation reveals that all feliform species tested 
possess the truncating mutation, but it is absent from caniform sequences, 
giving an approximate date for the disruption event. Lacking a B30.2 domain is 
found to render the gene non-functional as an anti-retroviral agent and the 
truncated protein is able to act as a dominant negative against human TRIM5α 
suggesting that the feline TRIM5 retains sufficient homology in the coiled-coil 
and downstream linker regions to the human orthologue in order to 
multimerise and disrupt TRIM5α activity. This finding indicates that caution 
should be taken when expressing exogenous TRIM5 genes in cat cells. The 
results explain the absence of post-entry restriction in the felids and have 
implications for cross-species transmission of lentiviruses and the development 
of animal models for HIV-1 infection.  
4.2 Results 
4.2.1 Domestic cat cells lack TRIM5α-like restriction  
It has previously been reported that, unlike other mammals, cells derived from 
domestic cats lack a post-entry restriction phenotype typical of TRIM5α 
(Towers et al. 2000). To confirm these findings, the domestic cat cell line CrFK 
was challenged with N- or B- tropic MLV that had previously been titrated and 
normalised on MDTF (Mus dunni tail fibroblast) cells, which lack restriction 
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activity (Bock et al. 2000). Additionally, to confirm the ability of exogenously 
expressed TRIM5α to mediate restriction in cat cells, CrFK cells transduced 
with huTRIM5α were also assayed (Figure 4-1). As has previously been reported, 
cat cells lack the ability to restrict N-tropic MLV, suggestive of an absence of 
functional TRIM5α. However, unlike canine D17 cells which support restriction 
by exogenously expressed TRIM5α genes weakly (Berube et al. 2007), CrFK 
allows potent restriction of MLV-N by the human variant, suggesting that the 
correct cellular environment and any potential cofactors of restriction are 
present in domestic cats.  
 
Figure 4-1 Cat cells lack MLV-N-specific post-entry restriction. Domestic cat cells 
were infected with MDTF-normalised doses of VSV-G pseudotyped N- or B-tropic MLV 
bearing a GFP reporter gene. CrFK cells were equally susceptible to N- and B-tropic 
strains indicating a lack of TRIM5α-like post-entry restriction. However, when 
transduced with huTRIM5α, a potent block to N-MLV is observed, indicating that cat 
cells are able to support the activity of the restriction factor.  
4.2.2 TRIM5 of domestic cats is truncated 
Using internal primers directed to huTRIM5α, an amplicon was identified from 
Mya-1 cDNA which was used to mine the nascent cat genome project (Pontius 
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and O'Brien 2007) for homologous sequences. This strategy was used rather 
than performing a cross-species BLAST search with non-feline TRIM5 sequences 
because of the large number of TRIM family members, and the danger that in 
an incomplete genome project, an incorrect match may have been identified. 
Contigs encoding exons 2 and 8 were found in the database, allowing the 
design of primers to the full-length open reading frame. The resulting TRIM5 
transcript from domestic cat T-cells (Mya-1) was cloned and sequenced and 
deposited in Genbank (Accession number GQ183880). The cat TRIM5 was found 
to share substantial homology to hu and rabbit (rb) TRIM5α; however the 5’ 
end of exon 8 bears a stop mutation at residue 299. The resulting protein thus 
encodes only the RBCC domain and does not possess any of the B30.2 variable 
regions that are known to be responsible for capsid recognition (Figure 4-2). 
Sequence downstream of the stop codon at position 299 bears multiple 
frameshift and stop codons, suggesting that lack of protein-level expression  
has permitted the accumulation of such errors. 




Figure 4-2 Domestic cat TRIM5 is truncated but shows considerable conservation 
when aligned to TRIM5α orthologues. The amino acid sequence of feTRIM5 was 
aligned to human and rabbit TRIM5α, revealing substantial conservation in the RBCC 
domain (RBCC identical residues: fe-hu 59%; fe-rb 59%; hu-rb 60%). The feTRIM5 
transcript bears a stop codon at position 299, before the B30.2 domain variable region v1, 
and encodes a truncated protein. Domain architecture is indicated with yellow bars; 
variable regions of B30.2 are labelled green; dark grey, conserved residue; light grey, 
conserved substitution. 
4.2.3 Cat TRIM5 is a true orthologue of primate TRIM5α. 
Confirmation was sought that the gene identified is a true orthologue of 
primate TRIM5 and not a closely related TRIM gene. Firstly, using areas of 
homology to other mammalian genes, a map of the cat chromosome D1 region 
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was established. This placed TRIM5 amongst its closest relatives: TRIM6, 
TRIM22 and TRIM34 (Figure 4-3A). As with other mammalian species the 
domestic cat TRIM gene cluster is flanked by olfactory genes. Haplotypes that 
are present in multiple species without karyotypic rearrangements are known 
as regions of conserved synteny. In this case synteny has been conserved 
between primates (human chr. 11, rhesus chr. 14) and carnivores (cat 
chromosome D1, dog chromosome 21). The presence of conserved synteny 
suggests that the gene identified is a true TRIM5 orthologue. However, it is 
noteworthy that the cat, cow and dog TRIM5 genes are orientated oppositely 
with respect to human and rhesus macaque TRIM5, suggesting an inversion 
event has occurred. The timing and relevance of this event are unknown but 
may for example affect interactions with enhancer/suppressor elements and 
therefore expression levels. Secondly, a Neighbour-Joining tree was drawn by 
aligning full length TRIM open reading frames (Figure 4-3B). This reveals 
feTRIM5 to be monophyletic with TRIM5 variants from other mammalian species 
and the position of feTRIM5 reflects the established evolution of the mammals. 
Importantly, feTRIM5 clusters distantly from other closely related TRIM genes 
such as TRIM6, TRIM22 and TRIM34, thus confirming the transcript identified as 
a true orthologue of TRIM5.  
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Figure 4-3 Conserved synteny and phylogenetic clustering indicate that cat TRIM5 
is a true TRIM5 orthologue.
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4.2.4 Exon structure of cat TRIM5 
Primate and non-primate TRIM5 orthologues are known to span eight exons 
(Nisole et al. 2005), with the largest being exons 2 (which includes the start 
codon ATG, the RING domain and the B-Box2 domain) and 8 (which codes for 
almost the entire B30.2 domain). The cat TRIM5 gene was found to share seven 
of the eight exons present in huTRIM5α, skipping the 27 nucleotide exon 7 and 
thus moving directly (but remaining in frame) from exon 6 to exon 8. This is a 
transcript that has not been described in humans. However, two novel isoforms 
of TRIM5 were found in the macaque species Macaca nemestrina: TRIM5η (eta) 
bears a 2bp deletion between exons 6 and 7 resulting in a frameshift and 
truncation, resulting in a protein of 300 residues, comparable in size to cat 
TRIM5; TRIM5θ (theta) skips exon 7, like the cat TRIM5, but remains in frame 
for the entire exon 8, resulting in a protein of 486 residues (Brennan et al. 
2007). Interestingly a TRIM5α transcript was not identified in this species, and 
the isoforms identified appeared to inhibit viral entry poorly and 
correspondingly, this species can be inoculated with lentiviruses including HIV-
1 (Agy et al. 1992) and HIV-2 (McClure et al. 2000). The role of these 
alternative isoforms is not clear, but the authors speculate that the deletion of 
exon 7 impacts on the stability of an α-helix thought to stabilise the N-terminal 
B30.2 domain, and thus reduces the antiretroviral activity of the protein. By 
analogy with the TRIM21 crystal structure (Keeble et al. 2008), the exon 7 
region may compromise the PRY subdomain scaffold structure which supports 
the v1 domain critical for lentiviral restriction (Perez-Caballero et al. 2005a; 
Stremlau et al. 2005; Yap et al. 2005).  




Figure 4-4 Exon structure of cat TRIM5. Transcripts encoding anti-retroviral human 
TRIM5α are comprised of eight genomic exons. Isoforms TRIM5γ and TRIM5δ encode 
variants that lack the C-terminal B30.2 domain, with TRIM5γ simply lacking the final 
exon 8, resulting in a stop mutation beyond the splice donor of exon 6 and TRIM5δ using 
an alternative splice acceptor in exon 8. Domestic cat TRIM5 is encoded by exons 2 to 8 
but skipping the 27 nucleotide exon 7. 
Although this study found transcripts of a similar size in diverse Feliform 
species, it is of course possible that a transcript that encodes all eight exons is 
expressed in cat cells but was not detected in this study. TRIM5 isoforms such 
as huTRIM5δ use an alternative splice acceptor in exon 8, downstream of the 
B30.2-encoding region. To rule out this possibility in domestic cats, 3’ RACE 
was performed, which allows the amplification of the 3’ terminus in an 
unbiased fashion (Frohman et al. 1988). No evidence for an alternative 
transcript was found, with sequences corresponding only to the transcript 
previously identified.  
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4.2.5 Evaluating the antiviral activity of cat TRIM5  
Primate TRIM5 is able to interact with incoming retroviral cores through an 
interaction between its B30.2 domain and viral capsid protein (Mische et al. 
2005; Sebastian and Luban 2005; Stremlau et al. 2006b). Given that domestic 
cat TRIM5 lacks a B30.2 domain, it was predicted that the gene product would 
be unable to restrict retroviruses. To test the ability of feTRIM5 to restrict 
retroviral infection, a murine cell line MDTF was stably transduced with 
huTRIM5α or feTRIM5. The MDTF cell line was chosen since, like CrFK, it lacks a 
post-entry restriction phenotype (Bock et al. 2000; Hatziioannou et al. 2004; 
Towers et al. 2000). Cells were challenged with dilution series of N or B tropic 
MLV, as well as HIV-1 and SIVmac VSV-G pseudotyped particles, bearing a green 
fluorescent protein (GFP) marker gene and expression of GFP was monitored by 
flow cytometry (Figure 4-5). Human TRIM5α restricted MLV-N and SIVmac, 
whilst cat TRIM5 restricted none of the virus particles tested. Thus, we can 
confirm feTRIM5 to be a non-functional restriction factor and furthermore we 
can ascribe the lack of post-entry restriction in domestic cat cells to the 
truncation of TRIM5.  




Figure 4-5 Domestic cat TRIM5 is a non-functional restriction factor. Permissive 
MDTF cells were transduced with domestic cat TRIM5 or human TRIM5α. Intact 
huTRIM5α specifically recognises and restricts N-tropic but not B-tropic MLV through 
an interaction of its B30.2 domain and the virus capsid. Domestic cat TRIM5, which 
lacks a B30.2 domain is unable to restrict MLV-N. 
4.2.6 Cat TRIM5 disrupts endogenous human TRIM5α activity 
In primates, alternative splice variants TRIM5γ and TRIM5δ lack a B30.2 domain 
and lose their ability to restrict retroviruses. Moreover, these isoforms have a 
dominant negative effect, disrupting TRIM5α restriction by forming multimers 
with full-length TRIM5α (Mische et al. 2005; Perez-Caballero et al. 2005a). To 
investigate whether the cat TRIM5 is able to perform this dominant negative 
activity, human TE671 cells which express endogenous levels of TRIM5α and 
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potently restrict MLV-N (Keckesova et al. 2004) were transduced with cat 
TRIM5 or a human TRIM5α mutated to bear a stop codon at the same location 
as the cat transcript, huTRIM5 P306STOP. Cells were then challenged with moi-
normalised N- or B-tropic MLV.   
Both cat TRIM5 and huTRIM5 P306STOP were found to have a dominant 
negative effect against endogenous TRIM5α as they were able to rescue titres 
of MLV-N. This suggests that feTRIM5 localises to the cytoplasm where it is able 
to form dimers with huTRIM5α to prevent full levels of restriction. The domain 
responsible for TRIM5 self interaction is the coiled coil and linker 2 region 
(Javanbakht et al. 2005; Perez-Caballero et al. 2005a). This suggests that 
sufficient homology exists in these regions between human and feline variants 
of TRIM5 to allow the formation of higher order complexes. The data also 
provide evidence that like human TRIM5, cat TRIM5 localises to the cytoplasm. 
Interestingly, feTRIM5 was able to provide higher levels of dominant negative 
activity than huTRIM5 P306STOP despite higher levels of expression of the 
latter. However further attempts to characterise this discrepancy by transient 
expression of different ratios of the two genes in conjunction with full-length 
TRIM5α proved unsuccessful (data not shown). 




Figure 4-6 Dominant negative activity of feTRIM5. In a similar manner to human 
isoforms TRIM5γ and δ which also lack a B30.2 domain, feTRIM5 is able to act as a 
dominant negative against TRIM5α, suggesting that feTRIM5 localises to the cytoplasm 
and shares sufficient homology with the human variant to interact and form non-antiviral 
dimers.  
4.2.7 Knock-down of endogenous TRIM5 in cat cells 
To demonstrate that endogenous TRIM5 in cat cells does not contribute an 
antiviral phenotype, TRIM5 knockdown CrFK cell lines were made by 
transducing cells with small-hairpin RNA constructs directed to feline TRIM5. 
Cells were also transduced with feline CD134 to allow replication of primary 
FIV isolates. Confirmation of the knockdown was sought by RT-PCR with 
feTRIM5-specific primers wam4 and wam13 with 2-fold serial dilutions of cDNA 
as template, which showed a four- to eight-fold reduction in TRIM5 expression. 
No difference in the ability to replicate in the cells was associated with 
knockdown of TRIM5, suggesting that TRIM5 does not impact on FIV replication.  
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clone CPG41. Cell-free aliquots were stored at -80 °C and examined for p24 
levels by ELISA (Figure 4-8). The results imply that conserved lentiviral 
structures are present in FIV CA that permit recognition and restriction by 
diverse TRIM5 and TRIMCyp homologues. 
 
Figure 4-8 FIV replication can be inhibited by diverse TRIM5 and TRIMCyp 
orthologues. CrFK CD134 cells expressing various TRIM5α variants were tested for 
their ability to support FIV replication. All TRIM5α variants prevented replication to 
some degree but owl monkey TRIMCyp (omk), cow and rhesus macaque (rh) TRIM5α 
prevented significant levels of replication. NC, uninfected negative control; CrFK, 
untransduced control. 
4.2.9 Evolutionary analysis of TRIM5 in the Feliformia 
In order to invade a new species, retroviruses must be able to evade 
destruction by host immune responses. The lack of antiretroviral TRIM5 in cats 
would therefore have implications for cross-species transmission if the 
disabling mutation was found to be conserved between species. An analysis of 
TRIM5 from various Feliform species was therefore conducted in order to 
determine the prevalence of the mutation. First, we compared TRIM5 
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Table 4.A Carnivoran samples for genomic DNA extraction. Exon 8 of TRIM5 was 
analysed by degenerate primer PCR using template genomic DNA extracted from the 
above tissues and cell cultures. Expected product sizes were 525bp for dog and 536bp for 
cat and amplicons were sequenced directly from gel purified PCR product. 
Sequencing of successfully amplified exon 8 fragments revealed that 
remarkably, all Feliform species bear the same stop codon as was found in 
domestic cat (Figure 4-10A). However, the stop codon was absent from the 
caniform species mink and dog. A phylogenetic tree of the exon 8 fragments 
(Figure 4-10B) is consistent with established carnivore phylogeny (Figure 
4-10C), confirming the origin of the genomic DNA and obviating the possibility 
of PCR contamination. The sequences derived from the analysis can be found in 
Appendix 3. 
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disrupted gene in fossa and hyena implies that the event took place before the 
Felidae diverged from the Hyaenidae and Eupleridae 47 mya (Bininda-Emonds 
et al. 1999). Thus, two independent mutations which disable TRIM5 restriction 
have occurred during carnivoran natural history. Although the truncation of 
TRIM5 is compatible with observations that cat cells lack restriction activity, 
other possibilities such as read-through transcripts or the splicing of another 
gene to the 3’ end of TRIM5 cannot be ruled out. Given the recent findings that 
fusions between TRIM5 and CypA have arisen at least twice in the primates 
(Sayah et al. 2004; Virgen et al. 2008; Wilson et al. 2008; Newman et al. 2008; 
Liao et al. 2007), 3’ primers directed to feline CypA were used in conjunction 
with various 5’ TRIM5 primers in RT-PCR reactions, but no product was 
detected. All published sequence downstream of feTRIM5 was examined for 
cyclophilin exons using BLAST, with no positive matches. Additionally, 3’ 
primers directed to TRIM22 were used in conjunction with TRIM5 5’ primers to 
detect for potential read-through transcripts, with no products detected. 
Finally rapid amplification of cDNA ends (3’ and 5’ RACE) was performed to 
sequence the transcript ends without bias. No transcript other than the one 
already described was found.  
4.3 Discussion 
There is evidence of strong positive selection in primate TRIM5α B30.2 domain, 
driven by a genetic conflict or ‘arms race’ between restriction factor and virus 
within the past 33 myr (Sawyer et al. 2005; Liu et al. 2005). The resulting 
orthologues are highly divergent in the variable domains of B30.2 and each 
have specific repertoires of restricted virus (Ohkura et al. 2006; Stremlau et al. 
2005; Nakayama et al. 2005). Non-primate species also possess antiretroviral 
TRIM5α orthologues including cows (Ylinen et al. 2006; Si et al. 2006) and 
rabbits (Schaller et al. 2007) which also show evidence of positive selection (Si 
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et al. 2006). Thus it is likely that ancestral mammalian TRIM5α, as well as the 
ancestral carnivoran TRIM5α, possessed antiviral activity and positive selection 
of TRIM5α driven by host-virus interactions may be a feature common amongst 
mammals. Therefore the findings that the Feliformia and at least one taxon in 
the Caniformia have maintained seemingly deleterious TRIM5 alleles are 
surprising and in direct contrast to non-carnivoran mammals, where TRIM5α 
evolution is characterised by strong positive selection and gene duplications. 
4.3.1 Implications of TRIM5 truncation for viral transmission and 
replication 
It is thought that escaping TRIM5α restriction may be a widespread 
requirement for retroviral zoonosis and population invasion in diverse 
mammalian species. Thus the loss of antiretroviral TRIM5 in carnivorans has 
implications for the evolution and cross-species transmission of retroviruses. 
Dogs are currently thought to be free of exogenous retroviral infection but high 
titres of replicating FIV can be obtained in canine cells which express the FIV 
receptor feline CD134 (Willett et al. 2006a), suggestive of a lack of 
intracellular defence (and potential vulnerability) to this pathogen. In the 
primates, molecular phylogenies of SIV from divergent species broadly reflect 
phylogenies of the host, suggesting that cross-species transmission is relatively 
rare and predominantly occurs between closely related species (VandeWoude 
and Apetrei 2006). In the felids, cross-species transmission of FIV also appears 
to be relatively rare given the high levels of viral sequence divergence within 
infected species (VandeWoude and Apetrei 2006; Pecon-Slattery et al. 2008a). 
However when cross-species transmission events do take place they frequently 
occur between distantly related species (Troyer et al. 2005). Accordingly, 
lentiviral evolution in the felids appears to more closely reflect current or 
historical geographical overlaps of species’ ranges rather than the phylogeny of 
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the host, most notably evidenced by a partition of phylogeny between old 
world and new world FIV strains which is not recapitulated in phylogenies of 
the host (Pecon-Slattery et al. 2008a; Pecon-Slattery et al. 2008b; Troyer et al. 
2005). For example, cross-species transmission of FIV is hypothesised to have 
taken place between the distantly related lion and Asian Pallas cat (Otocolubus 
manul) sometime during the Pleistocene, when the range of lions extended to 
Asia (Pecon-Slattery et al. 2008a). Additionally, the FIV strains infecting 
cheetahs and leopards are closely related, despite the host species belonging 
to divergent lineages of the felids: cheetahs belong to the Felis lineage, whilst 
leopards belong to the Panthera lineage (Johnson et al. 2006; Troyer et al. 
2005). In addition to these ancient cross-genus transmissions, recent zoonoses 
of FIV have also been documented: from captive snow leopard to tiger (Troyer 
et al. 2005); from domestic cat to puma (Carpenter et al. 1996) and Japanese 
Tsushima leopard cat (Nishimura et al. 1999); and multiple transmissions of FIV 
between free-ranging pumas, Florida panthers and bobcats have been reported 
(Franklin et al. 2007; Miller et al. 2006). Furthermore, experiments have shown 
that domestic cats can be infected with FIV strains from highly divergent 
species including lions and pumas (VandeWoude et al. 1997a; Terwee et al. 
2005; VandeWoude et al. 2003). The last common ancestor of these three 
species was at the late Miocene ~10 mya during the radiation of the modern 
felid genera. The ability of viruses to jump between relatively unrelated 
species and the number of recent transmissions point to a lack of host defence 
to FIV and is in contrast to the primates, where it has proven difficult to 
develop a non-human model for HIV-1 infection in all species but our closest 
relative, the chimpanzee. Thus the relative rarity of cross-species transmission 
in the felids appears to owe more to lack of inter-species contact than to 
robust defences.  
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The absence of antiretroviral TRIM5α in the felids may have effects on 
lentiviral evolution in this taxon. It is noteworthy that FIV is particularly 
sensitive to TRIM5α and rhTRIMCyp and omkTRIMCyp, with several studies 
reporting high levels of FIV restriction (Schaller et al. 2007; Saenz et al. 2005; 
Virgen et al. 2008). Thus the absence of TRIM5α or TRIMCyp may have 
permitted the evolution of FIV towards structural optima that would otherwise 
be strongly restricted. This hypothesis is consistent with studies of emergence 
of resistance to antiretroviral drugs, where mutants that escape the effects of 
the drug are usually less fit than susceptible strains, when replication is 
compared in the absence of the drug (for a review of fitness effects of drug 
resistance see Martinez-Picado and Martinez 2008). Although compensatory 
mutations allowing greater fitness eventually do usually occur, viruses often 
revert to wildtype once the drug treatment is ceased (Svedhem et al. 2002; 
Olivares et al. 2004). This comparison is an interesting one and future work 
detailing the fitness costs associated with escape from restriction factors 
would be informative. Conversely, experiments detailing the nature of 
lentiviral mutants that arise in long term culture where restriction is relieved 
may also help illuminate this aspect of the host-virus relationship. 
4.3.2 Possible causes of TRIM5 truncation 
Mammalian TRIM5 has been shown to be highly variable in both molecular 
sequence and in copy number, with as many as eight copies in the cow 
genome. However, the evolution of non-antiviral TRIM5 alleles has now been 
documented in several cases such as: dogs, where it is disrupted by the 
insertion of PNRC1, preventing expression at the RNA level (Sawyer et al. 
2007); humans, where a rare, dominant negative allele encoding a TRIM5α 
transcript truncated at the B30.2 v1 variable loop is present in West African 
populations (Torimiro et al. 2009); Macaca nemestrina where atypical isoforms 
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have replaced TRIM5α (Brennan et al. 2007); and the Feliformia where RNA 
expression is maintained but a stop mutation prevents antiretroviral activity. 
However, the selective pressure that has caused the maintenance of inactive 
TRIM5 alleles such as these is unclear.  
One possibility is the acquisition of a novel function of a truncated TRIM5 in 
cats. In this study, transcripts of the gene were detected in cDNA derived from 
domestic cat, wildcat, lion and cheetah, indicating maintenance of TRIM5 gene 
expression. Thus felid TRIM5 may have an alternative role that does not involve 
the B30.2 domain. This is plausible since many TRIM genes are expressed 
without an additional C-terminal domain, either through alternative splicing 
such as TRIM5δ and γ, or the absence of a B30.2 domain from the gene 
structure, such as TRIM19/PML, and have diverse or unknown functions 
(Sardiello et al. 2008). Indeed, the evolution of novel B30.2-lacking isoforms 
appears to be ongoing in the primates, with the discovery of TRIM5η and θ 
which appear to be unique to Macaca nemestrina (Brennan et al. 2007) and 
TRIM5 R332X in humans (Torimiro et al. 2009). Knowledge of the function of 
these truncated variants may go some way towards explaining the cause of 
multiple independent short TRIM5 isoforms in mammals. A second possible 
explanation for loss of active full length TRIM5α is an unknown cost associated 
with its expression. Although no evidence for this exists, a parallel can be 
drawn to human APOBEC3H, where destabilising mutations have arisen at least 
twice, potentially to limit exposure of cellular nucleic acids to a 
hypermutation-inducing enzyme (OhAinle et al. 2008). A potential cost 
associated with TRIM5α expression is the non-specific targeting of cellular 
proteins, although this remains speculation. Finally, it is presumed that the 
evolution of restriction factors is sculpted by previous encounters with 
retroviruses, thus an alternative explanation for the absence of TRIM5α 
restriction is that carnivorans were relatively unaffected by retroviruses. It is 
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noteworthy therefore that carnivorans appear to have suffered relatively little 
endogenous retrovirus activity compared to primates: there are 13,000 
LTR/ERV lineage-specific sequences in the dog genome compared to 133,000 in 
the human and 470,000 in the mouse genomes (Lindblad-Toh et al. 2005) (the 
annotated cat genome sequence awaits publication). Thus a period of low 
retroviral activity early in Carnivoran evolution may have reduced the pressure 
to maintain anti-retroviral TRIM5α and allowed the fixation of non-reversible 
disrupting alleles. Although there are now several cases of loss of antiviral 
activity, the nature of the evolutionary forces responsible may be different in 
each case, and are difficult to ascertain without knowledge of the pathogens 
that have historically affected each taxon or the function of the novel gene 
products.  
Canine cells support only low levels of restriction by exogenously expressed 
TRIM5α (Berube et al. 2007), suggesting that either a required co-factor of 
TRIM5α restriction is absent or that an endogenous dog protein is exerting a 
dominant negative effect. Since canine TRIM5 is known to be disrupted and not 
transcribed (Sawyer et al. 2007), the former explanation seems more likely. In 
contrast, feline cells, in which truncated TRIM5 is expressed and capable of 
dominant negative activity, readily support TRIM5α restriction (Saenz et al. 
2005). Presumably, the high levels of expression associated with eukaryotic 
expression vectors saturate the endogenous levels of truncated TRIM5, 
obscuring any dominant negative effect. The ability to host exogenous TRIM5α 
suggests that cats have maintained the as-yet-unidentified co-factors necessary 
for restriction, whilst dogs have not. Thus it remains possible that other post-
entry restriction factors are operating in cat cells that use the same pathways. 
Interestingly, TRIM22, a gene known to be upregulated upon interferon 
stimulation (Rajsbaum et al. 2008), is under adaptive selection in the 
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Carnivorae (Sawyer et al. 2007), suggestive of a possible role in antiviral 
activity.  
4.4 Conclusions 
The lack of TRIM5α-mediated post-entry restriction in the carnivorans contrasts 
strongly to the primates where TRIM5α can reduce retroviral infectivity by 
several orders of magnitude in non-permissive cells. This is thought to provide 
a barrier to transmission that must be overcome for successful invasion. Since 
primates and carnivorans are currently affected by closely related lentiviruses 
that infect and deplete similar cell populations, insight may be gained from 
direct comparisons between these taxa into the comparative role of TRIM5α 
and other restriction factors in the evolution and cross-species transmission of 
lentiviruses. This will be particularly powerful upon the completion of the cat 
genome project as the nature and extent of endogenised retroviruses in the 
felids as well as the host defences may be more fully analysed. Of particular 
interest is the APOBEC3 gene family which has recently been shown to be 
expanded and active in felids (Munk et al. 2008), and tetherin which appears 
increasingly to be a potent block to a broad range of enveloped viruses that 
must be overcome for successful replication (Neil et al. 2008; Jouvenet et al. 
2009). Thus the nature of these restriction factors and the extent to which 
they may compensate for TRIM5α are worthy of future study. 
 Chapter 5. The role of Cyclophilin A in the 
replication of feline immunodeficiency virus 
5.1 Summary 
Full levels of infectivity for HIV-1 are dependent on the host factor cyclophilin 
A (CypA), a peptidyl-proline isomerase that interacts with an exposed proline-
rich loop in capsid (CA) and catalyses cis-trans isomerisation of the G89-P90 
bond. Previous studies have shown that CypA is also bound by FIV (Lin and 
Emerman 2006), but does not interact with HIV-2, SIVmac or EIAV (Yoo et al. 
1997; Braaten et al. 1996), suggesting that the interaction is widely conserved 
but not absolutely required. The role of the CA-CypA interaction is not fully 
defined but may promote the viral stage known as uncoating – a post-entry 
restructuring of viral components that promotes reverse transcription and 
entry to the nucleus. For primate lentiviruses, the affinity of the CA-CypA 
interaction appears to be maintained within a narrow window, even in mutants 
that are able to replicate under conditions of CypA inhibition (Yoo et al. 1997; 
Ylinen et al. 2009). To investigate the effects of CA-CypA inhibition for FIV, 
replicating virus and pseudotyped FIV particles are used to demonstrate that 
like HIV-1, inhibition of CypA prevents full levels of infectivity and that CypA is 
required during post-entry stages of the lifecycle. We next ask whether the 
affinity of the CA-CypA interaction is conserved between primate and feline 
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lentiviruses, and find that for a domestic cat strain of FIV, binding affinity to 
its cognate CypA is almost identical to that reported for HIV-1. Examination of 
a non-domestic strain of FIV isolated from lions (FIV-Ple, also known as LLV) 
possesses a higher affinity for CypA.  
CypA can also play a part in post-entry restriction: rhesus macaque TRIM5α 
restricts HIV-1 more readily when CypA is present, suggesting that structural 
changes induced by the isomerase activity are better recognised by the 
restriction factor (Keckesova et al. 2006; Berthoux et al. 2005; Stremlau et al. 
2006a). To assess the sensitivity of FIV to promotion of TRIM5α restriction by 
CypA, FIV pseudotypes were used to demonstrate a cell type-dependent 
decrease in infectivity associated with CypA inhibition in human cells. 
However, TRIM5α restriction of FIV is only weakly enhanced by CypA inhibition 
and TRIM5 is non-functional in cat cells, indicating that FIV does not use the 
CA-CypA interaction to protect from TRIM5α, and suggesting, more generally, 
that lentiviral CA-CypA interaction is maintained even in the absence of TRIM5. 
TRIM5-CypA fusion proteins in rhesus macaques (rh) and owl monkeys (omk) are 
able to strongly restrict lentiviral replication (Wilson et al. 2008; Sayah et al. 
2004; Newman et al. 2008; Virgen et al. 2008). Mutations in the rhTRIMCyp 
cyclophilin domain D66N and R69H remodel the interacting surface by causing a 
change from ‘open palm’ to ‘closed fist’ conformation, resulting in a change in 
specificity from viruses that interact with CypA (e.g. HIV-1) to viruses that do 
not (e.g. HIV-2; Price et al. 2009). Uniquely, FIV is restricted strongly by both 
rh and omk variants, suggesting an alternative binding mechanism for this 
virus. ITC was performed to confirm that FIV capsid N-terminal domain (CAN) is 
able to bind the mutant rhTRIMCyp cyclophilin domain. To investigate how FIV 
is able to interact with both Cyp variants, crystal structures of FIV CAN were 
solved and showed that FIV has a shortened proline rich loop that is displaced 
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relative to the HIV-1 loop by ~15Å and hence is unaffected by the change from 
‘closed fist’ to ‘open palm’ conformation. We next asked how FIV is able to 
interact with CypA at a similar affinity to HIV-1, given that its proline-rich loop 
is substantially shorter and its binding surface is therefore reduced. Structure-
guided models were used to predict that FIV CA R89 makes stabilising 
hydrophobic and cation-π interactions with the CypA hydrophobic pocket. In 
support of this model, mutagenesis of this residue negatively impacts binding 
affinity. In contrast, mutation of P90 was found to completely ablate CypA 
binding in findings reminiscent of HIV-1. However, unlike its primate 
counterpart, the P90A mutant is found to be non-functional in tissue culture 
assays, suggesting critical structural significance. Finally, an alternative 
potential binding partner, Ranbp2, located at the nuclear pore is identified 
that bears a cyclophilin domain. FIV CA is found to interact with this protein in 
immunoblotting assays, and the potential for future work on this binding 
partner is discussed.  
The study finds that diverse lentiviruses have a conserved interaction with 
CypA that is beneficial to both HIV and FIV in cells of their respective hosts. 
The affinity of the interaction is maintained within a narrow range despite the 
highly divergent structure of the proline-rich loops. FIV is proposed to bind 
cyclophilin in a manner that allows promiscuous binding to both rhTRIMCyp and 
cytosolic free CypA. This mechanism is supported by structural and biophysical 
data.  
5.2 Results 
5.2.1 Identification of feline CypA  
An analysis of the nascent cat genome project (Pontius and O'Brien 2007) 
revealed the presence of two regions with high CypA homology, present in BAC 
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clones/contigs AC235013 and AANG01610851. To establish whether the genes 
are expressed in cat cells, total RNA was extracted from Mya-1 cells and RT-
PCR using primers specific to each CypA was performed. Products were cloned 
into prokaryotic expression vector pOPTH and sequencing confirmed 100% 
identity to published genomic sequences. Interestingly, the AC235013 sequence 
bears an arginine to cysteine substitution at position 69; this position is known 
to switch the specificity of rhesus TRIMCyp restriction from HIV-1 to HIV-2 
(Wilson et al. 2008; Virgen et al. 2008). However, when RNA preps were DNase 
treated before reverse transcription, amplification of the gene encoded by 
AC235013 was no longer successful, suggesting that previous amplification was 
from contaminating genomic DNA. In contrast, amplification of AANG01610851 
CypA (bearing R69) was DNase resistant, indicating that the latter is expressed 
in cat cells, confirming it as the biologically relevant version.  
An alignment of feline and human (NM_021130) CypA reveals 97% identity 
between the homologues (Figure 5-1), suggestive of highly conserved structure 
and function. In contrast, FIV and HIV-1 CA share only partial homology with 
29% identical residues, reducing to 23% in the N-terminal domain (CAN) (Figure 
5-2A). The sequence of the proline-rich loop is highly divergent, with the FIV 
loop shorter by four residues. Given this high level of sequence divergence, the 
finding that both capsids bind the relatively invariant CypA (Lin and Emerman 
2006) is therefore interesting as it suggests that either the capsids share 
conservation of structure despite divergent primary sequences, or that the 
capsids use alternative mechanisms to interact with CypA. Amongst strains of 
FIV, homology of CAN is substantially higher at 53% identical and 70% conserved 
residues (Figure 5-2B). Conservation is almost total within the proposed 
proline-rich loop, suggesting a biologically important and conserved 
interaction.  




Figure 5-1 Human and feline CypA share 97% identical residues. Beta strands are 
denoted by arrows and helices are denoted by cylinders. Residues F60, M61, F113 and 
L122 which create the substrate-binding hydrophobic pocket are marked by black bars. 
Large functional differences between the CypA homologues are unlikely given the high 
levels of identity. Identical residues in grey. 
 
 
Figure 5-2 Alignment of lentiviral capsid sequences. A) FIV and HIV-1 CA N-
terminal domains show substantial variation (23% identical residues, 43% conserved). 
Secondary structures are shown for HIV-1 CA, with arrows representing beta strands and 
cylinders representing alpha-helices (numbered for HIV-1). The proline-rich loop 
between helices 4 and 5 is present in both sequences (single bar) but is highly divergent 
in both its length and primary sequence. The nature of the isomeric peptidyl-proline bond 
(double bar) is also divergent, with FIV possessing RP compared to HIV-1’s GP. B) 
Capsid sequences from FIV strains isolated from diverse host species show substantial 
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conservation throughout CA and show high levels of conservation in the proline-rich 
loop. P90, shown to be crucial for CypA interaction and proposed site for cis-trans 
isomerisation (Lin and Emerman 2006) is indicated with a double bar. 
5.2.2 Biological effects of FIV CA-CypA interaction 
The inhibitor of the CA-CypA interaction, cyclosporine A (CsA), is an 
immunosuppressant that interferes with the intracellular T-cell activation 
pathway. CsA analogues NIM811 and Debio-025 were designed as non-
immunosuppressive CsA analogues that do not provide the calcineurin binding 
surface when complexed with CypA. The drugs were assayed for their toxic 
effect on activated feline T-cells Mya-1 (Miyazawa et al. 1989) and on naive 
CD3+ T-cell line CLL (Willett et al. 2006a) (Figure 5-3). Mya-1 cell viability was 
found to be substantially reduced after 5 days incubation with 2μM CsA, 
whereas NIM811 and Debio-025 showed a reduced toxic effect. CLL cells were 
largely unaffected by the presence of the drugs, as is expected given their lack 
of mitogen stimulation and activation.  
 
Figure 5-3 Relative toxicity of CypA-binding drugs. Cell viability was measured after 
5 days incubation in 2μM drug or solvent only (ethanol). For stimulated T-cell line Mya-
1, CsA was found to exert a 67% reduction on the percentage of viable cells, compared to 
a 27% reduction by non-immunosuppressive Debio-025. In contrast, CLL cells 
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transduced with feline CD134 were found to be unaffected by any of the drugs, 
indicative of their naive state.  
The ability of FIV to replicate in the presence of CsA and its analogues was 
assayed by challenging CLL CD134 and Mya-1 with FIV-Fca GL8 (Figure 5-4). In 
both CLL and Mya-1, a reduction in FIV replication was seen upon the addition 
of inhibitors, suggesting that the CA-CypA interaction is important for 
replication of FIV. Inhibition of replication was more pronounced in Mya-1, in 
particular with CsA, an effect presumably due to the toxicity effects of the 
inhibitors on Mya-1 cell viability.  
 
Figure 5-4 Inhibitors of the CA-CypA interaction impair FIV replication. CLL 
CD134 and Mya-1 cells were challenged with FIV-Fca GL8 and incubated with CsA and 
its analogues NIM811 and Debio-025 at 2µM. Supernatant aliquots were frozen and 
subsequently analysed for reverse transcriptase activity. A repeatable decrease in RT 
activity was observed in the presence of the inhibitors, suggesting that the CA-CypA 
interaction is important for replication of FIV.  
 For HIV-1, the effects of the CA-CypA interaction are manifest during the early 
post-entry stage of replication (Towers et al. 2003). To establish at which 
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stage of replication the CA-CypA interaction is important in the FIV lifecycle, 
the drugs were added to cells transfected with FIV-GFP(VSV)-encoding plasmids 
(virus production) or to target cells (virus entry). When added during virus 
production, supernatant was subsequently pelleted through a 20% sucrose 
cushion to remove traces of the inhibitor (Figure 5-5). A small non-significant 
increase in titre (two-tailed t-test; p = 0.094 for control vs 2μM CsA) was 
observed when inhibitors were added during virus production. A similar effect 
is seen in HIV-1 production in human cells, with a ~10% increase in viral titre 
reported by Towers et al. (2003). However, during viral entry, a 13-27% 
decrease in titre was observed at 0.5μM inhibitor that was significant (two-
tailed t-test; CsA p = 0.012; NIM811 p = 0.018; Debio-025 p = 0.0008 for control 
vs 0.5μM inhibitor). Although small in magnitude, repeated over several cycles 
of infection, this decrease in titre could substantially reduce the titre of 
replicating virus and is likely to be the cause of the reduced replication of FIV 
in Figure 5-4. We can therefore conclude that CypA acts as a cofactor for viral 
replication in cells of its host and that CypA exerts its effect post entry, early 
in the lifecycle. The findings are reminiscent of HIV-1, but of a much lower 
magnitude: HIV-1 pseudotype infectivity is reduced approximately three-fold 
during early replication stages of infection in human Jurkat and TE671 cells 
(Towers et al. 2003; Hatziioannou et al. 2005). However, for HIV-1, CsA 
treatment is proposed to increase susceptibility to an unidentified restriction 
factor in human cells (Keckesova et al. 2006; Sokolskaja et al. 2006) so much 
of the decrease in infectivity may be attributed to this factor. 




Figure 5-5 Effect of CypA inhibitors on FIV pseudotype production and entry. A) 
293T cells, transfected with FP93, GinSin and VSV-G expressor MDG were incubated 
with CypA inhibitors. Viral supernatant was pelleted over a sucrose cushion to remove 
inhibitors and titrated onto CrFKs at an moi of ~0.1. A small but non-significant increase 
in titre was observed for both CsA and NIM811. B) FIV-GFP(VSV) pseudotypes were 
titrated onto CrFKs pre-incubated with CypA inhibitors at an moi of ~0.1. A significant 
decrease in titre was seen for 0.5μM of all the drugs, an effect that seemed to diminish as 
concentrations increased further. A toxic effect of NIM811 on CrFK cells was observed 
at 4 μM and no data was recorded for these samples. n = 3. 
Restriction of HIV-1 by rhesus macaque TRIM5α is enhanced by the presence of 
CypA, suggesting that CypA perfoms a catalytic role that promotes the TRIM5α-
CA interaction (Keckesova et al. 2006; Berthoux et al. 2005; Stremlau et al. 
2006a). In contrast, in humans cells it is probable that CypA both aids in 
uncoating and protects HIV-1 from an unidentified post-entry restriction factor 
(Keckesova et al. 2006; Sokolskaja et al. 2006). To assess whether CsA affects 
huTRIM5α-mediated or other restrictions of FIV in human cells, FIV-GFP(VSV) 
pseudotypes were titrated onto human TE671 and HeLa cells in the presence of 
CsA or solvent only (Figure 5-6). In TE671 cells, no change in FIV infectivity was 
observed, suggesting that in these cells FIV is not targeted by the unidentified 
human factor, nor does the CypA-CA interaction alter the huTRIM5α-mediated 
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restriction of FIV. However, in HeLa cells, which are known to express much 
higher levels of CypA, a much lower level of infection is achieved, which 
reduces further on the addition of CsA. Although the causes of these cell type-
specific responses are unknown, by analogy with HIV they suggest a role for 
CypA in either uncoating or protection from restriction factors. 
 
Figure 5-6 Differing effects of CsA treatment on FIV infectivity in human cells. 
TE671 and HeLa cells, which express low and high levels of CypA respectively, were 
infected with FIV (VSV)-pseudotyped particles in the presence or absence of CsA. The 
results suggest that in HeLa cells, CypA aids in FIV infectivity, possibly by aiding 
uncoating or protecting from a restriction factor such as TRIM5α.  
To investigate whether restriction of FIV by TRIM5α can be modulated by the 
CA-CypA interaction, CrFK cells transduced with huTRIM5α were challenged 
with FIV-luc(VSV) pseudotypes (Figure 5-7). An approximately 10-fold reduction 
in titre is observed in cells expressing huTRIM5α, and a reduction in titre 
associated with addition of CsA is more pronounced in the presence of TRIM5α. 
However the magnitude of the change is small, and given that TRIM5 is non-
functional as a restriction factor in cat cells (Chapter 4; McEwan et al. 2009), 
the FIV CA-CypA interaction is unlikely to have evolved for this purpose.  




Figure 5-7 Effect of CsA and TRIM5α on FIV infectivity. CrFK cells transduced with 
human TRIM5α were challenged with FIV-luc(VSV) pseudotypes. TRIM5α reduces FIV 
infectivity by an order of magnitude. CsA has a greater effect on the infectivity in the 
presence of TRIM5α, suggesting that isomerase activity of CypA may protect FIV 
slightly from TRIM5α-mediated restriction. However, FIV has evolved in the absence of 
functional TRIM5α (Chapter 4; McEwan et al. 2009), making deliberate evasion of 
restriction by this mechanism an unlikely biological scenario. 
5.2.3 ITC reveals lentiviral CA-CypA affinity to be conserved 
To investigate the binding properties of FIV capsid for CypA, the CAN of FIV-Fca 
and FIV-Ple E Sangre as well as domestic cat and lion CypA genes were cloned 
into prokaryotic expression vector pOPTH and recombinant His-tagged proteins 
were purified by Ni-affinity chromatography. Further purification of proteins 
was performed by ion exchange chromatography and, for CAN constructs, 
subsequent gel filtration (see Materials and Methods). The proteins were 
prepared for isothermal titration calorimetry assays that measure the change 
in enthalpy associated with intermolecular interactions when CypA is titrated 
into CAN (Figure 5-8 and Table 5.A). The analysis reveals that FIV-Fca CAN binds 
its cognate CypA partner with a stoichiometry of 1:1 and a Kd of 6.2 μM, a 
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figure that compares closely to HIV-1 CA-CypA interaction of 5.3 μM. FIV-Ple 
CAN was found to bind lion CypA with a slightly higher affinity, at 2.2 μM. 
Changing the species of the CypA had little effect on the Kd, suggesting that as 
predicted, the species-specific differences between feline and human CypA 
have little effect on the interaction. 
 
Figure 5-8 Isothermal titration calorimetry reveals FIV to bind CypA. Example trace 
of ITC shows heat associated with multiple injections of CAN into cell bearing cat CypA. 
The reaction has a stoichiometry (N) of approximately 1:1, Kd of 6.2μM and is 
exothermic, ΔH = -8579 cal/mol. 
 
Cat CypA Lion CypA Human CypA 
FIV-Fca 6.2 7.8 7.2 
FIV-Ple 1.9 2.2 3.0 
HIV-1 n.d. n.d. 5.3 
Table 5.A Binding constants for capsid and CypA variants. Various CAN domains 
were assessed for their ability to bind CypA. Shown are Kd values in µM. FIV-Ple is 
found to have the highest binding affinity at 2.2μM for its cognate CypA, whilst FIV-Fca 
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and HIV-1 Kd values are very similar. 
affinity of the interaction, and all interactions were within a narrow range of 2
5.2.4 Structural analysis of feline cyclophilin A
The similarity of binding constants between human and feline CypA are in 
accordance with the high levels of 
structure of feCypA was solved and reveals almost total conservation of 
structure around the hydrophobic pocket (
substitutions between t
Figure 5-9 Superimposed structure
structure of feline CypA (light blue) was solved and superimposed on published hu
CypA (white) structure bound to HIV
in green; PDB: 1AK4). Around the hydrophobic pocket, which interacts with HIV
structural conservation is high. A rotated view (right) shows feline mutations I5, D23, 
D84 and M131 (sticks) to be on the posterior and lateral surfaces, making substantial 
differences in biological activities of human and feline CypA unlikely.
5.2.5 FIV interacts with both CypA and rhesus TRIMCyp
The cyclophilin domain of rhesus macaque TRIMCyp b
relative to wildtype CypA that alter its specificity from HIV
 
Changing the CypA variant had littl
 
similarity between these proteins. A crystal 
Figure 5-9). The four amino acid 
he species are found on the distal surfaces.
s of human and feline cyclophilin A.
-1 capsid (proline-rich loop AGPIAP motif shown 
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HIV-2 binding (Price et al. 2009). Substitutions D66N and R69H result in a 15Å 
remodelling of a 10-residue lobe to give the closed fist conformation and 
precluding HIV-1 CA binding. FIV is unique in that it can be restricted by both 
owl monkey TRIMCyp, whose CypA domain resembles wildtype CypA, and 
rhTRIMCyp. To formally demonstrate FIV CA-rhTRIMCyp binding, ITC was 
performed using CAN and the Cyp domain of rhTRIMCyp and, as predicted an 
interaction was observed. However, suggestions that FIV’s high sensitivity to 
rhTRIMCyp restriction may be due to high binding affinities were unfounded as 
the Kd was found to be lower than for feCypA (Table 5.B), suggesting that the 
sensitivity is achieved through other means. 
 
Cat CypA rhTCyp 
FIV-Fca 6.2 10.9 
FIV-Ple 1.9 7.3 
Table 5.B. Binding constants for FIV CAN-rhesus TRIMCyp. FIV is particularly 
sensitive to restriction by rhesus macaque TRIMCyp (Virgen et al. 2008), but the 
sensitivity is not conferred by a higher affinity interaction between CA and rhTRIMCyp 
compared to CypA. 
5.2.6 Crystal structure of FIV capsid  
Despite being highly divergent at the protein level, HIV-1 and FIV both interact 
with CypA at affinities within a small range of Kd values. Especially interesting 
is the conformation of the highly divergent predicted proline-rich loop raising 
interesting questions about the comparative structures. Do FIV and HIV-1 share 
a similar structure in order to interact with CypA or is binding by FIV achieved 
via a different mechanism? And what is the basis of FIV’s dual specificity for 
CypA and rhTCypA? In order to address these questions, a crystal structure of 
FIV CAN was sought and solved to a resolution of 2.3Å.  
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The structure of FIV CAN is the first published to date. Comparison of the 
structure with HIV-1 capsid (1AK4; Gamble et al. 1996) reveals a remarkably 
conserved wedge-shaped structure, with the proline-rich loop extending 
outwards between helices 4 and 5 (Figure 5-10). The α-helices display a 
strikingly similar orientation in most regions of the protein, representing 
conserved exposed regions of capsid core meta-structure. One particular region 
of dissimilarity is in the FIV region corresponding to HIV-1 helices 5 and 6 which 
appear to be fused creating a longer kinked C-terminal helix. The α-6 α-7 
linker region in HIV-1 bears a proline-proline dipeptide that re-orientates the 
strand the downwards into the α-6 helix. This linker region, including the PP 
dipeptide, is missing in FIV, resulting in the enlarged fusion helix.  
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Figure 5-10 Superimposed structure of FIV and HIV-1 capsid N-terminal domains. 
Despite only 23% identical residues, FIV (dark red) and HIV-1 (1AK4) (grey) capsids 
share remarkable structural conservation, characterised by a wedge-shaped structure 
comprising the major helices 1, 2, 3, 4 and 7 (HIV-1 numbering) with a proline-rich loop 
extending outwards between helices 4 and 5. The side chains in the crest of the proline-
rich loops are shown as sticks (FIV: 87GPRPL91 , HIV-1: 89GPIAP93, isomerised bond 
underlined) and reveal FIV to have a divergent loop that is displaced by ~13Å. A side 
view (below) clearly shows the fusion of helices 6 and 7 that creates the larger FIV N-
terminal α-helix. 
5.2.7 Proline-rich loop mutants identify important residues in the CA-
CypA interaction 
As is evident from the primary sequence alignment, the proline-rich loop for 
FIV is considerably shorter than in HIV-1, raising interesting questions about 
how the shorter FIV loop is still able to bind CypA. To address this issue, two 
alternative methods were employed. Firstly, it was attempted to crystallise 
CAN-CypA complexes. CAN and huCypA as well as CAN and rhTCypA were mixed 
at 1:1 molar ratio and run on a gel filtration column to purify the larger, 
complexed species. However, crystallisation of the complex was unsuccessful 
with only uncomplexed CAN or CypA crystals forming. Secondly, it was 
attempted to use 4-mer or 5-mer oligopeptides corresponding to the proline-
rich loop of FIV CA with feCypA to grow complexed crystals. However, initial 
ITC experiments to confirm binding of the peptides were unable to show an 
interaction. A crystal screen was performed nonetheless and yielded crystals 
for the 4-mer peptide. Subsequent X-ray diffraction revealed that the peptide 
had not bound, with the symmetric unit comprising only feCypA.  
A model of the FIV CA-CypA interaction was therefore made by superimposing 
the CA structure on HIV-1-CypA structure. The model suggests that the short 
FIV proline-rich loop has a reduced region of contact with CypA, not extending 
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CypA interaction, and provides some insight as to why FIV and HIV-1 diverge at 
this residue. In contrast, mutating the P90 residue to alanine was found to 
prevent detectable interaction with CypA, indicating the structural importance 
of this residue. A P90A mutant of replication-competent FIV molecular clone, 
as well as pseudotyped mutant was also generated but unlike HIV-1 where 
mutating P90 prevents the CypA interaction but allows infection, the FIV P90A 
mutants were found to be non-functional. This finding has been repeated by 
others (G. Towers, personal communication) but is in contradiction to Lin and 
Emerman (2007) who were able to produce viable pseudotype with the P90A 
mutation. The discrepancy is potentially explained by the use of alternative 
strains of FIV (Lin and Emerman used 34TF10, whereas this study used GL8) but 




Table 5.C Binding affinity for FIV CA mutants with cat CypA. CAN mutants R89G, 
which is hypothesised to contribute to the binding of the CypA catalytic domain through 
cation-π interactions, and P90A, which is proposed to be the site of cis-trans isomerase 
activity, were assayed for their ability to bind cat CypA by ITC. As predicted, R89 
contributes to the strength of interaction with Cyp as mutation to the corresponding HIV-
1 residue glycine reduces binding affinity substantially. Mutation of P90 prevents 
detectable interaction. 
Structure-guided models were used to assess how FIV is able to interact with 
both wildtype CypA and rhTRIMCyp. The model suggests that that the shorter 
FIV proline-rich loop is deflected away from the 66-73 loop by a kink generated 
by proline 85, so that when bound to rhTRIMCyp with its ‘closed fist’ 
conformation, the 66-73 loop does not interfere with binding (Figure 5-12). 
 Kd (μM) 
FIV-Fca WT 5 
FIV-Fca R89G 21 
FIV-Fca P90A None detected 
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Figure 5-13 The presence of a proline-rich loop is not a feature unique to viruses 
which bind CypA. Alignment of amino acid sequences to HIV-1 shows that a proline-
rich region is present in HIV-2 which does not bind CypA and is even present in EIAV. 
Y or N indicates studies demonstrating CypA binding or its absence; HIV-1 domain 
architecture is shown.  
These observations support the hypothesis that the primary function of the 
proline-rich loop is to interact with an alternative protein that resembles 
CypA, as this would explain the close resemblance to the CypA-binding loop in 
viruses such as HIV-2. A search was therefore carried out for genes which 
contain a CypA domain, and that might be important for post-entry stages of 
the lifecycle. Most notably, a protein was identified in a BLAST search of 
human RefSeq protein sequences that bears a domain closely related to CypA, 
named Ranbp2 or Nup358. Ranbp2 is a large (358 kDa) protein located at the 
nuclear membrane that is involved in conversion of RanGTP to RanGDP, a 
process important for translocation of cellular proteins across the nuclear 
membrane. Consistent with a possible role in the lentiviral lifecycle, the 
protein has been identified in three out of four whole genome siRNA screens as 
a necessary cofactor for HIV replication (Bushman et al. 2009; Konig et al. 
2008; Brass et al. 2008; Ranbp2 was not identified in Zhou et al. 2008). An 
obvious potential role of Ranpb2 is interaction with capsid present in the RT-
complex to facilitate entry to the nucleus, a requirement for replication in 
non-dividing cells. However, being a major component of the nuclear pore 
complex, it is unclear whether knockdown of Ranbp2 specifically prevents HIV-
1 nuclear import or simply structurally compromises the nuclear pore.  
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The N-terminal domain of CA bears the proline-rich loop responsible for 
interacting with CypA. It was therefore decided to use CAN, in order to identify 
bands which only interact with this domain (Figure 5-15). Human cell lysate 
was found to interact with FIV CAN at ~130 kDa and a doublet at ~65 kDa. The 
bands at 55 and 110 kDa were no longer present, perhaps indicative of a CA C-
terminal-specific interaction. The human cell lysate was also probed with α-
Ranbp2 polyclonal antibody and found to identify the same bands at ~130 kDa 
and a doublet at 65 kDa. The data therefore represent strong evidence that FIV 
CA can interact with Ranbp2. However, bands at the expected Ranbp2 size of 
358 kDa were faint or not identified. This suggests that the protein is perhaps 
poorly transferred to the membrane in its full size and the bands indentified 
are likely to be either Ranbp2 isoforms or products of proteolysis. The P90A 
mutant, previously shown to be non-functional for replication and unable to 
bind CypA, was found to identify the same bands. The result is surprising given 
the hypothesised lack of interaction for this protein. One possible explanation 
for this binding is the large excess of CA used to probe the membrane and the 
non-stringent binding conditions may have allowed complete saturation of the 
sites available for binding on the membrane. Further optimisation of this 
technique may allow detection of bands of differential intensity that better 
reflect the binding affinity. 
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is modestly increased by treatment with CsA, suggesting that in this system 
CypA can protect against restriction. In contrast restriction of HIV-1 by 
rhTRIM5α is promoted by CypA (Keckesova et al. 2006; Berthoux et al. 2005; 
Stremlau et al. 2006a). The best current model of the effects of CypA on 
lentiviral infectivity suggests that CypA performs a catalytic isomerisation that 
alters capsid conformation which subsequently alters the ability of other 
cellular restriction factors to recognise and destroy incoming capsid (Towers 
2007; Luban 2007). This suggests that in the context of TRIM5α, where binding 
is mediated by variable domains in the B30.2 domain, its ability to bind and 
restrict can be modulated by CypA (potentially increasing rhTRIM5α’s affinity 
for HIV-1; decreasing huTRIM5α’s affinity for FIV). Although CypA has been 
shown to perform such a catalytic role on CA in vitro, the in vivo relevance of 
isomerisation has yet to be formally demonstrated. Other hypotheses, such as 
generation of a novel CA-CypA complexed surface that is subsequently 
recognised by restriction factors, or CypA-dependent recruitment of cellular 
machinery cannot be ruled out. Study in this field is impeded by the absence of 
CypA mutants that bind CA but do not perform the catalytic function, and 
similarly, functional CA mutants that bind CypA but cannot be isomerised. Thus 
like some of the primate lentiviruses, infectivity of FIV is influenced by the CA-
CypA interaction but its precise role remains unclear. 
Unlike the surfaces of restriction factors that interact with pathogens, CypA is 
remarkably conserved. Its ubiquitous expression and relative invariance suggest 
a critical house-keeping role, although its function is elusive. Yeast mutants 
lacking all twelve cyclophilin genes remain viable, although display retarded 
growth (Dolinski et al. 1997). Moreover, the contribution of each knockout 
gene is additive, suggesting that the cyclophilins do not complement each 
other’s function and that each cyclophilin has a specific role, rather than each 
contributing to a protein folding phenotype. Roles for individual proteins have 
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been ascribed to several cyclophilins such as signal transduction (Duina et al. 
1996) and rhodopsin folding (review Gothel and Marahiel 1999; Stamnes et al. 
1991) but CypA has no precise role defined to date. Nevertheless, it is likely 
that CypA is constrained by cellular tasks and is unable to undergo the high 
levels of positive selection that interaction with pathogens usually entails. 
However, the TRIMCyp fusion protein is presumably relieved of its cellular role 
and, in rhesus macaques, has acquired mutations that remodel the binding 
surface and promote HIV-2 restriction (Wilson et al. 2008; Virgen et al. 2008; 
Price et al. 2009). The ability of FIV to bind both Cyp variants demonstrates 
that binding to CypA and rhTRIMCyp are not properties mutually exclusive to an 
individual virus.  
It is becoming clear that lentiviruses maintain the affinity of the CA-CypA 
interaction within a narrow range. It would be expected that HIV-1 growing in 
the absence of CypA (e.g. under CsA inhibition) would acquire mutations to 
increase the affinity in order to maintain a given level of CA-Cyp interactions. 
However, the mutants arising possess Kd values within the same low 
micromolar range but may be more sensitive to the activity of CypA, perhaps 
by being more liable to uncoating by low levels of peptidyl-proline 
isomerisation. The finding that FIV binds CypA with almost identical affinity as 
HIV-1 is surprising given the evolutionary distances and scarce amino acid 
identity between the viruses and implies that binding to CypA is very tightly 
regulated on the part of the virus. Moreover it appears that viruses can employ 
a CypA-dependent or –independent strategy with no more than a few point 
mutations. HIV-2 can switch to CypA binding with a single mutation at A88 
(Price et al. 2009) and HIV-1 CsA-independent strains are circulating in humans 
at 4-7% of strains in the Los Alamos database (Chatterji et al. 2005). These 
findings were the rationale for investigating other proteins with cyclophilin 
domains which raises the potential lentiviral co-factor Ranbp2. Future work 
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will attempt to demonstrate a functional association between capsid and this 
protein. It is of note that Ranbp2 interacts with microtubules in the cytoplasm 
and since lentiviral particles are known to use the microtubules for transport 
towards the nucleus (Arhel et al. 2006; McDonald et al. 2002), this suggests a 
potential role of the Ranbp2 Cyp domain in permitting docking of the RT 
complex at the nuclear pore before transport across the nuclear membrane. If 
nuclear entry is found to be dependent on Ranbp2, there are likely to be 
implications for strategies to disrupt the HIV lifecycle through cyclophilin 
inhibitors. For example, it has been proposed to make artificial restriction 
factors involving CypA, such as Fv1Cyp and huTRIM5-CypA fusion protein. 
However, given the ease with which lentiviruses are able to dispense with the 
CypA interaction the restriction factors are unlikely to be robust against escape 
mutants. The cyclophilin domain of Ranbp2 is fairly divergent from cytosolic 
CypA, with the human versions sharing 66% identity, potentially making it 
possible to maintain Ranbp2 binding whist switching on or off CypA binding. 
Thus, if the CA-Ranbp2 interaction is proven to be required for infection of 
non-dividing cells, inhibition of this interaction or restriction factors that 
mimic the Ranbp2 Cyp domain are more likely to be successful.  
 Chapter 6. Characterisation of intrinsic 
immunity to lentiviruses in African lion cells. 
6.1 Summary 
The feline immunodeficiency virus infects numerous Feliform species as 
species-specific viral strains. In each host, the virus has undergone 
considerable selection to allow successful replication and population invasion. 
In contrast, hosts will attempt to limit infection, and genetic variants that 
confer resistance to viral replication will be selected, creating a molecular 
arms race between host and pathogen. In order to assess the impact of such 
antagonistic relationships in the felids, a comparison was made between a 
relatively recent host of the virus, the domestic cat (<10,000 years infected) 
and a more ancient host, the African lion which is likely to have been infected 
with lentiviruses since the early Pleistocene (Antunes et al. 2008). Lion cells 
support very low levels of replication of both domestic cat and lion variants of 
FIV. In contrast, domestic cat cells support high titre replication of all viruses 
assayed. The results are interpreted as evidence of the existence of a block to 
lentiviral replication in lion cells relative to the novel host, the domestic cat. 
This block is termed lion cell non-permissivity (LNP) and is further explored in 
this study. LNP is found to be a dominant post-entry block to replication that 
targets both feline and primate lentiviruses. TRIM5α is truncated in lion cells, 
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eliminating this protein as a candidate for LNP. Moreover, treatment of lion 
cells with proteasome inhibitor MG312 does not affect the level of restriction, 
nor does treatment with As2O3, a drug that disrupts sub-cellular localisation 
and antiviral activity of TRIM proteins (Zhu et al. 1997; Anderson et al. 2006). 
Furthermore, unlike TRIM5α restriction, LNP does not target the N-terminal 
domain of capsid. The identity of the cause of LNP is unknown but does not act 
in a manner similar to previous well characterised post-entry restriction 
factors.  
Subsequently, a comparative analysis of the APOBEC3 (A3) family of restriction 
factors is performed between lions and domestic cats. In domestic cats, read-
through fusion protein A3CH is a potent restriction factor whilst single domain 
proteins A3C and A3H are inactive against FIV (Munk et al. 2008). In lions, A3CH 
retains this antiviral activity but surprisingly, FIV replication is also blocked by 
single domain protein, lion A3H. This result is of interest as for most A3 
proteins, two domains are required for antiviral activity with one domain 
specialising in RNA binding and the other in single-stranded (ss) DNA 
deamination. A homology model is used to predict the residues in lion A3 that 
potentially permit RNA binding and dimerisation. The study shows that lions 
possess a strong intrinsic immune protection from lentiviruses and provide 
evidence of evolution of host restriction in the felids in response to ongoing 
infections.  
6.2 Results 
6.2.1 Lion T-cells poorly support the replication of FIV-Fca 
To investigate the ability of host cells to support the replication of FIV, 
concanavalin A stimulated, IL-2 dependent T-cells were challenged with four 
viral strains, two lion derived strains (FIV-Ple E Sangre and Ple B 458) as well as 
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two molecular clones of domestic cat FIV (FIV-Fca GL8 and Petaluma). The lion 
cells used in this experiment are derived from an uninfected Angolan lion, 
whilst Mya-1 T-cells (Miyazawa et al. 1989) were used for domestic cat. Puma 
T-cells were derived from a specific-pathogen free North American puma 
(Puma concolor). Frozen viral supernatant was examined for reverse 
transcriptase activity as a marker of retroviral replication. Cells from domestic 
cat supported replication of all viruses tested, whist Angolan lion and Puma 
cells supported only very low titres of FIV-Fca but did permit FIV-Ple B 
replication (Figure 6-1). Interestingly, the lion cells used in this experiment 
were unable to support the growth of FIV-Ple E, a strain circulating in southern 
African lions (Pecon-Slattery et al. 2008a). The findings are reminiscent of 
VandeWoude et al. (1997) who found that lion cells poorly supported the 
replication of FIV-Fca. However, these findings go further as they suggest that 
even host-adapted strains FIV-Ple B 458 and FIV-Ple E Sangre are poorly 
infectious in lion cells.  
 
Figure 6-1 Host permissivity to FIV replication. FIV is able to replicate to high titres 
in cells of the domestic cat, whereas Angolan lion and Puma cells poorly support growth 
of domestic cat strains of FIV (GL8 and Petaluma) and only support growth of lion-
derived FIV in a strain-dependent manner. 
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The data imply that either the viruses are unable to make use of the lion/puma 
cell host machinery or there exists a dominant block to replication in these 
cells. Given that lions are the natural host of FIV-Ple, the former case is 
unlikely since considerable host-adaptation will have taken place in the time 
since lentiviruses entered the species, estimated between 169,000 and 3.6 mya 
(Antunes et al. 2008; Pecon-Slattery et al. 2008b). Furthermore FIV-Ple strains 
are able to replicate to high titres in domestic cat cells, a non-native host, 
implying that the ability to replicate to high titre is a factor that is host- but 
not virus-dependent. The only strain that produced a positive RT result  in lion 
cells at seven days post-infection was FIV-Ple B, a strain that uses non-CD134, 
non-CXCR4 entry receptors (Chapter 3; McEwan et al. 2008). This raised the 
possibility that mutations in either of these receptors are responsible for the 
non-permissive phenotype in lion cells. 
6.2.2 Contribution of receptor variation to LNP 
To test the hypothesis that LNP is due to lion mutations in CD134 or CXCR4, 
variants of the receptor and co-receptor from cats and lions were cloned and 
sequenced. Analysis of the sequences reveals that lion and feline CD134 share 
97% amino acid identity with a cluster of amino acid mutations in the predicted 
signal peptide region and a G59S point mutation in the predicted Env binding 
site, cysteine-rich domain 1 (CRD1), which could potentially alter Env binding 
and entry. An alignment of feline and lion CD134 has been presented previously 
in Figure 3-8. A comparison of the lion and feline CXCR4 seven-transmembrane 
domain protein shows 99% amino acid identity with only a single amino acid 
change, a serine to asparagine substitution in extracellular loop 2 (ECL2), 
creating a potential N-glycosylation site in lion CXCR4 at position N193. 
Whether this site is in reality glycosylated in lion CXCR4 has not been studied 
but any of these interspecific polymorphisms could potentially alter the Env-
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receptor interaction and be responsible for LNP. CD134 and CXCR4 of each 
species were therefore stably expressed in all four combinations on NP2 cells 
and challenged with HIV-luc particles pseudotyped with a panel of FIV Env 
glycoproteins (Figure 6-2). Permissivity of the cell lines was not substantially 
altered by changing the combinations of receptor and co-receptor, suggesting 
that domestic cat and lion CD134 and CXCR4 support infection of FIV at similar 
levels. These data indicate that LNP cannot be explained by differences in 
entry receptors as lion CD134 and CXCR4 support levels of infection directly 
comparable to those of the domestic cat for a range of FIV envelopes.  
 
Figure 6-2  FIV usage of lion CD134 and CXCR4. Cat and lion FIV entry receptor 
CD134 and co-receptor CXCR4 from domestic cats and lions were expressed in all four 
combinations on NP2 cells and challenged with panel of HIV-luc(FIV) pseudotypes 
using various Env isolates from domestic cats. Levels of entry were similar regardless of 
receptor combination indicating that lion cell non-permissivity is not due to differences 
in efficiency of the entry receptors between cats and lion. 
6.2.3 LNP operates post-entry against primate lentiviruses. 
The finding that species-specific polymorphisms in receptor and co-receptor do 
not account for the differing levels of infectivity suggests that receptor binding 
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and entry are not the stages responsible for LNP. However, it remains possible 
that receptor expression levels differ between the species or access to 
receptors is somehow impeded in lion cells. To obviate this problem, pan-
tropic VSV-G-pseudotyped particles were used in preference to FIV Env for the 
remainder of this study. In order to assess the breadth of LNP lentiviral targets, 
lion cells and domestic cat cells were challenged with primate lentivirus 
pseudotypes. Lion T-cells were found to permit much lower levels of infection 
compared to domestic cat cells. Furthermore a differential level of restriction 
was found between the viruses used: HIV-1 was restricted at a low level, whilst 
SIV from rhesus macaques (SIVmac) was restricted at much higher levels, a 
difference that was found to be repeatable and statistically significant (Figure 
6-3).  
 
Figure 6-3 Lion cells differentially restrict primate lentiviruses. A) GFP-bearing 
VSV-G-pseudotyped particles of primate lentiviruses display a reduced titre on lion 
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compared to domestic cat T-cells. B) Expressed as fold restriction, HIV-1 is restricted 
about 20-fold whilst SIVmac is restricted about 80-fold and HIV-2 is restricted at an 
intermediate level. There is a significant difference between levels of restriction between 
HIV-1 and SIVmac (unpaired two-tailed t-test, n=3). 
To assess the relative ability of T-cells to support lentiviral infection, 
pseudotypes were titrated onto permissive CrFK as well as Mya-1 and Angola-1 
cells (Figure 6-4). Mya-1 and Angola-1 cells supported levels of infection far 
below CrFKs. For FIV, the levels of infection achieved in lion cells were too low 
for meaningful interpretation. Optimisation of the pseudotype production 
protocol by altering the ratio of plasmids transfected, use of phenol red-free 
medium and transfection reagent all allowed marginal increases in titre, but 
titres were always in the region of 105 infectious units per ml. Titres of HIV-1 
were much higher, possibly due to the fact that pseudotypes were produced in 
human cells.  
 
Figure 6-4 Titration of HIV and FIV pseudotypes. 10-fold serial dilutions of 
pseudotype were titrated onto CrFK, Mya-1 and Angola-1 lions T-cells and GFP positive 
cells were enumerated. Multiplicities of infection (number of infectious units per cell) 
were calculated for undiluted supernatant and show that CrFKs are ~1,000 times more 
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susceptible to HIV infection than Mya-1. Lion cells display a further ~25-fold restriction 
to HIV compared to Mya-1 cells. 
The results imply that LNP operates post-entry and has a broad specificity of 
infection. The difference in restriction levels between SIVmac and HIV-1 allows 
further dissection of the LNP phenotype.  
6.2.4 Mapping the viral determinants of LNP  
Given that post-entry restriction factors such as Fv1 and TRIM5α are known to 
target incoming viral capsids, it was proposed that LNP might also employ this 
strategy. Although it is known that lions lack a functional TRIM5α (McEwan et 
al. 2009; Chapter 4) and Fv1 is specific to mice (Best et al. 1996), it was 
hypothesised that LNP may share its target in common with these post-entry 
restriction mechanisms. In order to test this hypothesis, a chimeric HIV-1-
SIVmac construct was used, HIV S/H CA (Owens et al. 2003). HIV S/H CA is an 
HIV-1 gag-pol expressor with the N-terminal 146 amino acids of capsid replaced 
with that of SIVmac. It was found that using this construct gave no significant 
increase in levels of restriction relative to HIV-1, indicating that LNP does not 
target the N-terminal domain of capsid. As a control, the chimeric and 
wildtype viruses were assayed against puma cells but found to lack the LNP 
phenotype, providing evidence that LNP is specific to the Panthera lineage. 




Figure 6-5 Chimeric lentiviral capsid is not targeted by LNP. HIV-1 and chimeric 
S/H capsids were restricted only mildly, whilst SIV capsid was restricted strongly. Puma 
cells were used as a comparison and show no restriction of pseudotypes when compared 
to domestic cats. 
6.2.5 Sensitivity of LNP to proteasome inhibitor and arsenic compounds 
MG132 is a protease inhibitor that relieves the block to reverse transcription 
imposed by TRIM5α on restricted lentiviruses (Anderson et al. 2006; Wu et al. 
2006). Another drug, As2O3, has been shown to rescue restriction of HIV-1 by 
TRIM5α (Berthoux et al. 2003; Saenz et al. 2005). The activity of As2O3 is poorly 
defined but may exert its effects by disrupting the formation of cytosolic 
protein concentrations known as cytoplasmic bodies, which contain TRIM family 
proteins such as TRIM5α (Campbell et al. 2007) and PML (also known as TRIM19) 
(Reymond et al. 2001; Zhu et al. 1997). Furthermore, the drug has been shown 
to disrupt an unidentified restriction phenotype against HIV-1 in human 
dendritic cells (Pion et al. 2007). However, no effect was observed when lion 
and cat cells were treated with the drugs (Figure 6-6), suggesting that the 
restriction is not caused by proteasome-dependent pathways or arsenic-
sensitive proteins. 




Figure 6-6 Protease inhibitor and arsenic trioxide do not relieve LNP. Cat and lion 
T-cells were incubated with MG132 (1 µg/ml) or As2O3 (2 µM) prior to infection. No 
substantial change was observed in the restriction of HIV-1. For As2O3 experiment, n =3. 
6.2.6 Analysis of feline APOBEC3 genes 
It has previously been reported that the domestic cat genome bears an 
expanded cluster of APOBEC3 genes (Munk et al. 2008). In order to test 
whether extended periods of endemic lentiviral infection have altered the 
restrictive ability of lion APOBECs, A3C, A3H and A3CH were amplified from 
lion and domestic cat cDNA and cloned into eukaryotic expression vector 
VR1012. The cloned genes were sequenced and found to bear 100% identity to 
published sequences, except lion A3CH, as this is the first published sequence 
for this gene. The lion A3C transcript cloned was found to encode A3C1 variant 
as described previously (Munk et al. 2008). Homology between feline A3H and 
the huA3G catalytically active CD2 is low but the Zn-coordinating motif is 
present in both (Figure 6-7). Restriction by human A3G is contingent on both 
RNA-binding and catalytic functions, and accordingly it has previously been 
reported that domestic cat A3C and A3H are inactive against FIV, whilst two-
domain read-through protein A3CH is highly active.  




Figure 6-7 Alignment of feline A3H and human A3G C-terminal catalytic domain. 
The domains share only 33% sequence identity, but share the Zn-coordinating H/C-X-E-
X23-28-P-C-X2-C motif. The three arginine residues of huA3G predicted to form the 
charged single-stranded DNA binding groove (Chen et al. 2008) are marked with double 
black bars and are conserved in the feline variant. 
To assess the impact of the felid A3 genes on the infectivity of FIV, VR1012-A3 
plasmids were co-transfected with FIV∆Vif-GFP(VSV)-encoding plasmids FP93, 
GinSin and MDG. The viral titre was then assayed by plating supernatant onto 
fresh target 293T cells (Figure 6-8). 0.25µg of plasmids encoding read-through 
transcript A3CH from both lions and cats was sufficient to completely abolish 
the production of infectious FIV virions. The feline single domain A3C and A3H 
were unable to restrict virus, suggesting that in domestic cats fusion of the two 
domains is necessary to produce a functional restriction factor. In contrast, the 
lion A3H protein was able to restrict the production of infectious virions, 
despite being a single domain protein, raising questions concerning the 
mechanism of restriction for the single-domain restriction factor.  




Figure 6-8 Titrations of feline and lion APOBECs. 293T cells were transfected with 
plasmids encoding FIV-GFP(VSV) pseudotype and VR1012-A3, normalised with empty 
VR1012 vector. Pseudotype was harvested, plated onto fresh 293T cells and GFP 
expression examined. Read-through transcripts from both species prevented production 
of infectious virus above 0.25µg plasmid. A strong restriction was also provided by lion, 
but not feline, single domain protein A3H.  
For both HIV-1 and FIV, the APOBEC restriction is largely overcome by the 
expression of accessory protein Vif (Munk et al. 2008; Sheehy et al. 2002). To 
assess the ability of Vifs to counteract the restriction phenotype, genes were 
cloned from FIV-Ple strains B and E and were co-transfected into viral 
producing cells. Given the ability of FIV-Ple B to replicate in lion cells, it was 
expected that this Vif variant may provide the strongest rescue of titre. 
However, very little Vif-dependent rescue was observed against any of the A3s, 
with the exception of liA3C1 (Figure 6-9). It is possible that this poor Vif 
activity is due to poor or mis-located expression (see 6.3 Discussion), making it 
difficult to draw robust conclusions from these data. 




Figure 6-9 Lentiviral restriction imparted by feline and lion APOBEC3 genes. A 
strong restriction phenotype is associated with the lion A3s as well as feline A3CH. With 
the potential exception of liA3C1, Vifs were unable to overcome the restriction. 
However, this may owe more to problems with expression than biological activity. 
6.2.7 Structural comparisons of feline APOBEC3H 
In human cells, the antiviral APOBEC3s are two-domain proteins with both RNA 
binding ability (associated with CD1) and ssDNA deaminase activity (associated 
with CD2). It was therefore surprising to find antiviral activity associated with 
the lion single domain proteins. Structural studies of human A3G CD2 have 
revealed the presence of a positively charged groove that permits interaction 
with the negatively charged nucleic acid backbone (Holden et al. 2008; Chen et 
al. 2008). In the absence of a DNA-A3G complex structure, the precise 
orientation of the nucleic acid across the groove is not clear and remains 
controversial (Bransteitter et al. 2009) but is thought to bring the catalysed 
base into the proximity of the catalytically active Zn2+ ion (Furukawa et al. 
2009; Chen et al. 2008; Holden et al. 2008).  
Domestic cat A3H only poorly restricts FIV, whilst the lion variant potently 
prevents the production of infectious virions. Recent work in our lab suggests 
that the puma A3H variant also possesses antiviral activity. The ability of these 
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non-domestic cat variants to restrict is unusual, given that the proteins are 
single domain cytidine deaminases. To investigate possible mechanisms of 
action, an alignment of feline and lion A3H variants was made (Figure 6-10). 
Residues shared by lion and puma variants but absent in the feline A3H were 
identified (V7D, H43D, E51K, A65S, G140S, P106R/H (R in lion; H in puma), 
A179P, cat numbering). Four of the seven substitutions replace neutral 
residues with charged ones or switch the charge, suggesting a possible role in 
alteration of protein-protein or protein-nucleic acid interactions. 
 
Figure 6-10 Alignment of cat and lion A3H. Whilst feline A3H is unable to restrict 
FIV, the lion version restricts almost as well as the two-domain A3CH. Possible causes 
of the large change in phenotype are the two substitutions in the catalytic domain as well 
as four charge switch substitutions. 
Next a homology model of feline A3H was created using the two APOBEC 
crystal structures solved to date, huAPOBEC2 and huAPOBEC3G CD2 domain 
(PDB: 2NYT and 3E1U respectively) (Prochnow et al. 2007; Holden et al. 2008). 
The model predicts the conservation of the prototypic APOBEC structure: a 
central β-sheet surrounded by six α-helices (Figure 6-11). APOBEC3G CD2 
structurally differs from A2 primarily in its longer loops that protrude from the 
structure between conserved β-strands and α-helices (Holden et al. 2008). 
Superimposed structures of feline A3H on human A3G CD2 suggest that again 
the main structural difference is the length and orientation of the loops, with 
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the feline variant possessing shorter loop-3 and a deflected loop-1. Moreover, 
the model suggests that charge-switch mutations V7D, E51K and P160R/H are 
located on the surface of the protein predicted to interact with viral single-
stranded DNA (Furukawa et al. 2009; Chen et al. 2008; Bransteitter et al. 
2009). Of particular interest is the P160R/H mutation that varies between all 
three species. The residue is neutral in cats but positively charged in both lions 
and pumas. Analogy with recent human A3G-ssDNA binding models (Chen et al. 
2008; Furukawa et al. 2009), suggests that this residue has the potential to 
make electrostatic interactions with the negatively charged nucleic acid 
backbone, potentially increasing the affinity of binding in the non-domestic 
species.  
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homologues is present within the loop domains. Loop-3, known to make contact with 
nucleic acid bases (Bransteitter et al. 2009), is considerably shorter in the feline version 
but loop-7, involved in dimerisation in CD1 (Huthoff et al. 2009), is conserved.  
Recently, a homology model of a human single domain protein A3C, that is 
active against SIVmac but not HIV-1, has been presented (Stauch et al. 2009). 
Activity for this protein is dependent on RNA binding which is mediated by a 
novel substrate binding pocket and subsequent dimerisation performed by 
exposed aromatic residues that permit packaging into SIV∆Vif particles. The 
catalytic site is therefore unoccupied by RNA and free to bind ssDNA once 
reverse transcription is under way in the target cell. Human A3G also forms 
RNA-dependent dimers: CD1 domain residues R24 and R30 interact with RNA 
(Huthoff et al. 2009) which subsequently promotes intermolecular interactions 
via aromatic residues Y124, F126 and W127 present in CD1 loop-7 region 
(Huthoff et al. 2009; Gooch and Cullen 2008). However unlike the single 
domain A3C, dimerisation is not necessary for huA3G antiviral function (Opi et 
al. 2006).  
The mode of activity observed for liA3H suggests that virion incorporation 
takes place, given that the restriction observed is post-entry, making RNA-
dependent dimerisation a likely mechanism for this protein. A comparison with 
A3C also shows that of the four residues known to comprise the novel RNA-
binding pocket (K22, T92, R122 and N177), two are identical (R122 and T92), 
one is conserved (K22R), making it possible that RNA binding for liA3H takes 
place at this alternative location. Inspection of the feline sequence also 
reveals a patch of aromatic residues in loop-7 including Y122 and W115, 
leading to the hypothesis that feline A3H exists as a dimer through interactions 
at this surface. A homology model (Figure 6-12) also predicts adjacent W117 at 
the crest of α-helix 4 to be exposed and may also contribute to intermolecular 
interactions. This loop is absolutely conserved between feline and lion 
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interesting case as it is predicted to combine these functions in a single domain 
protein. Future work should evaluate how A3H impacts on viral infectivity 
alone and in concert with A3C – both as the fusion protein and individual 
proteins. 
6.3 Discussion 
Studies of host-retrovirus interactions in primates have suggested that genes 
which provide resistance to circulating or endogenous pathogens will be 
selected for, and, given time, will confer host resistance to the pathogen. It is 
likely that APOBEC proteins have had a part to play in this process. For 
example the human endogenous retrovirus, HERV-K, is present in multiple 
copies in the human genome as the relic of an infection. Some of these 
insertions have occurred comparatively recently, since the divergence with 
chimpanzees (Belshaw et al. 2005). The sequences show large numbers of G to 
A base substitutions, evidence of APOBEC-mediated antiviral activity (Lee et 
al. 2008; Perez-Caballero et al. 2008). Furthermore, a reconstructed consensus 
HERV-K is strongly restricted by huA3F, suggesting a causal role of APOBECs in 
the demise of this parasite (Lee and Bieniasz 2007). It is therefore of interest 
that lions, which are thought to have harboured lentiviruses for many hundreds 
of thousands of years, display a very different permissiveness compared to a 
fairly recent host, the domestic cat.  
It has previously been suggested that a certain amount of host adaptation has 
taken place in lion FIV strains that reduces pathogenicity and therefore 
prolongs the lifetime of infection[burk] (Carpenter and O'Brien 1995). 
However, the findings presented in this study show that both FIV-Fca and FIV-
Ple, which replicates to a high titre in domestic cat cells, are poorly infectious 
in lion cells but conversely, these strains are replication-competent in feline 
cells. The simplest explanation for the findings is that lion cells actively 
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prevent FIV replication, rather that the virus attenuating to preserve the 
health of its host. Indeed a lentiviral post-entry restriction (LNP) was described 
that prevents post-entry stages of human, feline and simian lentiviral 
infections. The factor or factors responsible for LNP remain unidentified. 
Experiments to test whether lion A3 proteins could block replication at a post-
entry stage were performed, but no evidence of a post-entry APOBEC-mediated 
block was found (data not shown). However, a post-entry APOBEC block cannot 
be ruled out until the ability of lion APOBECs to perform RNA-directed 
mutagenesis has been studied. Another potential candidate for LNP is TRIM22, 
a protein known to be under positive selection in the Carnivorae, possibly 
complementing the absence of TRIM5α (Sawyer et al. 2007). Despite repeated 
attempts to clone the TRIM22 gene from cat and lion cDNA, this study was 
unable to examine the role of this gene. However, the finding that LNP does 
not target the N-terminal domain of capsid makes TRIM22 an unlikely 
candidate, since TRIM5α is known to interact with this viral domain. 
Furthermore, no effect on LNP was observed by treating cells with arsenic 
trioxide, a compound that is known to disrupt TRIM protein activity (Zhu et al. 
1997; Campbell et al. 2007; Saenz et al. 2005). An unidentified block to HIV-1 
post-entry stages has been described in Mya-1 domestic cat T-cells (Munk et al. 
2007). It is possible that the restriction described is performed by the same 
factor as LNP, given that both act at the same stage in the lifecycle. This study 
used Mya-1 as a permissive cell line relative to lion cells, but in reality both 
species may be restrictive with more active variants present in lion cells. 
Interestingly, the FIV-Ple B strain was able to replicate in lion cells (albeit at a 
lower level than in cat cells), suggesting that FIV-Ple B is able to neutralise or 
escape LNP. Given that FIV-Ple B and E share considerable levels of identity 
across the genome with the exception of env (Pecon-Slattery et al. 2008a), it is 
possible that resistance is somehow provided by this same gene product, for 
example by employing divergent entry pathways or actively overcoming 
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restriction. This is not without precedence, since HIV-2 uses its Env 
glycoprotein to fulfil the role of HIV-1 Vpu in overcoming tetherin restriction 
(Bour et al. 1996; Jia et al. 2009). Like the discovery of alternate entry 
receptors, the differential permissivity of lion cells to the B and E clade viruses 
has implications for the pathology and management of FIV in free-ranging 
lions. However, further questions need to be answered before the implications 
become clear: for instance, does the differential in vitro permissivity correlate 
with in vivo viral titre? And is the differential permissivity specific to the 
Angolan lions from which the T-cells in this study were derived or is it 
widespread amongst lion populations? Furthermore, despite evidence of T-
lymphocyte depletion (Roelke et al. 2009), the tissue tropism of FIV-Ple has not 
formally been demonstrated and replication may be more efficient in other 
cell populations. 
It has been reported that lion populations in the west of southern Africa do not 
harbour FIV (Antunes et al. 2008). This is in stark contrast to eastern 
populations where seropositivity can approach 100% in adult lions (Ramsauer et 
al. 2007; Roelke et al. 2009; Brown et al. 1994). The absence of FIV in western 
areas has been explained by the lower population density (Antunes et al. 
2008). However, several felid species that exist at low population densities are 
known to bear FIV, such as Pallas cats (Barr et al. 1995) and pumas (reviewed 
in Poss et al. 2008). With the source of the lion cells used in this study, Angola, 
being on the west coast of southern Africa, it is possible that LNP is present in 
the localised lion population and has contributed to the absence of FIV west of 
the Kalahari. If confirmed, the lion would provide the first extant example of a 
host acquiring resistance to its own lentivirus and would be of substantial 
interest in the study of host-parasite ecology. On a molecular level, isolating 
the factor responsible for LNP is of substantial interest given the broad 
specificity of its activity. A potential strategy for its isolation is a cDNA library 
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screen: expressing lion cDNA clones in permissive cells and screening for 
antiviral activity. The technique is limited as it would not identify the cause if 
LNP were a function of two or more proteins or a recessive property, but with 
previous restriction phenotypes (rhesus macaque Lv1 and non-permissivity of 
CEM cells) the technique has proved successful and lead to the isolation of 
TRIM5α and huA3G (Stremlau et al. 2004; Sheehy et al. 2002). 
A single domain APOBEC presents problems for the host: RNA-binding and RNA-
directed catalytic activity allows virion packaging but risks targeting self RNA 
whilst ssDNA-binding and -deamination prevents virion incorporation. Two 
strategies to overcome this problem have been described for APOBEC proteins 
so far: the possession of an additional RNA-binding pseudocatalytic domain, 
such as huA3G CD1 (Huthoff and Malim 2007), or the presence of an additional 
RNA binding pocket for single domain proteins, such as huA3C (Stauch et al. 
2009). These strategies permit both encapsidation and deaminase activities 
without high levels of host mRNA mutation. A previous study of domestic cat 
APOBECs found little or no anti-lentiviral activity associated with the single 
domain proteins (Munk et al. 2008). Like human A3 proteins, two covalently-
joined domains in the form of read-through protein A3CH, were found to be 
required, presumably with each domain specialising separately in RNA binding 
and ssDNA deamination (Munk et al. 2008). Whilst we repeated the finding that 
feline single domain A3 proteins are poorly active against FIV, this study 
presents the single domain lion APOBEC3H protein capable of potent antiviral 
activity. The lion A3H protein is therefore of considerable interest as it 
prompts questions as to the mechanism of action for a single domain cytidine 
deaminase. Here, we have proposed a model for the activity of A3H which 
shares conserved residues with the A3C RNA-binding pocket and a potential 
dimerisation domain. Future work should use such structural information to 
define which mutations are responsible for rendering the lion and puma A3H 
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variants more potent against FIV compared to the domestic cat variant and the 
mechanism of antiviral activity should be addressed. Although RNA-binding and 
dimerisation are the most attractive hypotheses for liA3H activity, other 
mechanisms such as the formation of A3C/A3H heterodimers to allow RNA 
binding and deaminase activity are also potential in vivo methods of 
overcoming the problems associated with single domain proteins. Also possible 
is the presence of deaminase-independent activity as has been described for 
A3G (Newman et al. 2005; Bishop et al. 2008). This issue could be resolved by 
introducing mutations into the catalytic domain of liA3H in order to determine 
the relative contributions of deamination and deaminase-independent 
restriction. 
Human APOBEC3 activity is overcome by HIV-1 Vif protein (Sheehy et al. 2002). 
Whilst this study was able to demonstrate some Vif-dependent rescue of viral 
infectivity in the context of lion A3C1 restriction, no rescue was observed 
against other A3 proteins. It is likely that this inability of Vifs to counteract 
APOBECs is due to poor expression or mis-localisation of Vif. The problems are 
overcome by codon optimisation to alter the third base in each codon to better 
reflect mammalian codon usage. Doing so has been shown to improve mRNA 
nuclear export (Nguyen et al. 2004) and restore FIV Vif localisation to the 
cytoplasm (Paul et al. 2007). Time constraints prevented the construction of 
such codon optimised Vifs but future work will better assess the ability of FIV 
strains to overcome APOBEC-mediated restriction.  
Although APOBECs are unlikely to be the cause of post-entry LNP in lion cells, 
it remains possible that the block to replicating FIV is partially due to A3 
proteins. This issue could be addressed by recovering viral sequences from 
infected cells in order to quantify the extent of G to A substitutions. 
Additionally, it remains possible that the felid APOBECs have alternative or 
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additional viral targets: potent restriction of FFV and partial restriction of FeLV 
by feline APOBECs has been observed (Munk et al. 2008; Lochelt et al. 2005). 
However, FIV is likely to be the principal driver of positive selection in the 
lions given the pathogenicity and prevalence of FIV in wild lion populations and 
the apparent absence of FeLV, RD114 and FFV in this species (Antunes et al. 
2008; Roelke et al. 2009). Furthermore, the very fact that lion APOBECs have 
evolved to potently restrict FIV is in itself further evidence that FIV is a major 
target of restriction, making lions an ideal species for the study of ongoing 
arms race between host and lentivirus and potentially giving a glimpse of the 
future for lentiviral infections in other species.  
 Chapter 7. Concluding Remarks 
‘A slow sort of country,’ said the Queen. ‘Now here, you see, it 
takes all the running you can do, to keep in the same place. If you 
want to get somewhere else, you must run at least twice as fast as 
that!’ 
-  Alice in Wonderland, Lewis Carroll 
 
The words of the Red Queen have been used to describe situations in biology 
involving a continuous arms race between conflicting species, where an 
advantage for one species is quickly counteracted by a reactionary change in 
the other (Van Valen 1973). During retroviral infection, natural selection in the 
parasite acts to increase transmission whilst selection in the host acts to 
suppress replication. An antagonistic relationship therefore develops that 
drives innovation and selection of measures that promote the cause of each 
genetic entity. Accordingly, positive selection is apparent in host gene 
products that provide resistance to infection providing evidence of ongoing and 
historical conflicts. In contrast, the high mutation rate on the part of the 
retroviruses obscures the effects of historical conflicts but provides an efficient 
means of isolating important functions by examining variable and constant 
regions as well as monitoring escape mutants. Despite the ability to rapidly 
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evolve resistance to host defences, the vast majority of retroviruses are 
extinct, as evidenced by the large number of endogenous retroviral sequences 
present in mammalian genomes (8% of human genomic DNA), suggesting that 
the host usually wins out in these battles when played out over evolutionary 
time.  
The lentivirus is a comparatively new type of retrovirus, the oldest mammalian 
encounter dated to 7-12 mya (Katzourakis et al. 2007; Gilbert et al. 2009), and 
is still spreading through the taxa, arriving in humans within the past 150 years 
(Worobey et al. 2008). Few endogenous lentiviruses have been found, which 
has lead some commentators to suggest that their tropism precludes entry to 
the germline (Stoye 2006). While this may be a contributing factor, it seems 
likely that simply not enough time has elapsed for substantial levels of 
endogenisation. Our scope for investigation is also limited to the species for 
which bioinformatic datasets are available. Two endogenisation events have 
been described which occurred in the Leporidae (rabbits and hares) and the 
prosimian species grey mouse lemur (Gifford et al. 2008; Katzourakis et al. 
2007). However, no replication-competent lentivirus has been isolated from 
the entire Lagomorpha order or from any prosimian species, suggesting that 
the viruses that gave rise to these endogenous sequences, and their close 
relatives, are likely to be extinct. We therefore have an idea of the timescale 
required for a species to clear a lentiviral infection: less than 12-7 my in 
rabbits and less than 4.3 my in lemurs (Katzourakis et al. 2007; Gifford et al. 
2008; Gilbert et al. 2009; van der Loo et al. 2009). The means by which these 
hosts cleared there infections is unknown but is likely to have involved multiple 
factors acting at diverse stages in the lentiviral lifecycle. The discovery of an 
active TRIM5α in rabbits (Schaller et al. 2007) points to the involvement of this 
protein but restriction of the endogenous RELIK lentivirus has not to date been 
demonstrated.  
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In this study we have identified felid species, the domestic cat and African 
lion, which represent recent and anciently infected hosts. The presumed age of 
infection in the lions, greater than 324,000 years since the genetic coalescence 
of modern lions (Antunes et al. 2008) and up to the earliest time of global 
dissemination of the virus, 3.6 mya (Troyer et al. 2008; Pecon-Slattery et al. 
2008b), puts it within an order of magnitude of the lifetime of previous, 
extinct lentiviral infections, making an ideal host in which to examine the 
changes in the host brought about by long-term lentiviral infection. The post-
entry restriction factor TRIM5α was found to be truncated and non-functional 
in all felids examined, indicative of a disrupting mutation early in Feliform 
evolution. Nonetheless, we found that lion cells potently hindered the 
replication of FIV and primate lentiviruses. This is in direct contrast to the 
domestic cat, whose cells support FIV replication to a high titre. We found 
evidence that the APOBEC3 class of restriction factors is active in the felids, 
and in lions potently restricts FIV and found evidence of a post-entry block to a 
broad range of viruses.   
Lentiviruses, almost by definition, should replicate in the cells of their natural 
host, meaning that restriction factors must largely be overcome. What 
therefore is the role of restriction factors? It has been proposed that their 
primary role is to prevent cross-species transmission by restricting viruses 
before they can establish themselves in a novel host (Cullen 2006). Whilst 
restriction of viruses undergoing zoonosis undoubtedly takes place, it is 
probable that host restriction factors are under selective pressure to target 
endemic pathogens, even if they contribute only minimally to control of 
infection. Recent evidence implies that even a small decrease in viral titre can 
make large differences to pathology. For example, the murine APOBEC3 locus 
exerts a minor effect on Friend Virus 3 (FV3) replication in vitro yet appears to 
contribute to its clearance by a neutralising antibody response (reviewed in 
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Ross 2009; Santiago et al. 2008). As has been noted above, the neutralisation 
of human APOBEC3G is not complete, with low levels of packaged restriction 
factor and induced mutation observable in clinical HIV-1 isolates (Nowarski et 
al. 2008; Zhang et al. 2003), suggesting that even this low level of activity 
could aid in the antiviral response. Also in humans, TRIM5α restricts HIV-1 at a 
low level (30% reduction; this study, Figure 4-5). Eight non-synonymous TRIM5α 
polymorphisms have been identified (Javanbakht et al. 2006b) and one of 
these, R136Q, effects a very modest increase in HIV-1 restriction in vitro, yet 
contributes strongly to survival in AIDS patients after X4 switching, raising 
percent survival at 3 years post switch from 19% to 45% for RQ heterozygotes 
and 70% for QQ homozygotes (van Manen et al. 2008). Conversely, mutation 
H43Y, which impairs TRIM5α E3-ligase activity (Sawyer et al. 2006) accelerates 
disease progression in humans, with 100% progression to AIDS observed in YY 
homozygotes within seven years of seroconversion compared to 55% for HH 
homozygotes (van Manen et al. 2008). Thus it seems probable that even the 
modest restriction provided by TRIM5α against HIV-1 contributes substantially 
to limiting the pathology of infection. Furthermore, many of these restriction 
factors can be up-regulated by interferon, which contributes further to levels 
of restriction (Rajsbaum et al. 2008; Carthagena et al. 2008; Vetter et al. 
2009). Thus those restriction factor alleles conferring even minor increases in 
restriction are likely to be preferentially inherited and the cumulative effect of 
many such restrictions may eventually lead to a non-permissive phenotype. A 
by-product of this process is the potent restriction of retroviruses from other 
species that share structural features or similar replication strategies, but have 
not been in locked-step coevolution, leading to a powerful barrier to cross-
species transmission. These data imply that the many log restrictions that 
researchers in the field are accustomed to are probably not the phenotypes on 
which natural selection routinely works but effects of using viruses and 
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restriction factors that have not been involved in coevolutionary host-parasite 
relationships.  
The forces that drove the disruption of TRIM5α in both the Caniformia and 
Feliformia are unclear. Red Queen situations are characterised by Darwinian 
struggles between competing biological entities but an alternative view of 
evolution, termed the ‘Court Jester model,’ recognises that abiotic factors also 
influence evolution, speciation and extinction (Benton 2009). Such factors have 
no doubt impinged on felid and lentiviral evolution, for example in the 
oceanographic events that permitted felid and FIV migration into North 
America leading to their subsequent isolation and diversification. Furthermore, 
certain attributes of modern felids, such as the low genetic diversity in modern 
cheetah populations (Menotti-Raymond and O'Brien 1993) that has led to high 
levels of susceptibility to viral infection (e.g. to Feline infectious peritonitis 
virus; Heeney et al. 1990) cannot be ascribed to the Red Queen hypothesis 
alone. In this instance, it is likely that a combination of climatic changes and 
hunting by humans lead to the expunging of genetic diversity during the 
extinction of the Pleistocene megafauna ~12,000 years before present 
(Menotti-Raymond and O'Brien 1993; Barnosky et al. 2004). Thus changes in 
abiotic factors may have had a role to play, for example by genetic isolation of 
ancestral feliform and caniform species, in sculpting the genetic constitution 
of modern species. From a Red Queen point of view, however, a potential 
biotic change that may have lead to the truncation of TRIM5α is a temporary 
dearth in retroviral infection. Assessing the validity of such hypotheses is 
impossible but is supported by low levels of taxon-specific ERV sequences and 
by a paucity of retroviruses in other carnivoran species such as the dog. The 
loss of functional TRIM5α appears to have rendered domestic cat cells 
exceptionally permissive to infection, with diverse retroviral pseudotypes able 
to infect cell lines and replication-competent retroviruses RD114, FIV, FeLV 
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and FFV all circulating in this species. This permissiveness is not present in 
lions however, and the lack of TRIM5α restriction appears to be compensated 
for by an alternative potent post-entry restriction. Along with puma cells, they 
can prevent the replication of FIV and display potent APOBEC3 activity. These 
findings are in support of the Red Queen hypothesis and suggest that resistance 
to infection is developing in these species via a combination of post-entry and 
APOBEC3-mediated restriction. Although it is probable that FIV-Ple overcomes 
such restrictions to a sufficient degree in order to replicate and be 
transmitted, as with murine FV3 and human HIV-1 infection, the restrictive 
phenotype is likely to play a considerable part in controlling the course of 
infection and pathology. It may be no coincidence, therefore, that conflicting 
conclusions about the pathology of FIV infection of African lions have been 
drawn over the past fifteen years (Carpenter and O'Brien 1995; Roelke et al. 
2009; Roelke et al. 2006; Hofmann-Lehmann et al. 1996). The alternative 
receptor tropisms present in lion FIV isolates may also have confounded these 
studies as the subtypes are likely to alter in tissue tropism and presumably 
cytopathology. Future research should further elucidate the prevalence, causes 
and in vivo effects of restriction in lions. Comparisons with other species that 
display evidence of historic lentiviral infection such as rabbits and Madagascan 
lemurs may expose the processes involved in species-level clearance of 
lentiviral infection. 
 
 Appendix 1: Primers  
 
Name Sequence (5' to 3') 
feT5fwd TGTGTGCCGAATCAGGTACT 
feT5rev TCTTCTGCAGCATGTCCATC 
gex8 feT5 f ATCCCTYTYACAGKGTCACA 
gex8 feT5 r MATGAARAGAAYKTATAGATGAGAAACC 









feCXCR4 F GCGAATTCACCATGGACGGGTTTCGTATATAC 
feCXCR4 R CGGTGGATCCGAGGAGTGAAAACTTGAAGA 
feCD134 F CGATCTAGAATGAGGGTGGTTGTGGGGGCT 
feCD134 R ATGGGATCCCGCTGGGGACCCCTGGGGGGCTC 
LLV-E 5' Not ACTGGTCGACACCATGGCAGAAGGAGGAAGAGT 
LLV-E 3' Sal ACAGCGGCCGCTTAGGTATTAGACTCATCAT 
LLV-B 5' Sal ACTGGTCGACACCATGGCGGAAGGAGGAAG 
LLV-B 3' Not ACAGCGGCCGCTCAGACTACTCCTAGAAACT 
LLV-E Vif F ACTGGTCGACACCATGAGTGGTGAAGATATAAGTCAGG 
LLV-E Vif R ACAGCGGCCGCCTAGCCACCTTTCCCTATTAAATATAG 
LLV-B Vif R ACAGCGGCCGCCTACCACATGCTTTCATAGCTAATCTT 
LiA3C1 F ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAAACCCAATGC 
LiA3C1 R ACAGCGGCCGCTCACCTAAGGATTTCTTGAAGCTCTGCAGCC 
LiA3C2 F ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAAACCCAATGG 
LiA3C2 R AS LIA3C1-R 
LiA3H F ACTGGTCGACACCATGAATCCACTACAAGAAGACATATTC 
LiA3H R ACAGCGGCCGCTCATTCAAGTTTCAAATTTCTGAAATCATTC 
FeA3Ca F AS LIA3C2-F 
FeA3Ca R AS LIA3C1-R 
FeA3H F ACTGGTCGACACCATGAATCCACTACAGGAAGTCATATTC 









feCypC/R 3' SalI GCTAGTCGAGTTAGATTTGTTCACAGTC 
feCypA R69 5' 
Nde 
AACATATGGTCAACCCCATCGTG 
feCypA C69 5' 
Nde 
AACATATGTTCTTTGACATTACCAT 
feCypA R/C 3' 
Mlu 
AAACGCGTTTAGATTTGTCCACAGTCA 
GL8 gag F GCCACCAGGGTGCGCTGCA 
GL8 gag R GCCCATGGATTATTTGGATCT 
GL8 G87A GGTAATGGTCTAGGTGCATCA     
GL8 P90A GGTAATGCTCTAGGACCATCA     
LLVE CA 5' 
nde#2 
AACCATATGCCTATACAAGTGGTAAATGGAGTACC 
LLVE CA 3' 
mlu#2 
TGCACGCGTGCTTTTTGCTTTTACCTTCATCAAA 
feT5TaqMan 5' GCTGTTGACCGACCTCATCT 
feT5TaqMan 3' AAGACCCTGCTCCTTTCCAT 
feT5 Probe  FAM-CAACGATGGACATGCTGCAGGA-TAMRA  
wam13 TCAGTGTGGAATCACGTGAGC 
wam4 CTGCTATGGCTTCTGAACTCCTG 
G8 CAN5’ Nde ACCATATGCCTATTCAAACAGTAAATGGA 






Appendix 2: Buffers and solutions 
Beads wash buffer: 50 mM Tris, 300 mM NaCl, 1 mM DTT, pH 8.0 
CHAPS lysis buffer: 30 mM Tris-Cl, 150 mM NaCl, 1% CHAPS w/v, pH 7.5 
EB: 10 mM Tris-Cl, pH 8.5 
FW basic buffer: 20 mM HEPES, 50 mM KCl, 10 mM MgCl2, 1 mM DTT, 0.1% 
Triton X-100, pH 7.5 
FW blocking buffer: 5% nonfat dry milk in far-Western basic buffer 
FW wash buffer 1: 0.2% Triton X-100, PBS 
FW wash buffer 2: 0.2% Triton X-100, 100 mM KCl, PBS 
LB: 10% Bacto-Tryptone w/v, 5% yeast extract w/v, 85 mM NaCl, pH 7.5  
PBS: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM KH2PO4 
SDB: 10 mM HEPES, 4 mM MnCl2, 50 µg/ml dextran sulphate, 1% Triton X-100 
v/v, pH 7.6 
SDS-PAGE loading buffer: 0.25 M Tris-HCl, 2.5% SDS w/v, 10% glycerol v/v, 1% 
β-mercaptoethanol v/v, 0.02% bromophenol blue, pH 6.8 
TBE (10x): Tris base 890 mM, Boric acid 890 mM, EDTA 2 mM 
TE: 10 mM Tris-HCl, 0.1 mM EDTA, pH 7.6 
TY broth: 5% Tryptone-peptone w/v, 3% yeast extract w/v, 10 mM CaCl2 
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Appendix 3: Carnivoran TRIM5 exon 8 
sequences 
The 5’ end of TRIM5 exon 8 was PCR amplified from genomic DNA isolated from 
tissue samples described in Table 4.A using primers gex8 feT5 f and gex8 feT5 r. 
The first 100 bp of exon 8 are given and the truncating stop codon, where present, is 
in bold. 
Mya-1 cells, domestic cat, Felis catus domesticus 
CTCACGTGATTCCACACTGACCCCAAAATACGACATATTTTGGCATTTCTACGGGATGA
AGACCAGTGAGATATATGTGCTGGTGGAAATCAAATAATGC 
Hyena, Crocuta crocuta 
CTCACGTGATTTCATACTGACCCCCGGATACAACATATTTTGGCAGTTCTACAGAATGA
AGACAAGTGAGATATGTATGCTGTTGGAAGTCAAATAATGC 
Cheetah, Acinonyx jubatus 
CTCACGTGATTCCACACTGACCCCAAAATACGACATATTTTGGCATTTCTACGGGACGA
AGACCAGTGAGATATATGTGCTGGTGGAAATCAAATAATG 
European wildcat, Felis catus sylvestris 
CTCACGTGATTCCACACTGACCCCAAAATACGACATATTTTGGCATTTCTACGGGACGA
AGACCAGTGAGATATATGTGCTGGTGGAAATCAAATAATG 
Lion, Panthera leo 
CTCACGTGATTCCACACTGACCCCAAAATACGACGTATTTTGGCATTTCTACGGGACGA
AGACCAATGAGAGATATGTGCTGTTGGAAATCATATAATG 





Fossa, Cryptoprocta ferox 
CTCACGTGATTTCATGCTGACCCCCAAATACAACATATTTTGGCAATTCTACAGAATGA
AGACAAGTGTGATATGTATGCTGTTGGAAGTCAAATAATGC 






Appendix 4: Phylogeny of the Carnivora 
 
 
Schematic Carnivora phylogeny, based on (Johnson et al. 2006) and (Bininda-Emonds et 
al. 1999). Progenitor miacids diverged into Caniformia and Feliformia in the Eocene. 
The late Miocene radiation has given rise to the modern Felidae genera, including 
Panthera and Felis.  
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